CUMULATIVE
SUPPLEMENT 6
JUNE 2004

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2004

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

Cumulative Supplement 6

June 2004

CONTENTS

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. Additional details will be made available in future Cumulative Supplement publications.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

CUMULATIVE SUPPLEMENT 6
June 2004

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BERLEX (BERLEX)	BERLEX INC (BERLEX INC)
BERLEX LABORATORIES INC (BERLEX LABS)	BERLEX INC (BERLEX INC)
BERLEX LABORATORIES INC SUB SCHERING AG (BERLEX)	BERLEX INC (BERLEX INC)
AMERSHAM HEALTH (AMERSHAM)	GE HEALTHCARE (GE HEALTHCARE)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribabvirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342) and Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade_Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is $110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at

http://www.fda.gov/cder/orange/24bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated approximately weekly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website, http://forms/psc.gov/forms/FDA/fda.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2003) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either

as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2003	MAR 2004	JUN 2004	SEP 2004
DRUG PRODUCTS LISTED	10665	10668	10702	
SINGLE SOURCE	2423 (22.7%)	2404 (22.5%)	2385 (22.3%)	
MULTISOURCE	8134 (76.3%)	8156 (76.5%)	8209 (76.7%)	
THERAPEUTICALLY EQUIVALENT	7856 (73.7%)	7885 (73.9%)	7995 (74.7%)	
NOT THERAPEUTICALLY EQUIVALENT	278 (2.6%)	271 (2.5%)	214 (2.0%)	
EXCEPTIONS[1]	108 (1.0%)	108 (1.0%)	108 (1.0%)	
NEW MOLECULAR ENTITIES APPROVED	6	3	1	
NUMBER OF APPLICANTS	601	586	602	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

INJECTABLE; INJECTION

AMINOSYN 7% (PH6) HOSPIRA	7% (7GM/100ML)	N17673	006	Nov 18, 1985	May	CAHN
AMINOSYN 8.5% @ HOSPIRA	8.5% (8.5GM/100ML)	N17673	004		May	CAHN
AMINOSYN 8.5% (PH6) HOSPIRA	8.5% (8.5GM/100ML)	N17673	007	Nov 18, 1985	May	CAHN
AMINOSYN II 10% HOSPIRA	10% (10GM/100ML)	N19438	005	Apr 03, 1986	May	CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER HOSPIRA	10% (10GM/100ML)	N20015	001	Dec 19, 1991	May	CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER HOSPIRA	15% (15GM/100ML)	N20041	001	Dec 19, 1991	May	CAHN
AMINOSYN II 3.5% @ HOSPIRA	3.5% (3.5GM/100ML)	N19438	001	Apr 03, 1986	May	CAHN
AMINOSYN II 5% @ HOSPIRA	5% (5GM/100ML)	N19438	002	Apr 03, 1986	May	CAHN
AMINOSYN II 7% HOSPIRA	7% (7GM/100ML)	N19438	003	Apr 03, 1986	May	CAHN
AMINOSYN II 8.5% HOSPIRA	8.5% (8.5GM/100ML)	N19438	004	Apr 03, 1986	May	CAHN
AMINOSYN-HBC 7% HOSPIRA	7% (7GM/100ML)	N19374	001	Jul 12, 1985	May	CAHN
AMINOSYN-HF 8% HOSPIRA	8% (8GM/100ML)	N20345	001	Apr 04, 1996	May	CAHN
AMINOSYN-PF 10% HOSPIRA	10% (10GM/100ML)	N19492	002	Oct 17, 1986	May	CAHN
AMINOSYN-PF 7% HOSPIRA	7% (7GM/100ML)	N19398	001	Sep 06, 1985	May	CAHN
AMINOSYN-RF 5.2% HOSPIRA	5.2% (5.2GM/100ML)	N18429	001		May	CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	001	Nov 07, 1988	May	CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	002	Nov 07, 1988	May	CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	003	Nov 07, 1988	May	CAHN
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER @ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	004	Nov 07, 1988	May	CAHN

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER HOSPIRA	3.5%;25GM/100ML	N19681	001	Nov 01, 1988	May	CAHN
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	3.5%;5GM/100ML	N19681	002	Nov 01, 1988	May	CAHN
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER HOSPIRA	4.25%;10GM/100ML	N19681	004	Nov 01, 1988	May	CAHN

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

HOSPIRA	4.25%;20GM/100ML	N19681	005	Nov 01, 1988	May CAHN

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	4.25%;25GM/100ML	N19681	003	Nov 01, 1988	May CAHN

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	5%;25GM/100ML	N19681	006	Nov 01, 1988	May CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;10GM/100ML;51MG/100ML;176.5 MG/100ML;22.4MG/100ML;104.5MG/100 ML;205MG/100ML	N19682	003	Nov 01, 1988	May CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/10 0ML;120MG/100ML;49.3MG/100ML	N19682	001	Nov 01, 1988	May CAHN

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/1 00ML;120MG/100ML;49.3MG/100ML	N19682	002	Nov 01, 1988	May CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/ 100ML;234MG/100ML	N17789	003		May CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG /100ML	N17789	005		May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/ 100ML;410MG/100ML	N19437	004	Apr 03, 1986	May CAHN

AMINOSYN II 7% W/ ELECTROLYTES

@ HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/1 00ML;410MG/100ML	N19437	006	Apr 03, 1986	May CAHN

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG /100ML;410MG/100ML	N19437	005	Apr 03, 1986	May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/ 100ML;49MG/100ML	N19437	007	Apr 03, 1986	May CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/ 100ML	N17789	002		May CAHN

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

>A>	AB		ANABOLIC LABS	325MG;50MG;40MG;30MG	N76560	001	Jun 10, 2004	Jun NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA	+	AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024	001		Apr CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>		+	MIKART	300MG;10MG	N40556	001	Jun 23, 2004	Jun NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

>A>	AA		MALLINCKRODT	325MG;7.5MG	N40545	001	Jun 30, 2004	Jun NEWA
>A>	AA			325MG;10MG	N40545	002	Jun 30, 2004	Jun NEWA
>A>	AA			500MG;7.5MG	N40550	001	Jun 30, 2004	Jun NEWA
>A>	AA			650MG;10MG	N40550	002	Jun 30, 2004	Jun NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVOCET A500

>D>			AAIPHARMA	500MG;100MG	N76429	001	Sep 10, 2003	Jun CFTG
>A>	AB			500MG;100MG	N76429	001	Sep 10, 2003	Jun CFTG
				500MG;100MG	N76429	001	Sep 10, 2003	May CRLD

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

			VINTAGE PHARMS	325MG;100MG	N76743	001	May 07, 2004	May NEWA
>A>	AB			500MG;100MG	N76750	001	Jun 28, 2004	Jun NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

	AP		HOSPIRA	EQ 500MG BASE/VIAL	N40108	001	Oct 30, 1995	May CAHN

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

	AT		HOSPIRA	250MG/100ML	N17656	001		May CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETADOTE

		+	CUMBERLAND PHARMS	6GM /30ML(200MG/ML)	N21539	001	Jan 23, 2004	Jan NEWA

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

	AN		HOSPIRA	10%	N73664	001	Aug 30, 1994	May CAHN
	AN			20%	N74037	001	Aug 30, 1994	May CAHN

ACITRETIN

CAPSULE; ORAL

SORIATANE

	CONNETICS	10MG	N19821	001	Oct 28, 1996	Mar	CAHN
+		25MG	N19821	002	Oct 28, 1996	Mar	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	HOSPIRA	EQ 500MG BASE/VIAL	N74663	001	Apr 22, 1997	May	CAHN
AP		EQ 500MG BASE/VIAL	N74758	001	Apr 22, 1997	May	CAHN
AP		EQ 1GM BASE/VIAL	N74663	002	Apr 22, 1997	May	CAHN
AP		EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	May	CAHN
AP	MAYNE PHARMA USA	EQ 50MG BASE/ML	N75065	001	Feb 25, 1999	Apr	CAHN

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

>D>	+	FUJISAWA HLTHCARE	3MG/ML	N19937	002	Oct 30, 1989	Jun	CFTG
>A>	AP +		3MG/ML	N19937	002	Oct 30, 1989	Jun	CFTG

>A> ADENOSINE

>A>	AP	BAXTER HLTHCARE	3MG/ML	N76500	001	Jun 16, 2004	Jun	NEWA
>A>	AP		3MG/ML	N76501	001	Jun 16, 2004	Jun	NEWA
>A>	AP	BEDFORD	3MG/ML	N76404	001	Jun 16, 2004	Jun	NEWA
>A>	AP	SICOR PHARMS	3MG/ML	N76564	001	Jun 16, 2004	Jun	NEWA

>D> ALATROFLOXACIN MESYLATE

>D> INJECTABLE; INJECTION

>D> TROVAN PRESERVATIVE FREE

>D>		PFIZER	EQ 200MG BASE/VIAL	N20760	001	Dec 18, 1997	Jun	DISC
>A>		@	EQ 200MG BASE/VIAL	N20760	001	Dec 18, 1997	Jun	DISC
>D>	+		EQ 300MG BASE/VIAL	N20760	002	Dec 18, 1997	Jun	DISC
>A>		@	EQ 300MG BASE/VIAL	N20760	002	Dec 18, 1997	Jun	DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

ALBUMOTOPE 125 I

>D>		@ ISO TEX	5-50uCi/AMP	N17836	001		Jun	CMFD

JEANATOPE

>A>		ISO TEX	100UCI/10ML(10UCI/ML)	N17836	003	Jun 08, 2004	Jun	NEWA
>A>			500uCi/0.5ML	N17836	001		Jun	CMFD
>A>	+		1,000uCi/ML	N17836	002		Jun	CMFD

>D> RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

>D>		MALLINCKRODT	10uCi/ML	N17844	001		Jun	DISC
>A>		@	10uCi/ML	N17844	001		Jun	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ACCUNEB

>D>	+	DEY	EQ 0.042% BASE	N20949	001	Apr 30, 2001	Jun	CFTG
>A>	AN +		EQ 0.042% BASE	N20949	001	Apr 30, 2001	Jun	CFTG

ALBUTEROL SULFATE

>D>	AN	BAUSCH AND LOMB	EQ 0.083% BASE	N75358	001	Mar 29, 2000	Jun	CRLD
>A>	AN +		EQ 0.083% BASE	N75358	001	Mar 29, 2000	Jun	CRLD
>D>	AN		EQ 0.5% BASE	N75050	001	Jun 18, 1998	Jun	CRLD

SOLUTION; INHALATION

ALBUTEROL SULFATE

>A> AN	+	BAUSCH AND LOMB	EQ 0.5% BASE	N75050	001	Jun 18, 1998	Jun	CRLD
>A> AN		NEPHRON	EQ 0.042% BASE	N76355	001	Jun 28, 2004	Jun	NEWA

PROVENTIL

>D>								
>D> AN	+	SCHERING	EQ 0.083% BASE	N19243	002	Jan 14, 1987	Jun	DISC
>A>		@	EQ 0.083% BASE	N19243	002	Jan 14, 1987	Jun	DISC
>D> AN	+		EQ 0.5% BASE	N19243	001	Jan 14, 1987	Jun	DISC
>A>		@	EQ 0.5% BASE	N19243	001	Jan 14, 1987	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

	+	PLIVA	EQ 4MG BASE	N76130	002	Sep 26, 2002	Jan	CRLD
	+		EQ 8MG BASE	N76130	003	Sep 26, 2002	Jan	CRLD

VOLMAX

		@ MURO	EQ 4MG BASE	N19604	002	Dec 23, 1992	Jan	DISC
		@	EQ 8MG BASE	N19604	001	Dec 23, 1992	Jan	DISC

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

AP		HOSPIRA	5ML/100ML;5GM/100ML	N83263	001		May	CAHN

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTANIL

AP		HOSPIRA	EQ 0.5MG BASE/ML	N75221	001	Oct 28, 1999	May	CAHN

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

>D>	+	DSM PHARMS	EQ 500MG BASE/VIAL	N20298	001	May 17, 1996	Jun	CAHN
>A>	+	NABI	EQ 500MG BASE/VIAL	N20298	001	May 17, 1996	Jun	CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP		HOSPIRA	EQ 50MG BASE/ML	N63263	001	Nov 30, 1994	May	CAHN
			EQ 62.5MG BASE/ML	N63283	001	Oct 31, 1994	May	CAHN
AP			EQ 250MG BASE/ML	N63264	001	Nov 30, 1994	May	CAHN
AP			EQ 250MG BASE/ML	N64098	001	Jun 26, 1995	May	CAHN
		@	EQ 250MG BASE/ML	N64099	001	Jun 20, 1995	May	CAHN

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		HOSPIRA	EQ 500MG BASE/100ML	N64146	001	Apr 02, 1997	May	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

		HOSPIRA	10% (10GM/100ML)	N17673	003		May	CAHN

AMINOSYN 10% (PH6)

		HOSPIRA	10% (10GM/100ML)	N17673	008	Nov 18, 1985	May	CAHN

AMINOSYN 3.5%

		HOSPIRA	3.5% (3.5GM/100ML)	N17789	004		May	CAHN

AMINOSYN 5%

		HOSPIRA	5% (5GM/100ML)	N17673	001		May	CAHN

AMINOSYN 7%

		@ HOSPIRA	7% (7GM/100ML)	N17673	002		May	CAHN

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

	HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N17673	005		May	CAHN

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	HOSPIRA	250MG/ML	N70888	001	Jun 16, 1988	May	CAHN

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	HOSPIRA	250MG/ML	N70010	001	Mar 09, 1987	May	CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	HOSPIRA	25MG/ML	N87242	001	Oct 26, 1983	May	CAHN
AP +		25MG/ML	N87601	001	Jul 23, 1982	May	CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

+	HOSPIRA	100MG/100ML	N88147	002	May 03, 1983	May	CAHN
+		200MG/100ML	N88147	003	May 03, 1983	May	CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	HOSPIRA	100MG/100ML	N18924	001	Dec 12, 1984	May	CAHN
@		200MG/100ML	N18924	002	Dec 12, 1984	May	CAHN
@		400MG/100ML	N18924	003	Dec 12, 1984	May	CAHN
@		500MG/100ML	N18924	004	Dec 12, 1984	May	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP	HOSPIRA	50MG/ML	N75955	001	Oct 18, 2002	May	CAHN

AMIODARONE HYDROCHLORIDE

AP	INTL MEDICATION SYS	50MG/ML	N21594	001	Feb 04, 2004	Feb	NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

	PFIZER	EQ 5MG BASE;EQ 10MG BASE	N21540	001	Jan 30, 2004	Jan	NEWA
		EQ 5MG BASE;EQ 20MG BASE	N21540	002	Jan 30, 2004	Jan	NEWA
		EQ 5MG BASE;EQ 40MG BASE	N21540	003	Jan 30, 2004	Jan	NEWA
		EQ 5MG BASE;EQ 80MG BASE	N21540	004	Jan 30, 2004	Jan	NEWA
		EQ 10MG BASE;EQ 10MG BASE	N21540	005	Jan 30, 2004	Jan	NEWA
		EQ 10MG BASE;EQ 20MG BASE	N21540	006	Jan 30, 2004	Jan	NEWA
		EQ 10MG BASE;EQ 40MG BASE	N21540	007	Jan 30, 2004	Jan	NEWA
+		EQ 10MG BASE;EQ 80MG BASE	N21540	008	Jan 30, 2004	Jan	NEWA

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

@	DR REDDYS LABS INC	2.5MG	N21435	001	Oct 31, 2003	Mar	DISC
@		5MG	N21435	002	Oct 31, 2003	Mar	DISC
@		10MG	N21435	003	Oct 31, 2003	Mar	DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	5MEQ/ML	N88366	001	Jun 13, 1984	May	CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

AMMONIUM LACTATE

>A>	AB	CLAY PARK	EQ 12% BASE	N75570	001	Jun 23, 2004	Jun	NEWA
	AB	TARO	EQ 12% BASE	N76216	001	May 28, 2004	May	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	TEVA	200MG/5ML;EQ 28.5MG BASE/5ML	N65089	001	May 25, 2004	May	NEWA
	AB		400MG/5ML;EQ 57MG BASE/5ML	N65089	002	May 25, 2004	May	NEWA
	AB		600MG/5ML;EQ 42.9MG BASE/5ML	N65162	001	Mar 12, 2004	Mar	NEWA

AUGMENTIN ES-600

	AB	+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755	001	Jun 22, 2001	Mar	CFTG

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	AP	+ APOTHECON	EQ 125MG BASE/VIAL	N61395	001		Jun	CAHN
>D>	AP	+	EQ 250MG BASE/VIAL	N61395	002		Jun	CAHN
>D>	AP	+	EQ 500MG BASE/VIAL	N61395	003		Jun	CAHN
>D>	AP	+	EQ 1GM BASE/VIAL	N61395	004		Jun	CAHN
>D>	AP	+	EQ 2GM BASE/VIAL	N61395	005		Jun	CAHN
>D>	AP	+	EQ 10GM BASE/VIAL	N61395	006		Jun	CAHN
>A>	AP	+ SANDOZ	EQ 125MG BASE/VIAL	N61395	001		Jun	CAHN
>A>	AP	+	EQ 250MG BASE/VIAL	N61395	002		Jun	CAHN
>A>	AP	+	EQ 500MG BASE/VIAL	N61395	003		Jun	CAHN
>A>	AP	+	EQ 1GM BASE/VIAL	N61395	004		Jun	CAHN
>A>	AP	+	EQ 2GM BASE/VIAL	N61395	005		Jun	CAHN
>A>	AP	+	EQ 10GM BASE/VIAL	N61395	006		Jun	CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

		BERTEK	20MG/2ML (10MG/ML)	N21264	001	Apr 20, 2004	Apr	NEWA
	+		30MG/3ML (10MG/ML)	N21264	002	Apr 20, 2004	Apr	NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

	+	SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646	001	Jan 29, 2004	Jan	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

	+	MAYNE PHARMA USA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920	001	Sep 21, 2000	Apr	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	MAYNE PHARMA USA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809	004	Aug 08, 1985	Apr	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+	AAIPHARMA LLC	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N21625	001	Jan 30, 2004	Jan	NEWA
+	MAYNE PHARMA USA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N21625	001	Jan 30, 2004	Apr	CAHN

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+	AAIPHARMA LLC	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N21643	001	Feb 18, 2004	Feb	NEWA
+	MAYNE PHARMA USA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N21643	001	Feb 18, 2004	Apr	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	MAYNE PHARMA USA	20MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.6MG/ML;330 UNITS/ML;1 IU/ML	N08809	005	Apr 22, 2004	May	NEWA

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

>D>	+	AAIPHARMA LLC	389MG;32.4MG;32MG	N10996	006	Mar 08, 1983	Jun	DISC
>A>	@		389MG;32.4MG;32MG	N10996	006	Mar 08, 1983	Jun	DISC

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP		HOSPIRA	10MG/ML	N74632	001	Dec 23, 1996	May	CAHN

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		HOSPIRA	10MG/ML	N74633	001	Dec 23, 1996	May	CAHN
AP			10MG/ML	N74639	001	Mar 25, 1997	May	CAHN

TRACRIUM

AP	+	HOSPIRA	10MG/ML	N18831	002	Jun 20, 1985	May	CAHN

TRACRIUM PRESERVATIVE FREE

AP	+	HOSPIRA	10MG/ML	N18831	001	Nov 23, 1983	May	CAHN

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

	HOSPIRA	0.05MG/ML	N21146	002	Jul 09, 2001	May	CAHN
+		0.1MG/ML	N21146	001	Jul 09, 2001	May	CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	VALEANT	0.025MG;1MG	N17744	002		May	CAHN

MOTOFEN HALF-STRENGTH

@	VALEANT	0.025MG;0.5MG	N17744	001		May	CAHN

AZACITIDINE

INJECTABLE; SUBCUTANEOUS

VIDAZA

+	PHARMION	100MG/VIAL	N50794	001	May 19, 2004	May	NEWA

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

@	SCHERING	1MG	N17601	001		May	DISC

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

@	SCHERING	1MG;120MG	N18506	001	Mar 23, 1982	May	DISC

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+	BEDFORD	EQ 100MG BASE/VIAL	N74419	001	Mar 31, 1995	May	CRLD

IMURAN

@	PROMETHEUS LABS	EQ 100MG BASE/VIAL	N17391	001		May	DISC

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

@	PFIZER	EQ 250MG BASE	N50670	001	Nov 01, 1991	Mar	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

AT		MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50416	002		Mar	CRLD

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64068	001	Oct 30, 1995	Mar	CRLD

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC

AT		AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N65088	001	Feb 06, 2004	Feb	NEWA

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	+	BAUSCH AND LOMB	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64064	001	Oct 30, 1995	Mar	CRLD

OINTMENT; OPHTHALMIC
NEOSPORIN

AT		MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50417	001		Mar	CRLD

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	+	BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	N64046	001	Jan 26, 1995	Mar	CRLD

POLYSPORIN

AT		MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	N61229	001		Mar	CRLD

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION
VANCERIL

>D>	BN	+ SCHERING	0.042MG/INH	N17573	001		Jun	CTEC
>A>		+	0.042MG/INH	N17573	001		Jun	CTEC

>D> VANCERIL DOUBLE STRENGTH

>D>		+ SCHERING	0.084MG/INH	N20486	001	Dec 24, 1996	Jun	DISC
>A>		@	0.084MG/INH	N20486	001	Dec 24, 1996	Jun	DISC

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ

>D>	BN	+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N19389	001	Jul 27, 1987	Jun	CTEC
>A>		+	EQ 0.042MG DIPROP/SPRAY	N19389	001	Jul 27, 1987	Jun	CTEC

>D> VANCENASE AQ

>D>	BN	+ SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589	001	Dec 23, 1987	Jun	DISC
>A>		@	EQ 0.042MG DIPROP/SPRAY	N19589	001	Dec 23, 1987	Jun	DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL
BENAZEPRIL HCL

AB		ANDRX PHARMS	5MG	N76267	001	Feb 11, 2004	Feb	NEWA
AB			10MG	N76267	002	Feb 11, 2004	Feb	NEWA
AB			20MG	N76267	003	Feb 11, 2004	Feb	NEWA
AB			40MG	N76267	004	Feb 11, 2004	Feb	NEWA
AB		EON	5MG	N76402	001	Feb 11, 2004	Feb	NEWA
AB			10MG	N76402	002	Feb 11, 2004	Feb	NEWA
AB			20MG	N76402	003	Feb 11, 2004	Feb	NEWA
AB			40MG	N76402	004	Feb 11, 2004	Feb	NEWA
AB		GENPHARM	5MG	N76476	001	Feb 11, 2004	Feb	NEWA
AB			10MG	N76476	002	Feb 11, 2004	Feb	NEWA
AB			20MG	N76476	003	Feb 11, 2004	Feb	NEWA
AB			40MG	N76476	004	Feb 11, 2004	Feb	NEWA
AB		IVAX PHARMS	5MG	N76333	001	Feb 11, 2004	Feb	NEWA
AB			10MG	N76333	002	Feb 11, 2004	Feb	NEWA
AB			20MG	N76333	003	Feb 11, 2004	Feb	NEWA
AB			40MG	N76333	004	Feb 11, 2004	Feb	NEWA
AB		KV PHARM	5MG	N76118	001	Feb 11, 2004	Feb	NEWA
AB			10MG	N76118	002	Feb 11, 2004	Feb	NEWA
AB			20MG	N76118	003	Feb 11, 2004	Feb	NEWA
AB			40MG	N76118	004	Feb 11, 2004	Feb	NEWA
AB		MYLAN	5MG	N76430	001	Feb 11, 2004	Feb	NEWA
AB			10MG	N76430	002	Feb 11, 2004	Feb	NEWA
AB			20MG	N76430	003	Feb 11, 2004	Feb	NEWA
AB			40MG	N76430	004	Feb 11, 2004	Feb	NEWA

TABLET; ORAL

BENAZEPRIL HCL

AB	RANBAXY	5MG	N76344	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76344	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76344	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76344	004	Feb 11, 2004	Feb	NEWA
AB	TEVA	5MG	N76211	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76211	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76211	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76211	004	Feb 11, 2004	Feb	NEWA

LOTENSIN

AB	NOVARTIS	5MG	N19851	001	Jun 25, 1991	Feb	CFTG
AB		10MG	N19851	002	Jun 25, 1991	Feb	CFTG
AB		20MG	N19851	003	Jun 25, 1991	Feb	CFTG
AB +		40MG	N19851	004	Jun 25, 1991	Feb	CFTG

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	ANDRX PHARMS	5MG;6.25MG	N76342	001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76342	002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76342	003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76342	004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG;6.25MG	N76631	001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76631	002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76631	003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76631	004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG;6.25MG	N76612	001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76612	002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76612	003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76612	004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG;6.25MG	N76348	001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76348	002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76348	003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76348	004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG;6.25MG	N76688	001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76688	002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76688	003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76688	004	Feb 11, 2004	Feb	NEWA

LOTENSIN HCT

AB	NOVARTIS	5MG;6.25MG	N20033	001	May 19, 1992	Feb	CFTG
AB		10MG;12.5MG	N20033	002	May 19, 1992	Feb	CFTG
AB		20MG;12.5MG	N20033	004	May 19, 1992	Feb	CFTG
AB +		20MG;25MG	N20033	003	May 19, 1992	Feb	CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB +	DERMIK LABS	5%;3%	N50557	001	Oct 26, 1984	Mar	CFTG

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB	ATRIX	5%;3%	N65112	001	Mar 29, 2004	Mar	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ATRIX	EQ 0.05% BASE	N76603	001	Jan 23, 2004	Jan	NEWA

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

		BETAMETHASONE SODIUM PHOSPHATE						
		@ STERIS	EQ 3MG BASE/ML	N85738	001		Feb	DISC
		CELESTONE						
		@ SCHERING	EQ 3MG BASE/ML	N17561	001		Feb	DISC

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

		URECHOLINE						
>A>		@ ODYSSEY PHARMS	5MG/ML	N06536	001		Jun	CAHN
>D>		@ PLIVA	5MG/ML	N06536	001		Jun	CAHN

TABLET; ORAL

		URECHOLINE						
>A>		@ ODYSSEY PHARMS	5MG	N06536	003		Jun	CAHN
>A>		@	10MG	N06536	002		Jun	CAHN
>A>		@	25MG	N06536	004		Jun	CAHN
>A>		@	50MG	N06536	005		Jun	CAHN
>D>		@ PLIVA	5MG	N06536	003		Jun	CAHN
>D>		@	10MG	N06536	002		Jun	CAHN
>D>		@	25MG	N06536	004		Jun	CAHN
>D>		@	50MG	N06536	005		Jun	CAHN

BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

		HALFLYTELY						
	+	BRAINTREE	5MG;210GM;0.74GM;2.86GM;5.6GM	N21551	001	May 10, 2004	May	NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

>D>		BRETYLIUM TOSYLATE						
>D>	AP	+ HOSPIRA	50MG/ML	N19033	001	Apr 29, 1986	Jun	DISC
>A>		@	50MG/ML	N19033	001	Apr 29, 1986	Jun	DISC
	AP	+	50MG/ML	N19033	001	Apr 29, 1986	May	CAHN
>D>	AP	INTL MEDICATION	50MG/ML	N70119	001	Apr 29, 1986	Jun	CRLD
>A>	AP	+	50MG/ML	N70119	001	Apr 29, 1986	Jun	CRLD
		BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	AP	+ HOSPIRA	200MG/100ML	N19008	002	Apr 29, 1986	May	CAHN
	AP	+	400MG/100ML	N19008	003	Apr 29, 1986	May	CAHN
		@	800MG/100ML	N19008	001	Apr 29, 1986	May	CAHN
		BRETYLIUM TOSYLATE IN PLASTIC CONTAINER						
	AP	+ HOSPIRA	50MG/ML	N19030	001	Apr 29, 1986	May	CAHN

BUMETANIDE

INJECTABLE; INJECTION

		BUMETANIDE						
	AP	HOSPIRA	0.25MG/ML	N74160	001	Oct 30, 1997	May	CAHN
	AP		0.25MG/ML	N74332	001	Oct 31, 1994	May	CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		BUPIVACAINE HCL						
	AP	HOSPIRA	0.25%	N18053	002		May	CAHN
	AP		0.25%	N70583	001	Feb 17, 1987	May	CAHN
	AP		0.25%	N70586	001	Mar 03, 1987	May	CAHN

		INJECTABLE; INJECTION						
		BUPIVACAINE HCL						
AP		HOSPIRA	0.25%	N70590	001	Feb 17, 1987	May	CAHN
AP			0.5%	N18053	001		May	CAHN
AP			0.5%	N70584	001	Feb 17, 1986	May	CAHN
AP			0.5%	N70597	001	Mar 03, 1987	May	CAHN
AP			0.5%	N70609	001	Mar 03, 1987	May	CAHN
AP			0.75%	N18053	003		May	CAHN
AP			0.75%	N70585	001	Mar 03, 1987	May	CAHN
AP			0.75%	N70587	001	Mar 03, 1987	May	CAHN
		BUPIVACAINE HCL KIT						
		@ HOSPIRA	0.075%	N19978	001	Sep 03, 1992	May	CAHN
		@	0.114%	N19978	002	Sep 03, 1992	May	CAHN
		@	0.23%	N19978	003	Sep 03, 1992	May	CAHN
		MARCAINE HCL						
AP	+	HOSPIRA	0.25%	N16964	001		May	CAHN
AP	+		0.5%	N16964	006		May	CAHN
		MARCAINE HCL PRESERVATIVE FREE						
AP	+	HOSPIRA	0.25%	N16964	012		May	CAHN
AP	+		0.5%	N16964	005		May	CAHN
AP	+		0.75%	N16964	009		May	CAHN
		INJECTABLE; SPINAL						
		BUPIVACAINE						
AP		HOSPIRA	0.75%	N71810	001	Dec 11, 1987	May	CAHN
		MARCAINE						
AP	+	HOSPIRA	0.75%	N18692	001	May 04, 1984	May	CAHN
		BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE						
		INJECTABLE; INJECTION						
		BUPIVACAINE HCL AND EPINEPHRINE						
	+	HOSPIRA	0.25%;0.005MG/ML	N71165	001	Jun 16, 1988	May	CAHN
			0.25%;0.005MG/ML	N71166	001	Jun 16, 1988	May	CAHN
			0.25%;0.005MG/ML	N71167	001	Jun 16, 1988	May	CAHN
	+		0.5%;0.005MG/ML	N71168	001	Jun 16, 1988	May	CAHN
			0.5%;0.005MG/ML	N71169	001	Jun 16, 1988	May	CAHN
			0.5%;0.005MG/ML	N71170	001	Jun 16, 1988	May	CAHN
	+		0.75%;0.005MG/ML	N71171	001	Jun 16, 1988	May	CAHN
		BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE						
		INJECTABLE; INJECTION						
		MARCAINE HCL W/ EPINEPHRINE						
AP	+	HOSPIRA	0.25%;0.0091MG/ML	N16964	004		May	CAHN
AP	+		0.5%;0.0091MG/ML	N16964	008		May	CAHN
		MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE						
AP	+	HOSPIRA	0.25%;0.0091MG/ML	N16964	013		May	CAHN
AP	+		0.5%;0.0091MG/ML	N16964	007		May	CAHN
AP	+		0.75%;0.0091MG/ML	N16964	010		May	CAHN
		BUPRENORPHINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		BUPRENORPHINE HCL						
AP		HOSPIRA	EQ 0.3MG BASE/ML	N74137	001	Jun 03, 1996	May	CAHN
		BUPROPION HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		BUPROPION HCL						
AB1		EON	100MG	N75932	001	Nov 25, 2003	May	CFTG

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1		EON	150MG	N75932	002	Mar 22, 2004	May	CTEC
AB			150MG	N75932	002	Mar 22, 2004	Mar	NEWA
AB1		IMPAX LABS	100MG	N75913	001	Jan 28, 2004	May	CTEC
AB			100MG	N75913	001	Jan 28, 2004	Jan	NEWA
AB1			150MG	N75913	002	Mar 22, 2004	May	CTEC
AB			150MG	N75913	002	Mar 22, 2004	Mar	NEWA
AB2			150MG	N75914	001	May 27, 2004	May	NEWA

WELLBUTRIN SR

AB1		GLAXOSMITHKLINE	100MG	N20358	002	Oct 04, 1996	May	CTEC
>D> AB	+		150MG	N20358	003	Oct 04, 1996	Jun	CTEC
>A> AB1	+		150MG	N20358	003	Oct 04, 1996	Jun	CTEC
AB	+		150MG	N20358	003	Oct 04, 1996	May	CTEC
AB	+		150MG	N20358	003	Oct 04, 1996	Mar	CFTG

ZYBAN

>D> AB	+	GLAXOSMITHKLINE	150MG	N20711	003	May 14, 1997	Jun	CTEC
>A> AB2	+		150MG	N20711	003	May 14, 1997	Jun	CTEC
AB	+		150MG	N20711	003	May 14, 1997	May	CFTG

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB		TEVA	30MG	N75022	004	Mar 25, 2004	Mar	NEWA

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP		HOSPIRA	1MG/ML	N75559	001	Mar 20, 2000	May	CAHN
AP			2MG/ML	N75559	002	Mar 20, 2000	May	CAHN

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		HOSPIRA	1MG/ML	N74620	001	Jan 22, 1997	May	CAHN
AP			1MG/ML	N74626	001	Jan 23, 1997	May	CAHN
AP			2MG/ML	N74620	002	Jan 22, 1997	May	CAHN
AP			2MG/ML	N74626	002	Jan 23, 1997	May	CAHN

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP		MAYNE PHARMA USA	0.001MG/ML	N75816	001	Jan 16, 2004	Jan	NEWA
AP			0.002MG/ML	N75816	002	Jan 16, 2004	Jan	NEWA

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

	+	HOSPIRA	100MG/ML	N21117	001	Jan 28, 2000	May	CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP		HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N18254	001		May	CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N17608	001		May	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@	HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N19685	005	Oct 17, 1988	May	CAHN
@		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N19685	006	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@	HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N19685	007	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N19685	002	Oct 17, 1988	May	CAHN
AP		20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N19685	008	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@	HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N19685	003	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N19685	004	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@	HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N19685	001	Oct 17, 1988	May	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121 MG/ML;16.1MG/ML	N18895	001	Jul 20, 1984	May	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

AT	+ HOSPIRA	17.6MG/100ML;325.3MG/100ML;119.3M G/100ML;643MG/100ML	N18608	001	Feb 26, 1982	May	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N18251	001		May	CAHN

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N17635	001		May	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N17641	001		May	CAHN

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N19416	001	Jan 17, 1986	May	CAHN

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB		DURAMED PHARMS BARR	12.5MG	N74477	001	Feb 13, 1996	May	CAHN
AB			25MG	N74477	002	Feb 13, 1996	May	CAHN
AB			50MG	N74477	003	Feb 13, 1996	May	CAHN
AB			100MG	N74477	004	Feb 13, 1996	May	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

		SHIRE PHARM	100MG	N20712	003	Sep 30, 1997	Mar	CRLD
			200MG	N20712	001	Sep 30, 1997	Mar	CRLD

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB		IMPAX LABS	25MG;100MG	N76521	001	May 14, 2004	May	NEWA
AB			50MG;200MG	N76521	002	May 14, 2004	May	NEWA
>A> AB		KV PHARM	50MG;200MG	N76663	001	Jun 24, 2004	Jun	NEWA
>A> AB		TORPHARM	25MG;100MG	N76212	001	Jun 16, 2004	Jun	NEWA
>A> AB			50MG;200MG	N76212	002	Jun 16, 2004	Jun	NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)

PARAPLATIN

	+	BRISTOL MYERS SQUIBB	EQ 600MG /60ML(10MG/ML)	N20452	004	Jan 15, 2004	Jan	NEWA

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

>D>		ABBOTT	2.5MG	N19204	001	Dec 28, 1988	Jun	DISC
>A>		@	2.5MG	N19204	001	Dec 28, 1988	Jun	DISC
>D>		+	5MG	N19204	002	Dec 28, 1988	Jun	DISC
>A>		@	5MG	N19204	002	Dec 28, 1988	Jun	DISC

CEFACLOR

CAPSULE; ORAL

CEFACLOR

AB		CARLSBAD	EQ 250MG BASE	N65146	001	Jan 22, 2004	Jan	NEWA
AB			EQ 500MG BASE	N65146	002	Jan 22, 2004	Jan	NEWA

FOR SUSPENSION; ORAL

CECLOR

AB		CEPH INTL	EQ 125MG BASE/5ML	N62206	001		May	CAHN
AB			EQ 187MG BASE/5ML	N62206	003	Apr 20, 1988	May	CAHN
AB			EQ 250MG BASE/5ML	N62206	002		May	CAHN
AB	+		EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

>D>								
>D> AB	+	LILLY	EQ 500MG BASE	N50673	002	Jun 28, 1996	Jun	DISC
>A>		@	EQ 500MG BASE	N50673	002	Jun 28, 1996	Jun	DISC

CEFACLOR

>D> AB		IVAX PHARMS	EQ 500MG BASE	N65057	001	Jan 05, 2001	Jun	CRLD
>A> AB	+		EQ 500MG BASE	N65057	001	Jan 05, 2001	Jun	CRLD

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

>D>	AP		MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N62988	001	Dec 29, 1989	Jun	DISC
>A>			@	EQ 250MG BASE/VIAL	N62988	001	Dec 29, 1989	Jun	DISC
>D>	AP			EQ 500MG BASE/VIAL	N62988	002	Dec 29, 1989	Jun	DISC
>A>			@	EQ 500MG BASE/VIAL	N62988	002	Dec 29, 1989	Jun	DISC
>D>	AP			EQ 1GM BASE/VIAL	N62988	003	Dec 29, 1989	Jun	DISC
>A>			@	EQ 1GM BASE/VIAL	N62988	003	Dec 29, 1989	Jun	DISC
>D>	AP			EQ 5GM BASE/VIAL	N62989	001	Dec 29, 1989	Jun	DISC
>A>			@	EQ 5GM BASE/VIAL	N62989	001	Dec 29, 1989	Jun	DISC
>D>	AP			EQ 10GM BASE/VIAL	N62989	002	Dec 29, 1989	Jun	DISC
>A>			@	EQ 10GM BASE/VIAL	N62989	002	Dec 29, 1989	Jun	DISC
>D>	AP			EQ 20GM BASE/VIAL	N62989	003	Dec 29, 1989	Jun	DISC
>A>			@	EQ 20GM BASE/VIAL	N62989	003	Dec 29, 1989	Jun	DISC

KEFZOL

>D>	AP	+	LILLY	EQ 250MG BASE/VIAL	N61773	001		Jun	DISC
>A>			@	EQ 250MG BASE/VIAL	N61773	001		Jun	DISC
>D>	AP			EQ 500MG BASE/VIAL	N61773	002		Jun	DISC
>A>			@	EQ 500MG BASE/VIAL	N61773	002		Jun	DISC
>D>	AP			EQ 1GM BASE/VIAL	N61773	003		Jun	DISC
>A>			@	EQ 1GM BASE/VIAL	N61773	003		Jun	DISC
>D>	AP			EQ 10GM BASE/VIAL	N61773	004		Jun	DISC
>A>			@	EQ 10GM BASE/VIAL	N61773	004		Jun	DISC
>D>	AP	+		EQ 20GM BASE/VIAL	N61773	005	Sep 08, 1987	Jun	DISC
>A>			@	EQ 20GM BASE/VIAL	N61773	005	Sep 08, 1987	Jun	DISC

CEFIXIME

SUSPENSION; ORAL

SUPRAX

		+	LUPIN	100MG/5ML	N65129	001	Feb 23, 2004	Feb	NEWA

TABLET; ORAL

SUPRAX

		+	LUPIN	400MG	N65130	001	Feb 12, 2004	Feb	NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

	AP		ACS DOBFAR	500MG/VIAL	N62640	001	Nov 20, 1985	Apr	CTNA
	AP			1GM/VIAL	N62640	002	Nov 20, 1985	Apr	CTNA
	AP			2GM/VIAL	N62640	003	Nov 20, 1985	Apr	CTNA

TAZICEF

	AP		HOSPIRA	500MG/VIAL	N62662	001	Mar 06, 1986	May	CAHN
	AP			1GM/VIAL	N62662	002	Mar 06, 1986	May	CAHN
	AP			1GM/VIAL	N64032	001	Oct 31, 1993	May	CAHN
	AP			2GM/VIAL	N62662	003	Mar 06, 1986	May	CAHN
	AP			2GM/VIAL	N64032	002	Oct 31, 1993	May	CAHN
	AP			6GM/VIAL	N62662	004	Mar 06, 1986	May	CAHN

TAZIDIME

			@ LILLY	1GM/VIAL	N62655	001	Nov 20, 1985	Apr	DISC
			@	2GM/VIAL	N62655	002	Nov 20, 1985	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	N65048	001	Jan 09, 2004	Jan		NEWA

KEFUROX

>D> AB	LILLY	EQ 750MG BASE/VIAL	N62591	001	Jan 10, 1986	Jun		DISC
>A>	@	EQ 750MG BASE/VIAL	N62591	001	Jan 10, 1986	Jun		DISC

INJECTABLE; INJECTION

CEFUROXIME

AP	HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048	002	Jan 09, 2004	Jan		NEWA
AP		EQ 7.5GM BASE/VIAL	N65046	001	Jan 09, 2004	Jan		NEWA

KEFUROX

>D> AP	LILLY	EQ 1.5GM BASE/VIAL	N62591	002	Jan 10, 1986	Jun		DISC
>A>	@	EQ 1.5GM BASE/VIAL	N62591	002	Jan 10, 1986	Jun		DISC
>D> AP		EQ 1.5GM BASE/VIAL	N62592	002	Jan 10, 1986	Jun		DISC
>A>	@	EQ 1.5GM BASE/VIAL	N62592	002	Jan 10, 1986	Jun		DISC
>D> AP		EQ 7.5GM BASE/VIAL	N62591	003	Dec 17, 1987	Jun		DISC
>A>	@	EQ 7.5GM BASE/VIAL	N62591	003	Dec 17, 1987	Jun		DISC

INJECTABLE; INTRAVENOUS

KEFUROX

>D> AP	LILLY	EQ 750MG BASE/VIAL	N62592	001	Jan 10, 1986	Jun		DISC
>A>	@	EQ 750MG BASE/VIAL	N62592	001	Jan 10, 1986	Jun		DISC

CEPHALEXIN

CAPSULE; ORAL

KEFLEX

>A> AB	ADVANCIS PHARM	EQ 250MG BASE	N50405	002		Jun		CAHN
>A> AB +		EQ 500MG BASE	N50405	003		Jun		CAHN
>D> AB	LILLY	EQ 250MG BASE	N50405	002		Jun		CAHN
>D> AB +		EQ 500MG BASE	N50405	003		Jun		CAHN

FOR SUSPENSION; ORAL

KEFLEX

>A>	@ ADVANCIS PHARM	EQ 100MG BASE/ML	N50406	003		Jun		CAHN
>A>	@	EQ 125MG BASE/5ML	N50406	001		Jun		CAHN
>A>	@	EQ 250MG BASE/5ML	N50406	002		Jun		CAHN
>D>	@ LILLY	EQ 100MG BASE/ML	N50406	003		Jun		CAHN
>D>	@	EQ 125MG BASE/5ML	N50406	001		Jun		CAHN
>D>	@	EQ 250MG BASE/5ML	N50406	002		Jun		CAHN

TABLET; ORAL

KEFLET

>D> AB	LILLY	EQ 250MG BASE	N50440	003	Feb 26, 1987	Jun		DISC
>A>	@	EQ 250MG BASE	N50440	003	Feb 26, 1987	Jun		DISC

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

ZYRTEC

	PFIZER	5MG	N21621	001	Mar 16, 2004	Mar		NEWA
+		10MG	N21621	002	Mar 16, 2004	Mar		NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

EVOXAC

>D> +	DAIICHI	EQ 30MG BASE	N20989	002	Jan 11, 2000	Jun		CAHN
>A> +		EQ 30MG BASE	N20989	002	Jan 11, 2000	Jun		CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

>D>		INJECTABLE; INJECTION						
>D>		LIBRIUM						
>D>	+	VALEANT PHARM INTL	100MG/AMP	N12301	001		Jun	DISC
>A>		@	100MG/AMP	N12301	001		Jun	DISC

CHLORHEXIDINE GLUCONATE

		SOLUTION; DENTAL						
		CHLORHEXIDINE GLUCONATE						
AT		MORTON GROVE	0.12%	N75006	001	Mar 03, 2004	Mar	NEWA

CHLOROPROCAINE HYDROCHLORIDE

		INJECTABLE; INJECTION						
		CHLOROPROCAINE HCL						
AP		HOSPIRA	2%	N87447	001	Apr 16, 1982	May	CAHN
AP			3%	N87446	001	Apr 16, 1982	May	CAHN
		NESACAINE						
>D>		ASTRAZENECA	2%	N09435	002		Jun	CTEC
>A>	AP		2%	N09435	002		Jun	CTEC

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

>A>		SUSPENSION, EXTENDED RELEASE; ORAL						
>A>		CODEPREX						
>A>	+	CELLTECH PHARMS	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Jun	NEWA

CHORIOGONADOTROPIN ALFA

		INJECTABLE; INJECTION						
		OVIDREL						
		@ SERONO INC	0.25MG/VIAL	N21149	001	Sep 20, 2000	May	DISC
		INJECTABLE; SUBCUTANEOUS						
		OVIDREL						
	+	SERONO INC	EQ 0.25MG /0.5ML	N21149	002	Oct 06, 2003	Apr	CPOT

CHROMIC CHLORIDE

		INJECTABLE; INJECTION						
		CHROMIC CHLORIDE IN PLASTIC CONTAINER						
	+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N18961	001	Jun 26, 1986	May	CAHN

CIMETIDINE HYDROCHLORIDE

		INJECTABLE; INJECTION						
		CIMETIDINE HCL						
AP		HOSPIRA	EQ 300MG BASE/2ML	N74296	001	Mar 28, 1997	May	CAHN
AP			EQ 300MG BASE/2ML	N74344	001	Jan 31, 1995	May	CAHN
AP			EQ 300MG BASE/2ML	N74345	001	Jan 31, 1995	May	CAHN
AP			EQ 300MG BASE/2ML	N74412	001	Mar 28, 1997	May	CAHN
AP			EQ 300MG BASE/2ML	N74422	001	Jan 31, 1995	May	CAHN
		CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		HOSPIRA	EQ 6MG BASE/ML	N74269	001	Dec 27, 1994	May	CAHN
	+		EQ 90MG BASE/100ML	N74468	005	Dec 29, 1994	May	CAHN
	+		EQ 120MG BASE/100ML	N74468	006	Dec 29, 1994	May	CAHN
	+		EQ 180MG BASE/100ML	N74468	003	Dec 29, 1994	May	CAHN
	+		EQ 240MG BASE/100ML	N74468	004	Dec 29, 1994	May	CAHN
	+		EQ 360MG BASE/100ML	N74468	001	Dec 29, 1994	May	CAHN
	+		EQ 480MG BASE/100ML	N74468	002	Dec 29, 1994	May	CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

		SENSIPAR							
		AMGEN	EQ 30MG BASE	N21688	001	Mar 08, 2004	Mar		NEWA
			EQ 60MG BASE	N21688	002	Mar 08, 2004	Mar		NEWA
	+		EQ 90MG BASE	N21688	003	Mar 08, 2004	Mar		NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		CIPROFLOXACIN							
>A>	AT	BAUSCH AND LOMB	EQ 0.3% BASE	N76754	001	Jun 09, 2004	Jun		NEWA
>A>	AT	NOVEX	EQ 0.3% BASE	N75928	001	Jun 09, 2004	Jun		NEWA

TABLET; ORAL

		CIPRO							
>D>		BAYER PHARMS	EQ 100MG BASE	N19537	001	Apr 08, 1996	Jun		CFTG
>A>	AB		EQ 100MG BASE	N19537	001	Apr 08, 1996	Jun		CFTG
>D>			EQ 250MG BASE	N19537	002	Oct 22, 1987	Jun		CFTG
>A>	AB		EQ 250MG BASE	N19537	002	Oct 22, 1987	Jun		CFTG
>D>			EQ 500MG BASE	N19537	003	Oct 22, 1987	Jun		CFTG
>A>	AB		EQ 500MG BASE	N19537	003	Oct 22, 1987	Jun		CFTG
>D>	+		EQ 750MG BASE	N19537	004	Oct 22, 1987	Jun		CFTG
>A>	AB +		EQ 750MG BASE	N19537	004	Oct 22, 1987	Jun		CFTG
>A>		CIPROFLOXACIN							
>A>	AB	BARR	EQ 250MG BASE	N74124	001	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N74124	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N74124	003	Jun 09, 2004	Jun		NEWA
>A>	AB	COBALT	EQ 250MG BASE	N76794	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N76794	003	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N76794	004	Jun 09, 2004	Jun		NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 100MG BASE	N75593	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 250MG BASE	N75593	003	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N75593	004	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N75593	001	Jun 09, 2004	Jun		NEWA
>A>	AB	EON	EQ 250MG BASE	N76593	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N76593	003	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N76593	004	Jun 09, 2004	Jun		NEWA
>A>	AB	GENPHARM	EQ 250MG BASE	N75817	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N75817	003	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N75817	004	Jun 09, 2004	Jun		NEWA
>A>	AB	HIKMA	EQ 250MG BASE	N76558	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N76558	003	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N76558	004	Jun 09, 2004	Jun		NEWA
>A>	AB	IVAX PHARMS	EQ 250MG BASE	N76089	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N76089	003	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N76089	004	Jun 09, 2004	Jun		NEWA
>A>	AB	MARTEC	EQ 250MG BASE	N76138	001	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N76138	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N76138	003	Jun 09, 2004	Jun		NEWA
>A>	AB	MYLAN	EQ 250MG BASE	N75685	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N75685	003	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N75685	001	Jun 09, 2004	Jun		NEWA
>A>	AB	RANBAXY	EQ 250MG BASE	N75747	001	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 500MG BASE	N75747	002	Jun 09, 2004	Jun		NEWA
>A>	AB		EQ 750MG BASE	N75747	003	Jun 09, 2004	Jun		NEWA
>A>	AB	SANDOZ	EQ 250MG BASE	N75939	002	Jun 09, 2004	Jun		NEWA

TABLET; ORAL
CIPROFLOXACIN

>A>		SANDOZ	EQ 500MG BASE	N75939	003	Jun 09, 2004	Jun	NEWA
>A>	AB		EQ 750MG BASE	N75939	004	Jun 09, 2004	Jun	NEWA
>A>	AB	TEVA	EQ 250MG BASE	N76136	001	Jun 09, 2004	Jun	NEWA
>A>	AB		EQ 500MG BASE	N76136	002	Jun 09, 2004	Jun	NEWA
>A>	AB		EQ 750MG BASE	N76136	003	Jun 09, 2004	Jun	NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CIPRO XR

	+	BAYER PHARMS	425.2MG;EQ 574.9MG BASE	N21473	002	Aug 28, 2003	Feb	CDFR

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION
UROLOGIC G IN PLASTIC CONTAINER

AT		HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N18904	001	May 27, 1983	May	CAHN

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE

AP		AM PHARM	1MG/ML	N76571	001	Apr 22, 2004	Apr	NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
BIAXIN XL

>D>	+	ABBOTT	500MG	N50775	001	Mar 03, 2000	Jun	CFTG
>A>	AB	+	500MG	N50775	001	Mar 03, 2000	Jun	CFTG
>A>		CLARITHROMYCIN						
>A>	AB	ANDRX PHARMS	500MG	N65145	001	Jun 24, 2004	Jun	NEWA

TABLET; ORAL
BIAXIN

AB	+	ABBOTT	250MG	N50662	001	Oct 31, 1991	May	CFTG
AB	+		500MG	N50662	002	Oct 31, 1991	May	CFTG
		CLARITHROMYCIN						
AB		ROXANE	250MG	N65178	002	May 25, 2004	May	NEWA
AB			500MG	N65178	001	May 25, 2004	May	NEWA

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE

AB	+	TEVA	2.68MG	N73283	001	Jan 31, 1992	Mar	CRLD
		TAVIST						
		@ NOVARTIS	2.68MG	N17661	001		Mar	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL

AB		COREPHARMA	EQ 150MG BASE	N65194	001	Mar 22, 2004	Mar	NEWA
AB			EQ 300MG BASE	N65194	002	Mar 22, 2004	Mar	NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN

	+	PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N62644	001	Apr 07, 1986	May	CRLD

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	HOSPIRA	EQ 150MG BASE/ML	N62800	001	Jul 24, 1987	May	CAHN
AP		EQ 150MG BASE/ML	N62801	001	Jul 24, 1987	May	CAHN
	@	EQ 150MG BASE/ML	N62943	001	Sep 29, 1988	May	CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	TARO PHARM INDS	EQ 1% BASE	N65184	001	Mar 31, 2004	Mar	NEWA

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL

CLOBEX

+	GALDERMA LABS	0.05%	N21644	001	Feb 05, 2004	Feb	NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

>D>	+ AAIPHARMA	0.1MG/ML	N20615	001	Oct 02, 1996	Jun	CRLD
>A>		0.1MG/ML	N20615	001	Oct 02, 1996	Jun	CRLD
>A>	+	0.5MG/ML	N20615	002	Apr 27, 1999	Jun	NEWA

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO

	ALAMO PHARMS	25MG	N21590	001	Feb 10, 2004	Feb	NEWA
+		100MG	N21590	002	Feb 10, 2004	Feb	NEWA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP	PADDOCK	EQ 150MG BASE/VIAL	N65177	001	Mar 19, 2004	Mar	NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

+	KING PHARMS	0.8MG/INH	N18887	001	Dec 05, 1985	Jan	CAHN

SOLUTION; INHALATION

INTAL

AN +	KING PHARMS	10MG/ML	N18596	001	May 28, 1982	Jan	CAHN

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.4MG COPPER/ML	N18960	001	Jun 26, 1986	May	CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP	BIONICHE ANIM HLTH	1MG/ML	N40451	001	Sep 23, 2003	Apr	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	AM PHARM	100MG/ML	N76512	001	Jan 15, 2004	Jan	NEWA

		INJECTABLE; INJECTION						
		CYTARABINE						
AP	+	MAYNE PHARMA USA	100MG/ML	N75383	001	Nov 22, 1999	Jan	CFTG
		DEFEROXAMINE MESYLATE						
		INJECTABLE; INJECTION						
		DEFEROXAMINE MESYLATE						
AP		ABBOTT	500MG/VIAL	N76019	001	Mar 17, 2004	Mar	NEWA
AP			2GM/VIAL	N76019	002	Mar 17, 2004	Mar	NEWA
AP		HOSPIRA	500MG/VIAL	N76019	001	Mar 17, 2004	May	CAHN
AP			2GM/VIAL	N76019	002	Mar 17, 2004	May	CAHN
		DESFERAL						
AP	+	NOVARTIS	500MG/VIAL	N16267	001		Mar	CFTG
AP	+		2GM/VIAL	N16267	002	May 25, 2000	Mar	CFTG
		DEMECLOCYCLINE HYDROCHLORIDE						
		TABLET; ORAL						
		DECLOMYCIN						
AB		ESP PHARMA	150MG	N50261	002		Mar	CFTG
AB	+		300MG	N50261	003		Mar	CFTG
		DEMECLOCYCLINE HCL						
AB		IMPAX LABS	150MG	N65094	001	Mar 22, 2004	Mar	NEWA
AB			300MG	N65094	002	Mar 22, 2004	Mar	NEWA
>D>		DESERPIDINE; METHYCLOTHIAZIDE						
>D>		TABLET; ORAL						
>D>		ENDURONYL						
>D>		ABBOTT	0.25MG;5MG	N12775	001		Jun	DISC
>A>		@	0.25MG;5MG	N12775	001		Jun	DISC
>D>		ENDURONYL FORTE						
>D>	+	ABBOTT	0.5MG;5MG	N12775	002		Jun	DISC
>A>		@	0.5MG;5MG	N12775	002		Jun	DISC
		DESIRUDIN						
		INJECTABLE; SUBCUTANEOUS						
		IPRIVASK						
	+	CANYON	15MG/VIAL	N21271	001	Apr 04, 2003	Apr	CAHN
		DESMOPRESSIN ACETATE						
		INJECTABLE; INJECTION						
		DESMOPRESSIN ACETATE						
AP		HOSPIRA	0.004MG/ML	N75220	001	Aug 28, 2000	May	CAHN
		DESOGESTREL; ETHINYL ESTRADIOL						
		TABLET; ORAL-28						
		CYCLESSA						
AB	+	ORGANON USA INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N21090	001	Dec 20, 2000	Feb	CFTG
		VELIVET						
AB		DURAMED PHARMS BARR	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N76455	001	Feb 24, 2004	Feb	NEWA
		DESOXIMETASONE						
		CREAM; TOPICAL						
		TOPICORT						
>D> AB	+	MEDICIS	0.25%	N17856	001		Jun	CAHN
>A> AB	+	TARO PHARMS NORTH	0.25%	N17856	001		Jun	CAHN

			CREAM; TOPICAL						
			TOPICORT LP						
>D>	AB	+	MEDICIS	0.05%	N18309	001		Jun	CAHN
>A>	AB	+	TARO PHARMS NORTH	0.05%	N18309	001		Jun	CAHN
			GEL; TOPICAL						
			TOPICORT						
>D>	AB	+	MEDICIS	0.05%	N18586	001	Mar 29, 1982	Jun	CAHN
>A>	AB	+	TARO PHARMS NORTH	0.05%	N18586	001	Mar 29, 1982	Jun	CAHN
			OINTMENT; TOPICAL						
			TOPICORT						
>D>			@ MEDICIS	0.05%	N18594	001	Jan 17, 1985	Jun	CAHN
>D>	AB	+		0.25%	N18763	001	Sep 30, 1983	Jun	CAHN
>A>			@ TARO PHARMS NORTH	0.05%	N18594	001	Jan 17, 1985	Jun	CAHN
>A>	AB	+		0.25%	N18763	001	Sep 30, 1983	Jun	CAHN
			DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
			SUSPENSION/DROPS; OPHTHALMIC						
			DEXACIDIN						
			@ NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544	001	Oct 29, 1984	Apr	DISC
			DEXMEDETOMIDINE						
			INJECTABLE; INJECTION						
			PRECEDEX						
		+	HOSPIRA	EQ 100UGM BASE/ML	N21038	001	Dec 17, 1999	May	CAHN
			DEXTROSE						
			INJECTABLE; INJECTION						
			DEXTROSE 10% IN PLASTIC CONTAINER						
	AP		HOSPIRA	10GM/100ML	N18080	001		May	CAHN
			DEXTROSE 2.5% IN PLASTIC CONTAINER						
			@ B BRAUN	2.5GM/100ML	N18358	001		May	DISC
			DEXTROSE 20% IN PLASTIC CONTAINER						
	AP		HOSPIRA	20GM/100ML	N18564	001	Mar 23, 1982	May	CAHN
			DEXTROSE 25%						
			HOSPIRA	250MG/ML	N19445	002	Nov 23, 1998	May	CAHN
			DEXTROSE 30% IN PLASTIC CONTAINER						
	AP		HOSPIRA	30GM/100ML	N19345	001	Jan 26, 1985	May	CAHN
			DEXTROSE 40% IN PLASTIC CONTAINER						
	AP		HOSPIRA	40GM/100ML	N18562	001	Mar 23, 1982	May	CAHN
			DEXTROSE 5% IN PLASTIC CONTAINER						
	AP		HOSPIRA	50MG/ML	N16367	002		May	CAHN
	AP			50MG/ML	N19222	001	Jul 13, 1984	May	CAHN
	AP			5GM/100ML	N19466	001	Jul 15, 1985	May	CAHN
	AP			5GM/100ML	N19479	001	Sep 17, 1985	May	CAHN
			DEXTROSE 50% IN PLASTIC CONTAINER						
			@ HOSPIRA	500MG/ML	N19445	001	Jun 03, 1986	May	CAHN
	AP			50GM/100ML	N18563	001	Mar 23, 1982	May	CAHN
	AP			50GM/100ML	N19894	001	Dec 26, 1989	May	CAHN
			DEXTROSE 60% IN PLASTIC CONTAINER						
	AP		HOSPIRA	60GM/100ML	N19346	001	Jan 25, 1985	May	CAHN
			DEXTROSE 70% IN PLASTIC CONTAINER						
	AP		HOSPIRA	70GM/100ML	N18561	001	Mar 23, 1982	May	CAHN
	AP			70GM/100ML	N19893	001	Dec 26, 1989	May	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610	001		May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19025	001	Dec 27, 1984	May	DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100 ML;16MG/100ML	N19515	001	May 08, 1986	May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML	N19513	001	May 08, 1986	May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;2 20MG/100ML;140MG/100ML	N18273	001		May	DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;2 22MG/100ML;526MG/100ML;502MG/100M L	N17609	001		May	CAHN

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;149MG/100ML	N18371	001		May	CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;224MG/100ML	N18371	003		May	CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;298MG/100ML	N18371	002		May	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML ;146MG/100ML;207MG/100ML	N19514	001	May 08, 1986	May	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML N18270 001 May DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100ML N18365 002 Jul 05, 1983 May CAHN

5GM/100ML;149MG/100ML;225MG/100ML N18365 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100ML N18876 001 Jan 17, 1986 May CAHN

5GM/100ML;149MG/100ML;300MG/100ML N18876 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100ML N18362 005 Mar 28, 1988 May CAHN

AP 5GM/100ML;74.5MG/100ML;450MG/100ML N18362 009 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;74.5MG/100ML;900MG/100ML N19691 002 Mar 24, 1988 May CAHN

AP 5GM/100ML;149MG/100ML;900MG/100ML N19691 004 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N18365 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100ML N19691 006 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;149MG/100ML;225MG/100ML N18365 001 May CAHN

5GM/100ML;298MG/100ML;225MG/100ML N18365 009 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N18876 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100ML N18362 010 Jul 05, 1983 May CAHN

AP 5GM/100ML;298MG/100ML;450MG/100ML N18362 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;149MG/100ML;900MG/100ML N19691 005 Mar 24, 1988 May CAHN

AP 5GM/100ML;298MG/100ML;900MG/100ML N19691 008 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;149MG/100ML;300MG/100ML N18876 002 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N18365 003 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 003 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 002 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100ML N19691 007 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;298MG/100ML;225MG/100ML N18365 004 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N18876 004 Mar 28, 1988 May CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N18362	003		May	CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N19691	009	Mar 24, 1988	May	CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

		HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N18365	005	Mar 28, 1988	May	CAHN
			5GM/100ML;149MG/100ML;225MG/100ML	N18365	007	Mar 28, 1988	May	CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N18876	005	Mar 28, 1988	May	CAHN
			5GM/100ML;149MG/100ML;300MG/100ML	N18876	009	Mar 28, 1988	May	CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N18362	008	Mar 28, 1988	May	CAHN
AP			5GM/100ML;149MG/100ML;450MG/100ML	N18362	004	Mar 28, 1988	May	CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N19691	001	Mar 24, 1988	May	CAHN
AP			5GM/100ML;149MG/100ML;900MG/100ML	N19691	003	Mar 24, 1988	May	CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		HOSPIRA	2.5GM/100ML;450MG/100ML	N18096	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

		HOSPIRA	5GM/100ML;225MG/100ML	N17606	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		HOSPIRA	5GM/100ML;300MG/100ML	N17799	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		HOSPIRA	5GM/100ML;450MG/100ML	N17607	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ABBOTT	5GM/100ML;900MG/100ML	N17585	001		May	CAHN

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPAQUE

	@	GE HEALTHCARE	30%	N16403	002		May	DISC

RENO-DIP

+		BRACCO	30%	N10040	012		May	CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAQUE-76

	@	GE HEALTHCARE	66%;10%	N86505	001		May	DISC

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP	+	HOSPIRA	5MG/ML	N71583	001	Oct 13, 1987	May	CAHN
AP			5MG/ML	N71584	001	Oct 13, 1987	May	CAHN
AP			5MG/ML	N72079	001	Dec 20, 1988	May	CAHN
AP		PARENTA PHARMS	5MG/ML	N76815	001	Apr 15, 2004	Apr	NEWA

DICLOFENAC POTASSIUM

TABLET; ORAL

		DICLOFENAC POTASSIUM					
AB		TORPHARM	50MG	N76561 001	Mar 18, 2004	Mar	NEWA

DICLOXACILLIN SODIUM

CAPSULE; ORAL

		DICLOXACILLIN SODIUM					
		SANDOZ	EQ 125MG BASE	N61454 002		Mar	CAHN
AB			EQ 250MG BASE	N61454 001		Mar	CAHN
AB	+		EQ 500MG BASE	N61454 003		Mar	CAHN

DIDANOSINE

FOR SOLUTION; ORAL

		VIDEX					
>D>		BRISTOL MYERS SQUIBB	10MG/ML	N20156 001	Oct 09, 1991	Jun	CRLD
>A>	+		10MG/ML	N20156 001	Oct 09, 1991	Jun	CRLD
>D>			100MG/PACKET	N20155 003	Oct 09, 1991	Jun	DISC
>A>		@	100MG/PACKET	N20155 003	Oct 09, 1991	Jun	DISC
>D>			167MG/PACKET	N20155 004	Oct 09, 1991	Jun	DISC
>A>		@	167MG/PACKET	N20155 004	Oct 09, 1991	Jun	DISC
>D>	+		250MG/PACKET	N20155 005	Oct 09, 1991	Jun	DISC
>A>		@	250MG/PACKET	N20155 005	Oct 09, 1991	Jun	DISC

DIGOXIN

INJECTABLE; INJECTION

		DIGOXIN					
AP		HOSPIRA	0.25MG/ML	N40093 001	May 16, 1996	May	CAHN
AP			0.25MG/ML	N40206 001	Aug 28, 1998	May	CAHN
		DIGOXIN PEDIATRIC					
AP		HOSPIRA	0.1MG/ML	N40092 001	Apr 25, 1996	May	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>D>		CARDIZEM SR					
>D>	AB1 +	AVENTIS PHARMS	60MG	N19471 001	Jan 23, 1989	Jun	DISC
>A>		@	60MG	N19471 001	Jan 23, 1989	Jun	DISC
>D>	AB1 +		90MG	N19471 002	Jan 23, 1989	Jun	DISC
>A>		@	90MG	N19471 002	Jan 23, 1989	Jun	DISC
>D>	AB1 +		120MG	N19471 003	Jan 23, 1989	Jun	DISC
>A>		@	120MG	N19471 003	Jan 23, 1989	Jun	DISC
		DILT-CD					
	AB3	TORPHARM	120MG	N76151 001	May 20, 2004	May	NEWA
	AB3		180MG	N76151 002	May 20, 2004	May	NEWA
	AB3		240MG	N76151 003	May 20, 2004	May	NEWA
	AB3		300MG	N76151 004	May 20, 2004	May	NEWA
		DILTIAZEM HCL					
>D>	AB1	BIOVAIL	60MG	N74845 001	Sep 15, 1999	Jun	DISC
>A>		@	60MG	N74845 001	Sep 15, 1999	Jun	DISC
>D>	AB1		90MG	N74845 002	Sep 15, 1999	Jun	DISC
>A>		@	90MG	N74845 002	Sep 15, 1999	Jun	DISC
>D>	AB1		120MG	N74845 003	Sep 15, 1999	Jun	DISC
>A>		@	120MG	N74845 003	Sep 15, 1999	Jun	DISC

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

>D>	AB1		MYLAN	60MG	N74910	001	May 02, 1997	Jun	CRLD
>A>		+		60MG	N74910	001	May 02, 1997	Jun	CRLD
>D>	AB1			90MG	N74910	002	May 02, 1997	Jun	CRLD
>A>		+		90MG	N74910	002	May 02, 1997	Jun	CRLD
>D>	AB1			120MG	N74910	003	May 02, 1997	Jun	CRLD
>A>		+		120MG	N74910	003	May 02, 1997	Jun	CRLD
>D>	AB1		TEVA	60MG	N74079	001	Nov 30, 1993	Jun	DISC
>A>		@		60MG	N74079	001	Nov 30, 1993	Jun	DISC
>D>	AB1			90MG	N74079	002	Nov 30, 1993	Jun	DISC
>A>		@		90MG	N74079	002	Nov 30, 1993	Jun	DISC
>D>	AB1			120MG	N74079	003	Nov 30, 1993	Jun	DISC
>A>		@		120MG	N74079	003	Nov 30, 1993	Jun	DISC

INJECTABLE; INJECTION

DILTIAZEM HCL

	AP		HOSPIRA	5MG/ML	N74941	001	Apr 15, 1998	May	CAHN
	AP			5MG/ML	N75004	001	Feb 16, 2000	May	CAHN
	AP			100MG/VIAL	N75853	001	Dec 17, 2002	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

			BIOVAIL	120MG	N21392	001	Feb 06, 2003	Jan	CRLD
				180MG	N21392	002	Feb 06, 2003	Jan	CRLD
				240MG	N21392	003	Feb 06, 2003	Jan	CRLD
				300MG	N21392	004	Feb 06, 2003	Jan	CRLD
				360MG	N21392	005	Feb 06, 2003	Jan	CRLD

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

>A>									
>A>	AP		AM PHARM	50MG/ML	N40519	001	Jun 23, 2004	Jun	NEWA
>D>		+	STERIS	50MG/ML	N80615	001		Jun	CFTG
>A>	AP	+		50MG/ML	N80615	001		Jun	CFTG

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

		+	IMCOR PH	0.92MG/VIAL;0.092MG/VIAL	N21191	001	May 31, 2002	Feb	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

	AP		HOSPIRA	50MG/ML	N40140	001	Nov 20, 1998	May	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

	AP		HOSPIRA	5MG/ML	N74601	001	Dec 19, 1997	May	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

>A>			@ ODYSSEY PHARMS	250MG	N07883	003		Jun	CAHN
>A>			@	500MG	N07883	002		Jun	CAHN
>D>			@ PLIVA	250MG	N07883	003		Jun	CAHN
>D>			@	500MG	N07883	002		Jun	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

		ABBOTT	EQ 125MG VALPROIC ACID	N18723	003	Oct 26, 1984	Jan	CRLD
			EQ 250MG VALPROIC ACID	N18723	001	Mar 10, 1983	Jan	CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP		HOSPIRA	EQ 12.5MG BASE/ML	N74086	001	Nov 29, 1993	May	CAHN
AP			EQ 12.5MG BASE/ML	N74292	001	Feb 16, 1995	May	CAHN
AP			EQ 1.25GM BASE/100ML	N74634	001	Sep 27, 1996	May	CAHN

DOBUTAMINE HCL IN DEXTROSE 5%

AP	+	HOSPIRA	EQ 50MG BASE/100ML	N20269	001	Oct 19, 1993	May	CAHN
AP	+		EQ 100MG BASE/100ML	N20269	002	Oct 19, 1993	May	CAHN
AP	+		EQ 200MG BASE/100ML	N20269	003	Oct 19, 1993	May	CAHN

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	EQ 50MG BASE/100ML	N20201	003	Oct 19, 1993	May	CAHN
AP	+		EQ 100MG BASE/100ML	N20201	002	Oct 19, 1993	May	CAHN
AP	+		EQ 200MG BASE/100ML	N20201	001	Oct 19, 1993	May	CAHN
AP	+		EQ 400MG BASE/100ML	N20201	006	Jul 07, 1994	May	CAHN

DOBUTREX

>D>								
>D> AP	+	LILLY	EQ 12.5MG BASE/ML	N17820	002		Jun	DISC
>A>		@	EQ 12.5MG BASE/ML	N17820	002		Jun	DISC

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP	+	HOSPIRA	40MG/ML	N18132	001		May	CAHN
AP			40MG/ML	N74403	001	May 23, 1996	May	CAHN
AP	+		80MG/100ML	N18132	002	Feb 04, 1982	May	CAHN
AP	+		80MG/ML	N18132	004	Jul 09, 1982	May	CAHN
AP	+		160MG/100ML	N18132	003	Feb 04, 1982	May	CAHN

DOPAMINE HCL IN DEXTROSE 5%

>D>								
>D> AP	+	HOSPIRA	1.6MG/ML	N20542	001	Aug 30, 1995	Jun	DISC
>A>		@	1.6MG/ML	N20542	001	Aug 30, 1995	Jun	DISC
AP	+		1.6MG/ML	N20542	001	Aug 30, 1995	May	CAHN

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	80MG/100ML	N18826	001	Sep 30, 1983	May	CAHN
AP	+		160MG/100ML	N18826	002	Sep 30, 1983	May	CAHN
AP	+		320MG/100ML	N18826	003	Sep 30, 1983	May	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>A> AB		CLONMEL HLTHCARE	EQ 1MG BASE	N76161	001	Jun 10, 2004	Jun	NEWA
>A> AB			EQ 2MG BASE	N76161	002	Jun 10, 2004	Jun	NEWA
>A> AB			EQ 4MG BASE	N76161	003	Jun 10, 2004	Jun	NEWA
>A> AB			EQ 8MG BASE	N76161	004	Jun 10, 2004	Jun	NEWA

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIN HCL

AA		PHARM ASSOC	EQ 10MG BASE/ML	N75924	001	Jan 15, 2004	Jan	NEWA

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

		BONE CARE	0.5UGM	N20862	002	Apr 23, 2004	Apr	NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

>D>								
>D>	AP	+ PHARMACIA AND UPJOHN	10MG/VIAL	N50467	001		Jun	DISC
>A>		@	10MG/VIAL	N50467	001		Jun	DISC
>D>	AP	+	20MG/VIAL	N50467	003	May 20, 1985	Jun	DISC
>A>		@	20MG/VIAL	N50467	003	May 20, 1985	Jun	DISC
>D>	AP	+	50MG/VIAL	N50467	002		Jun	DISC
>A>		@	50MG/VIAL	N50467	002		Jun	DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

	AB	WATSON LABS	EQ 50MG BASE	N65041	001	Apr 28, 2000	Apr	CAHN
	AB		EQ 100MG BASE	N65041	002	Apr 28, 2000	Apr	CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

	AB	WATSON LABS	EQ 50MG BASE	N61717	001		Apr	CAHN
	AB		EQ 100MG BASE	N61717	002		Apr	CAHN

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

	AP	HOSPIRA	2.5MG/ML	N71981	001	Feb 29, 1988	May	CAHN
	AP		2.5MG/ML	N72272	001	Aug 31, 1995	May	CAHN

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

		+ HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	N71982	001	May 04, 1988	May	CAHN

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

>A>	AB	CLAY PARK	1%	N76479	001	Jun 23, 2004	Jun	NEWA

EDETATE DISODIUM

INJECTABLE; INJECTION

ENDRATE

	AP	+ HOSPIRA	150MG/ML	N11355	001		May	CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

	AP	HOSPIRA	10MG/ML	N40131	001	Feb 24, 1998	May	CAHN

EFAVIRENZ

TABLET; ORAL
SUSTIVA

>D>		BRISTOL MYERS SQUIBB	300MG	N21360	001	Feb 01, 2002	Jun	DISC
>A>		@	300MG	N21360	001	Feb 01, 2002	Jun	DISC

ENALAPRILAT

INJECTABLE; INJECTION
ENALAPRILAT

	AP	HOSPIRA	1.25MG/ML	N75456	001	Aug 22, 2000	May	CAHN
	AP		1.25MG/ML	N75458	001	Aug 22, 2000	May	CAHN

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

	+	HOLLISTER STIER LABS	EQ 0.15MG /DELIVERY	N20800	002	May 28, 2004	May	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

	AP	HOSPIRA	0.005MG/ML;0.5%	N89635	001	Jun 21, 1988	May	CAHN
	AP		0.005MG/ML;1%	N89649	001	Jun 21, 1988	May	CAHN
	AP		0.005MG/ML;1.5%	N88571	001	Sep 13, 1985	May	CAHN
	AP		0.005MG/ML;1.5%	N89645	001	Jun 21, 1988	May	CAHN
	AP		0.005MG/ML;1.5%	N89650	001	Jun 21, 1988	May	CAHN
	AP		0.005MG/ML;2%	N89651	001	Jun 21, 1988	May	CAHN
	AP		0.01MG/ML;1%	N89644	001	Jun 21, 1988	May	CAHN
	AP		0.01MG/ML;2%	N89646	001	Jun 21, 1988	May	CAHN

PATCH; IONTOPHORESIS
LIDOSITE TOPICAL SYSTEM KIT

	+	VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504	001	May 06, 2004	May	NEWA

SOLUTION; IONTOPHORESIS
IONTOCAINE

	+	IOMED	0.01MG/ML;2%	N20530	001	Dec 21, 1995	May	MAGC

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

	AB	WARNER CHILCOTT	250MG	N62338	001		Jan	CMFD

SOLUTION; TOPICAL
C-SOLVE-2

>D>								
>D>	AT	BIOGLAN PHARMA	2%	N62468	001	Jul 03, 1985	Jun	DISC
>A>		@	2%	N62468	001	Jul 03, 1985	Jun	DISC

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE

		ALPHARMA	EQ 125MG BASE/5ML	N62353	001	Nov 18, 1982	Jan	CTEC
	+		EQ 250MG BASE/5ML	N62409	001	Dec 16, 1982	Jan	CRLD
		ILOSONE						
		@ LILLY	EQ 125MG BASE/5ML	N50010	001		Jan	DISC
		@	EQ 250MG BASE/5ML	N50010	002		Jan	DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

AP	+ HOSPIRA	EQ 500MG BASE/VIAL	N50182	002		May	CAHN
AP		EQ 500MG BASE/VIAL	N50609	001	Sep 24, 1986	May	CAHN
AP		EQ 500MG BASE/VIAL	N62638	001	Oct 31, 1986	May	CAHN
AP	+	EQ 1GM BASE/VIAL	N50182	003		May	CAHN
AP		EQ 1GM BASE/VIAL	N50609	002	Sep 24, 1986	May	CAHN
AP		EQ 1GM BASE/VIAL	N62638	002	Oct 31, 1986	May	CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

LEXAPRO

	FOREST LABS	5MG	N21323	001	Aug 14, 2002	Apr	CMFD

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

MENOSTAR

>A>	+ BERLEX LABS	0.014MG/24HR	N21674	001	Jun 08, 2004	Jun	NEWA

GEL, METERED; TOPICAL

ESTROGEL

	SOLVAY	0.06%	N21166	002	Feb 09, 2004	Feb	NEWA

GEL; TOPICAL

ESTROGEL

	SOLVAY	0.06%	N21166	001	Feb 09, 2004	Feb	NEWA
	+	0.06%	N21166	001	Feb 09, 2004	Mar	CRLD

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

	GALEN LTD	EQ 0.05MG BASE/24HR	N21367	001	Mar 20, 2003	May	CPOT
	+	EQ 0.1MG BASE/24HR	N21367	002	Mar 20, 2003	May	CPOT

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

	@ WYETH PHARMS INC	2.5MG	N04782	002		May	DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

	DURAMED	0.45MG	N20992	005	Feb 05, 2004	Feb	NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

	DURAMED	0.625MG	N21443	003	May 10, 2004	May	NEWA
	+	1.25MG	N21443	004	May 10, 2004	May	NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

	@ ELAN PHARMS	100MG	N16320	001		Feb	CAHN
	@	200MG	N16320	002		Feb	CAHN
	@	400MG	N16320	003		Feb	CAHN

TABLET; ORAL

MYAMBUTOL

	@	ELAN PHARMS	500MG	N16320	004	Feb	CAHN
AB		STAT TRADE	100MG	N16320	001	May	CMFD
	@		200MG	N16320	002	May	CAHN
AB			400MG	N16320	003	May	CMFD
	@		500MG	N16320	004	May	CAHN

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

	@	SCHERING	0.02MG	N05292	001	Apr	DISC
	@		0.05MG	N05292	002	Apr	DISC
	@		0.5MG	N05292	003	Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

PREVEN EMERGENCY CONTRACEPTIVE KIT

	+	DURAMED	0.05MG;0.25MG	N20946	001	Sep 01, 1998	Feb	CAHN

TABLET; ORAL-21

LEVLITE

AB2	+	BERLEX	0.02MG;0.1MG	N20860	001	Jul 13, 1998	May	CTEC

TABLET; ORAL-28

LESSINA-28

AB2		BARR	0.02MG;0.1MG	N75803	002	Mar 20, 2002	May	CTEC

LEVLITE

AB2		BERLEX	0.02MG;0.1MG	N20860	002	Jul 13, 1998	May	CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

AB		BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004	Apr	NEWA

OVCON-35

AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N18127	001		Apr	CFTG

TABLET; ORAL-28

BALZIVA-28

AB		BARR	0.035MG;0.4MG	N76238	001	Apr 22, 2004	Apr	NEWA

ORTHO-NOVUM 1/35-28

AB	+	ORTHO MCNEIL PHARM	0.035MG;1MG	N17919	002		Mar	CRLD

OVCON-35

AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Apr	CFTG

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

>D>	+	JOHNSON AND JOHNSON	0.025MG,0.025MG,0.25MG;0.18MG,0.25MG,0.215MG	N21241	001	Aug 22, 2002	Jun	CAHN
>A>	+	ORTHO MCNEIL PHARM	0.025MG,0.025MG,0.25MG;0.18MG,0.25MG,0.215MG	N21241	001	Aug 22, 2002	Jun	CAHN

PREVIFEM

AB		ANDRX PHARMS	0.035MG;0.25MG	N76334	001	Jan 09, 2004	Jan	NEWA

TRI-PREVIFEM

AB		ANDRX PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335	001	Mar 26, 2004	Mar	NEWA

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

>D>	+	MGI PHARMA INC	50MG/ML	N19545	001	Apr 20, 1987	Jun	DISC
>D>	@		50MG/ML	N19545	001	Apr 20, 1987	Jun	DISC

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

AB		WYETH PHARMS INC	400MG	N20584	001	Oct 25, 1996	May	CRLD
AB			500MG	N20584	003	Jan 20, 1998	May	CRLD

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

AP	+	HOSPIRA	2MG/ML	N18227	001	Sep 07, 1982	May	CAHN

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP		HOSPIRA	20MG/ML	N74320	001	Aug 30, 1995	May	CAHN
AP			20MG/ML	N74351	001	Aug 30, 1995	May	CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP		HOSPIRA	10MG/ML	N75870	001	Nov 23, 2001	May	CAHN
AP			10MG/ML	N75905	001	Nov 23, 2001	May	CAHN

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

AP	+	HOSPIRA	EQ 10MG BASE/ML	N19922	001	Sep 23, 1997	May	CAHN

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP		HOSPIRA	EQ 0.05MG BASE/ML	N19115	001	Jan 12, 1985	May	CAHN

FENTANYL CITRATE PRESERVATIVE FREE

AP		HOSPIRA	EQ 0.05MG BASE/ML	N72786	001	Sep 24, 1991	May	CAHN

TROCHE/LOZENGE; ORAL

ACTIQ

		CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Feb	CAHN
			EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Feb	CAHN
			EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Feb	CAHN
			EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Feb	CAHN
			EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Feb	CAHN
	+		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Feb	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

	+	GENSIA SICOR PHARMS	50MG/2ML (25MG/ML)	N76661	001	Apr 28, 2004	Apr	NEWA

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

			FLUDEOXYGLUCOSE F 18						
			@ DOWNSTATE CLINCL	4-90mCi/ML	N20306	002	Sep 25, 2001	May	DISC

FLUNISOLIDE

SPRAY, METERED; NASAL

			FLUNISOLIDE						
>D>	AB		BAUSCH AND LOMB	0.025MG/SPRAY	N74805	001	Feb 20, 2002	Jun	CRLD
>A>		+		0.025MG/SPRAY	N74805	001	Feb 20, 2002	Jun	CRLD
			NASALIDE						
>D>	AB	+	IVAX RES	0.025MG/SPRAY	N18148	001		Jun	DISC
>A>			@	0.025MG/SPRAY	N18148	001		Jun	DISC

FLUOCINONIDE

CREAM; TOPICAL

			FLUOCINONIDE EMULSIFIED BASE						
>A>	AB2		ALTANA	0.05%	N76586	001	Jun 23, 2004	Jun	NEWA

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

			FLUOXETINE HCL						
	AA		PAR PHARM	EQ 20MG BASE/5ML	N76458	001	May 14, 2004	May	NEWA

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

			FLUPHENAZINE DECANOATE						
			@ MAYNE PHARMA USA	25MG/ML	N74966	001	Apr 16, 1998	Apr	CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

>D>			PERMITIL						
>D>	AA	+	SCHERING	5MG/ML	N16008	001		Jun	DISC
>A>			@	5MG/ML	N16008	001		Jun	DISC

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

			FLOVENT HFA						
			GLAXOSMITHKLINE	0.044MG/INH	N21433	003	May 14, 2004	May	NEWA
				0.11MG/INH	N21433	002	May 14, 2004	May	NEWA
		+		0.22MG/INH	N21433	001	May 14, 2004	May	NEWA

CREAM; TOPICAL

			CUTIVATE						
	AB	+	GLAXOSMITHKLINE	0.05%	N19958	001	Dec 18, 1990	May	CFTG
			FLUTICASONE PROPIONATE						
	AB		ALTANA	0.05%	N76451	001	May 14, 2004	May	NEWA
	AB		ATRIX	0.05%	N76633	001	May 14, 2004	May	NEWA
	AB		CLAY PARK	0.05%	N76793	001	May 14, 2004	May	NEWA

OINTMENT; TOPICAL

			CUTIVATE						
	AB	+	GLAXOSMITHKLINE	0.005%	N19957	001	Dec 14, 1990	May	CFTG
			FLUTICASONE PROPIONATE						
	AB		ALTANA	0.005%	N76300	001	May 14, 2004	May	NEWA
	AB		CLAY PARK	0.005%	N76668	001	May 14, 2004	May	NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC

FOLLISTIM

>D>	BX	ORGANON USA INC	75 IU/VIAL	N20582	001	Sep 29, 1997	Jun	CTEC
>A>	+		75 IU/VIAL	N20582	001	Sep 29, 1997	Jun	CTEC
	BX		75 IU/VIAL	N20582	001	Sep 29, 1997	Mar	CDFR
>D>	BX		150 IU/VIAL	N20582	002	Sep 29, 1997	Jun	CTEC
>A>	+		150 IU/VIAL	N20582	002	Sep 29, 1997	Jun	CTEC
	BX		150 IU/VIAL	N20582	002	Sep 29, 1997	Mar	CDFR

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

		ORGANON USA INC	300 IU/0.525ML	N21211	001	Mar 23, 2004	Mar	NEWA
	+		600 IU/0.885ML	N21211	002	Mar 23, 2004	Mar	NEWA

GONAL-F

		SERONO INC	37.5 IU/VIAL	N21765	001	Mar 25, 2004	Mar	NEWA
	@		37.5 IU/VIAL	N21765	001	Mar 25, 2004	May	DISC
>D>	BX		75 IU/VIAL	N20378	001	Sep 29, 1997	Jun	DISC
>A>	@		75 IU/VIAL	N20378	001	Sep 29, 1997	Jun	DISC
	BX		75 IU/VIAL	N20378	001	Sep 29, 1997	Mar	CDFR
>D>			75 IU/VIAL	N21765	002	Mar 25, 2004	Jun	CRLD
>A>	+		75 IU/VIAL	N21765	002	Mar 25, 2004	Jun	CRLD
			75 IU/VIAL	N21765	002	Mar 25, 2004	Mar	NEWA
>D>	BX		150 IU/VIAL	N20378	002	Sep 29, 1997	Jun	DISC
>A>	@		150 IU/VIAL	N20378	002	Sep 29, 1997	Jun	DISC
	BX		150 IU/VIAL	N20378	002	Sep 29, 1997	Mar	CDFR
	+		150 IU/VIAL	N21765	003	Mar 25, 2004	Mar	NEWA
	@		150 IU/VIAL	N21765	003	Mar 25, 2004	May	DISC
			450 IU/VIAL	N20378	005	Mar 26, 2004	Mar	NEWA
	+		1,200 IU/VIAL	N20378	004	Feb 28, 2001	Mar	CAIN
	+		1,050 IU/VIAL	N20378	004	Feb 28, 2001	Apr	CPOT

GONAL-F RFF PEN

		SERONO INC	300 IU/0.5ML	N21684	001	May 25, 2004	May	NEWA
			450 IU/0.75ML	N21684	002	May 25, 2004	May	NEWA
	+		900 IU/1.5ML	N21684	003	May 25, 2004	May	NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

	+	NOVARTIS	6.6MG/ML	N20961	001	Aug 26, 1998	Jan	CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

	+	FONDA BV	5MG/0.4ML	N21345	002	May 28, 2004	May	NEWA
	+		7.5MG/0.6ML	N21345	003	May 28, 2004	May	NEWA
	+		10MG/0.8ML	N21345	004	May 28, 2004	May	NEWA

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB		EON	10MG	N76483	001	Apr 23, 2004	Apr	NEWA
AB			20MG	N76483	002	Apr 23, 2004	Apr	NEWA
AB			40MG	N76483	003	Apr 23, 2004	Apr	NEWA
AB		RANBAXY	10MG	N76580	001	Apr 23, 2004	Apr	NEWA
AB			20MG	N76580	002	Apr 23, 2004	Apr	NEWA

TABLET; ORAL
FOSINOPRIL SODIUM

AB	RANBAXY	40MG	N76580	003	Apr 23, 2004	Apr	NEWA

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVA

+	VERNALIS	EQ 2.5MG BASE	N21006	001	Nov 08, 2001	May	CAHN

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP	HOSPIRA	10MG/ML	N18667	001	May 28, 1982	May	CAHN
AP		10MG/ML	N70578	001	Jul 08, 1987	May	CAHN
AP		10MG/ML	N72080	001	Aug 13, 1991	May	CAHN
AP		10MG/ML	N74337	001	Oct 31, 1994	May	CAHN
AP		10MG/ML	N75241	001	May 28, 1999	May	CAHN

TABLET; ORAL
FUROSEMIDE

AB	VINTAGE PHARMS	20MG	N76796	001	Mar 26, 2004	Mar	NEWA
AB		40MG	N76796	002	Mar 26, 2004	Mar	NEWA
AB		80MG	N76796	003	Mar 26, 2004	Mar	NEWA

GABAPENTIN

TABLET; ORAL
GABAPENTIN

	IVAX PHARMS	100MG	N76017	001	Apr 28, 2004	Apr	NEWA
		300MG	N76017	002	Apr 28, 2004	Apr	NEWA
		400MG	N76017	003	Apr 28, 2004	Apr	NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON

>D>							
>D>	+ ORGANON USA INC	EQ 250UGM BASE/0.5ML	N21057	001	Jul 29, 1999	Jun	CTNA
>A>	GANIRELIX ACETATE INJECTION						
>A>	+ ORGANON USA INC	EQ 250UGM BASE/0.5ML	N21057	001	Jul 29, 1999	Jun	CTNA

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE

+	OSCIENT	EQ 320MG BASE	N21158	001	Apr 04, 2003	Apr	CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	HOSPIRA	EQ 10MG BASE/ML	N62420	001	Aug 15, 1983	May	CAHN
AP		EQ 10MG BASE/ML	N62612	004	Feb 20, 1986	May	CAHN
AP		EQ 40MG BASE/ML	N62420	002	Aug 15, 1983	May	CAHN
	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	HOSPIRA	EQ 1.2MG BASE/ML	N62414	001	Aug 15, 1983	May	CAHN
	@	EQ 1.2MG BASE/ML	N62588	001	Jan 06, 1986	May	CAHN
AP		EQ 1.4MG BASE/ML	N62414	002	Aug 15, 1983	May	CAHN
	@	EQ 1.4MG BASE/ML	N62588	002	Jan 06, 1986	May	CAHN
AP		EQ 1.6MG BASE/ML	N62414	003	Aug 15, 1983	May	CAHN
	@	EQ 1.6MG BASE/ML	N62588	003	Jan 06, 1986	May	CAHN
AP		EQ 1.8MG BASE/ML	N62414	004	Aug 15, 1983	May	CAHN

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ HOSPIRA	EQ 1.8MG BASE/ML	N62588	004	Jan 06, 1986	May	CAHN
AP		EQ 2MG BASE/ML	N62414	005	Aug 15, 1983	May	CAHN
	@	EQ 2MG BASE/ML	N62588	005	Jan 06, 1986	May	CAHN
AP		EQ 60MG BASE/100ML	N62414	006	Aug 15, 1983	May	CAHN
	@	EQ 60MG BASE/100ML	N62588	006	Jan 06, 1986	May	CAHN
AP		EQ 70MG BASE/100ML	N62414	007	Aug 15, 1983	May	CAHN
	@	EQ 70MG BASE/100ML	N62588	007	Jan 06, 1986	May	CAHN
AP		EQ 80MG BASE/100ML	N62414	008	Aug 15, 1983	May	CAHN
	@	EQ 80MG BASE/100ML	N62588	008	Jan 06, 1986	May	CAHN
AP		EQ 90MG BASE/100ML	N62414	009	Aug 15, 1983	May	CAHN
	@	EQ 90MG BASE/100ML	N62588	009	Jan 06, 1986	May	CAHN
AP		EQ 100MG BASE/100ML	N62414	010	Aug 15, 1983	May	CAHN
	@	EQ 100MG BASE/100ML	N62588	010	Jan 06, 1986	May	CAHN

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50039	002		Jan	CDFR

GENTAMICIN SULFATE

AT	ALTANA	EQ 3% BASE	N65121	001	Jan 30, 2004	Jan	NEWA

>A> GLUTAMINE

>A> FOR SOLUTION; ORAL

>A> NUTRESTORE

>A>	+ NUTRITIONAL RESTART	5GM/PACKET	N21677	001	Jun 10, 2004	Jun	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

AB	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178	001	Jul 31, 2000	Feb	CFTG
AB		2.5MG;500MG	N21178	002	Jul 31, 2000	Feb	CFTG
AB	+	5MG;500MG	N21178	003	Jul 31, 2000	Feb	CFTG

GLYBURIDE AND METFORMIN HCL

AB	IVAX PHARMS	1.25MG;250MG	N76345	001	Feb 18, 2004	Feb	NEWA
AB		2.5MG;500MG	N76345	002	Feb 18, 2004	Feb	NEWA
AB		5MG;500MG	N76345	003	Feb 18, 2004	Feb	NEWA

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	HOSPIRA	1.5GM/100ML	N17633	001		May	CAHN
AT		1.5GM/100ML	N18315	001		May	CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

	@ HOSPIRA	0.2MG/ML	N89393	001	Jun 15, 1988	May	CAHN

>D> GONADORELIN HYDROCHLORIDE

>D> INJECTABLE; INJECTION

>D> FACTREL

>D>	+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123	001	Sep 30, 1982	Jun	DISC
>A>	@	EQ 0.1MG BASE/VIAL	N18123	001	Sep 30, 1982	Jun	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

>D>			FULVICIN P/G						
>D>	AB		SCHERING	125MG	N61996 001			Jun	DISC
>A>			@	125MG	N61996 001			Jun	DISC
>D>	AB	+		250MG	N61996 002			Jun	DISC
>A>			@	250MG	N61996 002			Jun	DISC
>D>			FULVICIN P/G 165						
>D>	AB		SCHERING	165MG	N61996 003	Apr 06, 1982		Jun	DISC
>A>			@	165MG	N61996 003	Apr 06, 1982		Jun	DISC
>D>			FULVICIN P/G 330						
>D>	AB	+	SCHERING	330MG	N61996 004	Apr 06, 1982		Jun	DISC
>A>			@	330MG	N61996 004	Apr 06, 1982		Jun	DISC
			GRIS-PEG						
>D>	AB		PEDINOL	250MG	N50475 002			Jun	CRLD
>A>		+		250MG	N50475 002			Jun	CRLD

HALAZEPAM

TABLET; ORAL

			PAXIPAM						
			@ SCHERING	20MG	N17736 003			Apr	DISC
			@	40MG	N17736 004			Apr	DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

			HALOPERIDOL DECANOATE						
			@ MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176 001	Feb 09, 2000		Apr	CAHN
			@	EQ 100MG BASE/ML	N75176 002	Feb 09, 2000		Apr	CAHN

HALOTHANE

LIQUID; INHALATION

			HALOTHANE						
	AN	+	HOSPIRA	99.99%	N83254 001			May	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

			HEPARIN LOCK FLUSH						
	AP		HOSPIRA	10 UNITS/ML	N05264 001			May	CAHN
	AP			10 UNITS/ML	N40082 001	Feb 28, 1995		May	CAHN
	AP			10 UNITS/ML	N88097 001	Apr 28, 1983		May	CAHN
	AP			10 UNITS/ML	N88346 001	May 18, 1983		May	CAHN
			@	100 UNITS/ML	N05264 010			May	CAHN
	AP			100 UNITS/ML	N40082 002	Feb 28, 1995		May	CAHN
	AP			100 UNITS/ML	N88098 001	Apr 28, 1983		May	CAHN
	AP			100 UNITS/ML	N88347 001	May 18, 1983		May	CAHN
			HEPARIN LOCK FLUSH IN PLASTIC CONTAINER						
	AP		HOSPIRA	10 UNITS/ML	N05264 015	May 21, 1985		May	CAHN
	AP			100 UNITS/ML	N05264 016	May 21, 1985		May	CAHN
			HEPARIN SODIUM						
	AP	+	HOSPIRA	2,500 UNITS/ML	N88099 001	Apr 28, 1983		May	CAHN
	AP			5,000 UNITS/ML	N88100 001	Apr 28, 1983		May	CAHN
			@	10,000 UNITS/ML	N40095 001	Jul 26, 1996		May	CAHN
>D>	AP		LILLY	10,000 UNITS/ML	N05521 002			Jun	DISC
>A>			@	10,000 UNITS/ML	N05521 002			Jun	DISC

INJECTABLE; INJECTION

	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	HOSPIRA	200 UNITS/100ML	N18916	010	Jun 23, 1989	May	CAHN	
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%							
	@ HOSPIRA	10,000 UNITS/100ML	N18911	006	Jan 30, 1985	May	CAHN	
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	HOSPIRA	10,000 UNITS/100ML	N19339	003	Mar 27, 1985	May	CAHN	
	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%							
	@ HOSPIRA	10,000 UNITS/100ML	N18911	001	Jan 30, 1985	May	CAHN	
	@	10,000 UNITS/100ML	N18916	005	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%							
	@ HOSPIRA	10,000 UNITS/100ML	N18911	003	Jan 30, 1985	May	CAHN	
	@	10,000 UNITS/100ML	N18916	002	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%							
	@ HOSPIRA	5,000 UNITS/100ML	N18911	007	Jan 30, 1985	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER							
	HOSPIRA	5,000 UNITS/100ML	N19339	001	Mar 27, 1985	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
	HOSPIRA	5,000 UNITS/100ML	N18916	006	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%							
	@ HOSPIRA	5,000 UNITS/100ML	N18911	005	Jan 30, 1985	May	CAHN	
	@	5,000 UNITS/100ML	N18916	003	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	HOSPIRA	200 UNITS/100ML	N18916	011	Jun 23, 1989	May	CAHN	
	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	HOSPIRA	4,000 UNITS/100ML	N19805	001	Jan 25, 1989	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%							
	@ HOSPIRA	5,000 UNITS/100ML	N18911	009	Jan 30, 1985	May	CAHN	
	@	10,000 UNITS/100ML	N18911	008	Jan 30, 1985	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	HOSPIRA	5,000 UNITS/100ML	N19339	004	Mar 27, 1985	May	CAHN	
AP		5,000 UNITS/100ML	N19805	002	Jan 25, 1989	May	CAHN	
AP		10,000 UNITS/100ML	N19339	002	Mar 27, 1985	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
	HOSPIRA	5,000 UNITS/100ML	N18916	007	Jan 31, 1984	May	CAHN	
		10,000 UNITS/100ML	N18916	008	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%							
	@ HOSPIRA	5,000 UNITS/100ML	N18911	004	Jan 30, 1985	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@ HOSPIRA	5,000 UNITS/100ML	N18916	009	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%							
	@ HOSPIRA	100 UNITS/ML	N18911	002	Jan 30, 1985	May	CAHN	
	@	100 UNITS/ML	N18916	004	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%							
	@ HOSPIRA	1,000 UNITS/100ML	N18916	001	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM PRESERVATIVE FREE							
+	HOSPIRA	2,000 UNITS/ML	N05264	013	Apr 07, 1986	May	CAHN	
AP +		2,500 UNITS/ML	N05264	014	Apr 07, 1986	May	CAHN	
AP +		10,000 UNITS/ML	N89522	001	May 04, 1987	May	CAHN	
	PANHEPRIN							
	@ HOSPIRA	1,000 UNITS/ML	N05264	004		May	CAHN	
	@	5,000 UNITS/ML	N05264	006		May	CAHN	
	@	10,000 UNITS/ML	N05264	007		May	CAHN	
	@	20,000 UNITS/ML	N05264	008		May	CAHN	
	@	40,000 UNITS/ML	N05264	009		May	CAHN	

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

+	ISTA PHARMS	6,200 UNITS/VIAL	N21640	001	May 05, 2004	May	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

AB	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125	001	Dec 28, 1999	Mar	CFTG
AB		12.5MG;EQ 20MG BASE	N20125	002	Dec 28, 1999	Mar	CFTG
AB	+	25MG;EQ 20MG BASE	N20125	003	Dec 28, 1999	Mar	CFTG

QUINARETIC

AB	AMIDE PHARM	12.5MG;EQ 10MG BASE	N76374	001	Mar 31, 2004	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	N76374	002	Mar 31, 2004	Mar	NEWA
AB		25MG;EQ 20MG BASE	N76374	003	Mar 31, 2004	Mar	NEWA

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;80MG	N21162	002	Nov 17, 2000	May	CRLD
+		25MG;80MG	N21162	003	Apr 19, 2004	May	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

+	INTERPHARM	5MG;200MG	N76642	002	Mar 18, 2004	Mar	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	VINTAGE PHARMS	2.5%	N40503	001	Mar 12, 2004	Mar	NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

BX	BOCA PHARMA	1%;1%	N89440	001	May 17, 1988	Apr	CAHN

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT	TARO PHARM INDS	0.1%	N76364	001	Jan 14, 2004	Jan	NEWA

LOCOID

AT	+ FERNDALE LABS	0.1%	N19116	001	Feb 25, 1987	Jan	CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N85929	001		May	CAHN
AP		EQ 250MG BASE/VIAL	N85930	001		May	CAHN
AP		EQ 500MG BASE/VIAL	N85931	001		May	CAHN
AP		EQ 1GM BASE/VIAL	N85932	001		May	CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP		HOSPIRA	10MG/ML	N74598	001	Jun 19, 1997 May	CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP		HOSPIRA	25MG/ML	N87416	001	May	CAHN
	@		50MG/ML	N86821	001	May	CAHN
AP			50MG/ML	N87546	001	May	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HCL

	+	GENSIA SICOR PHARMS	5MG/VIAL	N65037	003	May 01, 2002 Feb	CTEC

INAMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

AP	+	HOSPIRA	EQ 5MG BASE/ML	N74616	001	Aug 03, 1998 May	CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS
NOVOLOG

	+	NOVO NORDISK	100 UNITS/ML	N20986	001	Jun 07, 2000 May	CAIN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION
LANTUS

	+	AVENTIS PHARMS	100 UNITS/ML	N21081	001	Apr 20, 2000 May	CAIN

>D> INSULIN GLULISINE RECOMBINANT

>D> INJECTABLE; SUBCUTANEOUS
>D> APIDRA

>D>	+	AVENTIS PHARMS	100 UNITS/ML	N21629	001	Apr 16, 2004 Jun	DISC
>D>	@		100 UNITS/ML	N21629	001	Apr 16, 2004 Jun	DISC
>A>	+		100 UNITS/ML	N21629	001	Apr 16, 2004 Apr	NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION
HUMALOG MIX 50/50

	+	LILLY	50 UNITS/ML;50 UNITS/ML	N21018	001	Dec 22, 1999 May	CAIN

HUMALOG MIX 75/25

	+	LILLY	75 UNITS/ML;25 UNITS/ML	N21017	001	Dec 22, 1999 May	CAIN

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION
HUMALOG

	+	LILLY	100 UNITS/ML	N20563	001	Jun 14, 1996 May	CAIN

HUMALOG PEN

	+	LILLY	100 UNITS/ML	N20563	002	Aug 06, 1998 May	CAIN

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

>D>		@ GE HEALTHCARE	55%	N20808	001	Aug 29, 1997	Jun	CMFD
>A>			55%	N20808	001	Aug 29, 1997	Jun	CMFD

VISIPAQUE 320

>D>		@ GE HEALTHCARE	65.2%	N20808	002	Aug 29, 1997	Jun	CMFD
>A>			65.2%	N20808	002	Aug 29, 1997	Jun	CMFD

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

	AP	HOSPIRA	41%	N74898	001	Dec 30, 1997	May	CAHN

IOPAMIDOL-200 IN PLASTIC CONTAINER

	AP	HOSPIRA	41%	N74636	001	Dec 30, 1997	May	CAHN

IOPAMIDOL-250

	AP	HOSPIRA	51%	N74898	002	Dec 30, 1997	May	CAHN
	AP		51%	N75005	001	Feb 24, 1998	May	CAHN

IOPAMIDOL-250 IN PLASTIC CONTAINER

	AP	HOSPIRA	51%	N74636	002	Dec 30, 1997	May	CAHN

IOPAMIDOL-300

	AP	HOSPIRA	61%	N74898	003	Dec 30, 1997	May	CAHN
	AP		61%	N75005	002	Feb 24, 1998	May	CAHN

IOPAMIDOL-300 IN PLASTIC CONTAINER

	AP	HOSPIRA	61%	N74636	003	Dec 30, 1997	May	CAHN
	AP		61%	N74637	001	Apr 03, 1997	May	CAHN

IOPAMIDOL-370

	AP	HOSPIRA	76%	N74898	004	Dec 30, 1997	May	CAHN
	AP		76%	N75005	003	Feb 24, 1998	May	CAHN

IOPAMIDOL-370 IN PLASTIC CONTAINER

	AP	HOSPIRA	76%	N74636	004	Dec 30, 1997	May	CAHN

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

		@ GE HEALTHCARE	500MG	N08032	001		May	DISC

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

	+	BERLEX	49.9%	N21425	003	Mar 12, 2004	Mar	NEWA
	+		62.3%	N21425	001	Sep 20, 2002	Mar	CPOT
	+		76.9%	N21425	002	Sep 20, 2002	Mar	CPOT

>D> IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

>D> INJECTABLE; INJECTION

>D> VASCORAY

>D>	+	MALLINCKRODT	52%;26%	N16783	001		Jun	DISC
>A>		@	52%;26%	N16783	001		Jun	DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

	AN	HOLOPACK INTL	0.02%	N75693	001	Jan 26, 2001	Apr	CAHN

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

AN		HOSPIRA	99.9%	N74097	001	Jan 25, 1993 May	CAHN

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

	+	SANDOZ	100MG/ML	N08662	001	Feb	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

		HOSPIRA	0.02MG/ML	N83283	001	May	CAHN
AP			0.2MG/ML	N83346	001	May	CAHN

ISUPREL

AP	+	HOSPIRA	0.2MG/ML	N10515	001	May	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

AB		SCHERING PLOUGH	30MG	N20225	001	Aug 12, 1993 Apr	CRLD
AB			60MG	N20225	002	Aug 12, 1993 Apr	CRLD

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB		EON	100MG	N76104	001	May 28, 2004 May	NEWA

SPORANOX

AB	+	JANSSEN PHARMA	100MG	N20083	001	Sep 11, 1992 May	CFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

AP		HOSPIRA	EQ 50MG BASE/ML	N74549	001	Jun 27, 1996 May	CAHN
AP			EQ 100MG BASE/ML	N74549	002	Jun 27, 1996 May	CAHN

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB		ALTANA	2%	N76294	001	Apr 28, 2004 Apr	NEWA
AB	+	TEVA	2%	N75581	001	Apr 25, 2000 Apr	CRLD

NIZORAL

	@	JANSSEN PHARMA	2%	N19084	001	Dec 31, 1985 Apr	DISC

SHAMPOO; TOPICAL

KETOCONAZOLE

AB		CLAY PARK	2%	N76419	001	Jan 07, 2004 Jan	NEWA

NIZORAL

AB	+	MCNEIL CONS SPECLT	2%	N19927	001	Aug 31, 1990 Jan	CFTG

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	+	BEDFORD	15MG/ML	N75222	001	Apr 26, 1999 Jan	CRLD
AP	+		30MG/ML	N75222	002	Apr 26, 1999 Jan	CRLD

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	@ HOSPIRA	15MG/ML	N74801	001	Jun 05, 1997	May	CAHN
		15MG/ML	N74802	001	Jun 05, 1997	May	CAHN
AP		15MG/ML	N74993	001	Jan 27, 1999	May	CAHN
AP		30MG/ML	N74801	002	Jun 05, 1997	May	CAHN
	@	30MG/ML	N74802	002	Jun 05, 1997	May	CAHN
AP		30MG/ML	N74993	002	Jan 27, 1999	May	CAHN

TORADOL

	@ ROCHE PALO	15MG/ML	N19698	001	Nov 30, 1989	Jan	DISC
	@	30MG/ML	N19698	002	Nov 30, 1989	Jan	DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+	NOVARTIS	EQ 0.025% BASE	N21066	001	Jul 02, 1999	Feb	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

AP	HOSPIRA	5MG/ML	N75239	001	Nov 29, 1999	May	CAHN
AP		5MG/ML	N75240	001	Nov 29, 1999	May	CAHN

LAMIVUDINE

TABLET; ORAL

EPIVIR

	GLAXOSMITHKLINE	150MG	N20564	001	Nov 17, 1995	May	CRLD
+		300MG	N20564	003	Jun 24, 2002	May	CRLD

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

+	GLAXOSMITHKLINE	25MG	N20241	005	Dec 27, 1994	Apr	CRLD
		200MG	N20241	003	Dec 27, 1994	Apr	CRLD

LANSOPRAZOLE

INJECTABLE; INTRAVENOUS

PREVACID IV

+	TAP PHARM	30MG/VIAL	N21566	001	May 27, 2004	May	NEWA

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP +	HOSPIRA	EQ 10MG BASE/ML	N40147	001	Jun 25, 1997	May	CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

	@ PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N20997	001	Aug 05, 1999	May	DISC
	@	EQ 5MG BASE/ML	N20997	002	Aug 05, 1999	May	DISC
	@	EQ 7.5MG BASE/ML	N20997	003	Aug 05, 1999	May	DISC

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

+	NOVARTIS	EQ 0.05% BASE	N20219	001	Nov 10, 1993	Feb	CAHN

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

		IQUIX						
+		SANTEN	1.5%	N21571	001	Mar 01, 2004	Mar	NEWA

LEVONORGESTREL

TABLET; ORAL

		PLAN B						
+		DURAMED	0.75MG	N21045	001	Jul 28, 1999	Feb	CAHN

LEVOTHYROXINE SODIUM*

TABLET; ORAL

		LEVO-T						
>D>	BX	ALARA PHARM	0.025MG	N21342	001	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.025MG	N21342	001	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.05MG	N21342	002	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.05MG	N21342	002	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.075MG	N21342	003	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.075MG	N21342	003	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.088MG	N21342	004	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.088MG	N21342	004	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.1MG	N21342	005	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.1MG	N21342	005	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.112MG	N21342	006	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.112MG	N21342	006	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.125MG	N21342	007	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.125MG	N21342	007	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.137MG	N21342	012	Dec 08, 2003	Jun	CTEC
>A>	AB2,		0.137MG	N21342	012	Dec 08, 2003	Jun	CTEC
>A>	AB3							
>D>	BX		0.15MG	N21342	008	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.15MG	N21342	008	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.175MG	N21342	009	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.175MG	N21342	009	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX		0.2MG	N21342	010	Mar 01, 2002	Jun	CTEC
>A>	AB2,		0.2MG	N21342	010	Mar 01, 2002	Jun	CTEC
>A>	AB3							
>D>	BX	+	0.3MG	N21342	011	Mar 01, 2002	Jun	CTEC
>A>	AB2,	+	0.3MG	N21342	011	Mar 01, 2002	Jun	CTEC
>A>	AB3							
		LEVOTHYROXINE SODIUM						
>D>	AB	MYLAN	0.025MG	N76187	001	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.025MG	N76187	001	Jun 05, 2002	Jun	CTEC
>A>	AB2,							
>A>	AB3							
>D>	AB		0.05MG	N76187	002	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.05MG	N76187	002	Jun 05, 2002	Jun	CTEC
>A>	AB2,							
>A>	AB3							
>D>	AB		0.075MG	N76187	003	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.075MG	N76187	003	Jun 05, 2002	Jun	CTEC
>A>	AB2,							
>A>	AB3							
>D>	AB		0.088MG	N76187	004	Jun 05, 2002	Jun	CTEC

* SEE PREFACE SECTION 1.4 LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOTHYROXINE SODIUM

>A>	AB1,	MYLAN	0.088MG	N76187 004	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						
>D>	AB		0.1MG	N76187 005	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.1MG	N76187 005	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						
>D>	AB		0.112MG	N76187 006	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.112MG	N76187 006	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						
>D>	AB		0.125MG	N76187 007	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.125MG	N76187 007	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						
>D>	AB		0.15MG	N76187 008	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.15MG	N76187 008	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						
>D>	AB		0.175MG	N76187 009	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.175MG	N76187 009	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						
>D>	AB		0.2MG	N76187 010	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.2MG	N76187 010	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						
>D>	AB		0.3MG	N76187 011	Jun 05, 2002	Jun	CTEC
>A>	AB1,		0.3MG	N76187 011	Jun 05, 2002	Jun	CTEC
>A>	AB2,						
>A>	AB3						

LEVOXYL

>D>	BX	JONES PHARMA	0.025MG	N21301 001	May 25, 2001	Jun	CTEC
>A>	AB1,		0.025MG	N21301 001	May 25, 2001	Jun	CTEC
	AB3						
>D>	BX		0.05MG	N21301 002	May 25, 2001	Jun	CTEC
>A>	AB1,		0.05MG	N21301 002	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.075MG	N21301 003	May 25, 2001	Jun	CTEC
>A>	AB1,		0.075MG	N21301 003	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.088MG	N21301 004	May 25, 2001	Jun	CTEC
>A>	AB1,		0.088MG	N21301 004	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.1MG	N21301 005	May 25, 2001	Jun	CTEC
>A>	AB1,		0.1MG	N21301 005	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.112MG	N21301 006	May 25, 2001	Jun	CTEC
>A>	AB1,		0.112MG	N21301 006	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.125MG	N21301 007	May 25, 2001	Jun	CTEC
>A>	AB1,		0.125MG	N21301 007	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.137MG	N21301 008	May 25, 2001	Jun	CTEC
>A>	AB1,		0.137MG	N21301 008	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.15MG	N21301 009	May 25, 2001	Jun	CTEC
>A>	AB1,		0.15MG	N21301 009	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.175MG	N21301 010	May 25, 2001	Jun	CTEC
>A>	AB1,		0.175MG	N21301 010	May 25, 2001	Jun	CTEC
>A>	AB3						
>D>	BX		0.2MG	N21301 011	May 25, 2001	Jun	CTEC
>A>	AB1,		0.2MG	N21301 011	May 25, 2001	Jun	CTEC
>A>	AB3						

TABLET; ORAL

LEVOXYL

>D>	BX	+	JONES PHARMA	0.3MG	N21301	012	May 25, 2001	Jun CTEC
>A>	AB1,	+		0.3MG	N21301	012	May 25, 2001	Jun CTEC
>A>	AB3							

SYNTHROID

>D>	BX		ABBOTT	0.025MG	N21402	001	Jul 24, 2002	Jun CFTG
>A>	AB2			0.025MG	N21402	001	Jul 24, 2002	Jun CFTG
>D>	BX			0.05MG	N21402	002	Jul 24, 2002	Jun CFTG
>A>	AB2			0.05MG	N21402	002	Jul 24, 2002	Jun CFTG
>D>	BX			0.075MG	N21402	003	Jul 24, 2002	Jun CFTG
>A>	AB2			0.075MG	N21402	003	Jul 24, 2002	Jun CFTG
>D>	BX			0.088MG	N21402	004	Jul 24, 2002	Jun CFTG
>A>	AB2			0.088MG	N21402	004	Jul 24, 2002	Jun CFTG
>D>	BX			0.1MG	N21402	005	Jul 24, 2002	Jun CFTG
>A>	AB2			0.1MG	N21402	005	Jul 24, 2002	Jun CFTG
>D>	BX			0.112MG	N21402	006	Jul 24, 2002	Jun CFTG
>A>	AB2			0.112MG	N21402	006	Jul 24, 2002	Jun CFTG
>D>	BX			0.125MG	N21402	007	Jul 24, 2002	Jun CFTG
>A>	AB2			0.125MG	N21402	007	Jul 24, 2002	Jun CFTG
>D>	BX			0.137MG	N21402	008	Jul 24, 2002	Jun CFTG
>A>	AB2			0.137MG	N21402	008	Jul 24, 2002	Jun CFTG
>D>	BX			0.15MG	N21402	009	Jul 24, 2002	Jun CFTG
>A>	AB2			0.15MG	N21402	009	Jul 24, 2002	Jun CFTG
>D>	BX			0.175MG	N21402	010	Jul 24, 2002	Jun CFTG
>A>	AB2			0.175MG	N21402	010	Jul 24, 2002	Jun CFTG
>D>	BX			0.2MG	N21402	012	Jul 24, 2002	Jun CFTG
>A>	AB2			0.2MG	N21402	012	Jul 24, 2002	Jun CFTG
>D>	BX	+		0.3MG	N21402	011	Jul 24, 2002	Jun CFTG
>A>	AB2	+		0.3MG	N21402	011	Jul 24, 2002	Jun CFTG

UNITHROID

>D>	AB		STEVENS J	0.025MG	N21210	001	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.025MG	N21210	001	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.05MG	N21210	002	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.05MG	N21210	002	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.075MG	N21210	003	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.075MG	N21210	003	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.088MG	N21210	004	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.088MG	N21210	004	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.1MG	N21210	005	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.1MG	N21210	005	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.112MG	N21210	006	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.112MG	N21210	006	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.125MG	N21210	007	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.125MG	N21210	007	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.15MG	N21210	008	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.15MG	N21210	008	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.175MG	N21210	009	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.175MG	N21210	009	Aug 21, 2000	Jun CTEC
>A>	AB3							
>D>	AB			0.2MG	N21210	010	Aug 21, 2000	Jun CTEC
>A>	AB1,			0.2MG	N21210	010	Aug 21, 2000	Jun CTEC
>A>	AB3							

TABLET; ORAL
UNITHROID

>D>	AB	+	STEVENS J	0.3MG	N21210 011	Aug 21, 2000	Jun	CTEC
>A>	AB1,	+		0.3MG	N21210 011	Aug 21, 2000	Jun	CTEC
>A>	AB3							

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

AP	HOSPIRA	0.5%	N88328 001	May 17, 1984	May	CAHN	
AP		1%	N40013 001	Jun 23, 1995	May	CAHN	
AP		1%	N83158 001		May	CAHN	
AP		1%	N88329 001	May 17, 1984	May	CAHN	
	@	1.5%	N88330 001	May 17, 1984	May	CAHN	
AP		2%	N40078 001	Jun 23, 1995	May	CAHN	
AP		2%	N83158 002		May	CAHN	
AP		2%	N88294 001	May 17, 1984	May	CAHN	
AP		2%	N88331 001	May 17, 1984	May	CAHN	
AP		20%	N83158 003		May	CAHN	

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	200MG/100ML	N18967 001	Mar 30, 1984	Apr	DISC	

LIDOCAINE HCL 0.2% IN DEXTROSE 5%

AP	HOSPIRA	200MG/100ML	N83158 005		May	CAHN	

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	200MG/100ML	N18388 001		May	CAHN	

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	400MG/100ML	N18967 002	Mar 30, 1984	Apr	DISC	

LIDOCAINE HCL 0.4% IN DEXTROSE 5%

AP	HOSPIRA	400MG/100ML	N83158 006		May	CAHN	

LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	400MG/100ML	N18388 002		May	CAHN	

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	800MG/100ML	N18967 003	Mar 30, 1984	Apr	DISC	

LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	800MG/100ML	N18388 003	Nov 05, 1982	May	CAHN	

LIDOCAINE HCL IN PLASTIC CONTAINER

AP	HOSPIRA	0.5%	N88325 001	Jul 31, 1984	May	CAHN	
AP		1%	N88299 001	Jul 31, 1984	May	CAHN	
AP		1.5%	N88326 001	Jul 31, 1984	May	CAHN	
AP		2%	N88327 001	Jul 31, 1984	May	CAHN	
AP		10%	N88367 001	Jul 31, 1984	May	CAHN	
AP		20%	N88368 001	Jul 31, 1984	May	CAHN	

LIDOCAINE HCL PRESERVATIVE FREE

AP	HOSPIRA	1%	N80408 001		May	CAHN	
AP		1.5%	N80408 002		May	CAHN	
AP		4%	N88295 001	May 17, 1984	May	CAHN	

LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	HOSPIRA	1%	N40302 001	Sep 28, 1998	May	CAHN	
AP		2%	N40302 002	Sep 28, 1998	May	CAHN	

INJECTABLE; SPINAL
LIDOCAINE HCL 5% AND DEXTROSE 7.5%

+	HOSPIRA	5%	N83914 001		May	CAHN	

SOLUTION; TOPICAL
LTA II KIT

AT	HOSPIRA	4%	N80409 001		May	CAHN	
AT		4%	N88542 001	Jul 31, 1984	May	CAHN	

SOLUTION; TOPICAL
PEDIATRIC LTA KIT

	AT	HOSPIRA	2%	N85995	001		May	CAHN

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION
TERRAMYCIN

	+	PFIZER	2%;50MG/ML	N60567	001		Feb	CRLD
	+		2%;125MG/ML	N60567	002		Feb	CRLD

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

>A>	AB	ABLE	150MG	N76823	001	Jun 29, 2004	Jun	NEWA
>A>	AB		300MG	N76823	002	Jun 29, 2004	Jun	NEWA
>A>	AB		600MG	N76823	003	Jun 29, 2004	Jun	NEWA
>D>		+ ROXANE	600MG	N17812	003	Jan 28, 1987	Jun	CFTG
>A>	AB	+	600MG	N17812	003	Jan 28, 1987	Jun	CFTG

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

	AB	ROXANE	450MG	N76691	001	Jan 05, 2004	Jan	NEWA

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

	AP	HOSPIRA	2MG/ML	N74243	001	Apr 12, 1994	May	CAHN
	AP		2MG/ML	N74280	001	May 27, 1994	May	CAHN
	AP		2MG/ML	N74282	001	May 27, 1994	May	CAHN
	AP		2MG/ML	N74300	001	Apr 12, 1994	May	CAHN
	AP		4MG/ML	N74243	002	Apr 12, 1994	May	CAHN
	AP		4MG/ML	N74280	002	May 27, 1994	May	CAHN
	AP		4MG/ML	N74282	002	May 27, 1994	May	CAHN
	AP		4MG/ML	N74300	003	Mar 19, 1997	May	CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
ADVICOR

	+	KOS	20MG;500MG	N21249	001	Dec 17, 2001	Feb	CRLD
	+		20MG;750MG	N21249	002	Dec 17, 2001	Feb	CRLD

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
NORMOSOL-R IN PLASTIC CONTAINER

		HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586	001		May	CAHN

SOLUTION; IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER

		@ HOSPIRA	14MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406	001		May	CAHN
			30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17637	002	Jul 08, 1982	May	CAHN

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

		HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406	002	Jul 08, 1982	May	CAHN

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP	HOSPIRA	500MG/ML	N75151	001	Apr 25, 2000	May	CAHN

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA	1GM/100ML	N20488	001	Jul 11, 1995	May	CAHN
+		2GM/100ML	N20488	002	Jul 11, 1995	May	CAHN

MAGNESIUM SULFATE IN PLASTIC CONTAINER

+	HOSPIRA	80MG/ML	N20309	002	Jun 24, 1994	May	CAHN
+		4GM/100ML	N20309	001	Jun 24, 1994	May	CAHN

MALATHION

LOTION; TOPICAL

OVIDE

>D> +	MEDICIS	0.5%	N18613	001	Aug 02, 1982	Jun	CAHN
>A> +	TARO PHARMS NORTH	0.5%	N18613	001	Aug 02, 1982	Jun	CAHN

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	EQ 0.1MG MANGANESE/ML	N18962	001	Jun 26, 1986	May	CAHN

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

@	HOSPIRA	10GM/100ML	N16269	002		May	CAHN

MANNITOL 10% IN PLASTIC CONTAINER

AP	HOSPIRA	10GM/100ML	N19603	002	Jan 08, 1987	May	CAHN

MANNITOL 15%

@	HOSPIRA	15GM/100ML	N16269	003		May	CAHN

MANNITOL 15% IN PLASTIC CONTAINER

AP	HOSPIRA	15GM/100ML	N19603	003	Jan 08, 1990	May	CAHN

MANNITOL 20%

@	HOSPIRA	20GM/100ML	N16269	004		May	CAHN

MANNITOL 20% IN PLASTIC CONTAINER

AP	HOSPIRA	20GM/100ML	N19603	004	Jan 08, 1990	May	CAHN

MANNITOL 25%

@	HOSPIRA	12.5GM/50ML	N16269	005		May	CAHN
AP		12.5GM/50ML	N16269	006	Aug 25, 1994	May	CAHN

MANNITOL 5%

@	HOSPIRA	5GM/100ML	N16269	001		May	CAHN

MANNITOL 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML	N19603	001	Jan 08, 1987	May	CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

@	HOSPIRA	540MG/100ML;2.7GM/100ML	N80224	001		May	CAHN

SORBITOL-MANNITOL IN PLASTIC CONTAINER

AT	HOSPIRA	540MG/100ML;2.7GM/100ML	N17636	001		May	CAHN
AT		540MG/100ML;2.7GM/100ML	N18316	001		May	CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

>D> AB	NOVARTIS	25MG	N17543	001		Jun	DISC

TABLET; ORAL
LUDIOMIL

>A>		@ NOVARTIS	25MG	N17543 001			Jun	DISC
>D>	AB	+	50MG	N17543 002			Jun	DISC
>A>		@	50MG	N17543 002			Jun	DISC
>D>	AB		75MG	N17543 003	Sep 30, 1982		Jun	DISC
>A>		@	75MG	N17543 003	Sep 30, 1982		Jun	DISC

MAPROTILINE HCL

>D>	AB	MYLAN	50MG	N72285 001	Oct 03, 1988		Jun	CRLD
>A>	AB	+	50MG	N72285 001	Oct 03, 1988		Jun	CRLD

MELOXICAM

SUSPENSION; ORAL
MOBIC

>A>		+ BOEHRINGER INGELHEIM	7.5MG/5ML	N21530 001	Jun 01, 2004		Jun	NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
PERGONAL

		@ SERONO	75 IU/AMP;75 IU/AMP	N17646 001			May	DISC

REPRONEX

		+ FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	Aug 27, 1999		May	CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL

AP	+	HOSPIRA	25MG/ML	N21171 001			May	CAHN
AP	+		50MG/ML	N21171 002			May	CAHN
AP	+		75MG/ML	N21171 003			May	CAHN
AP	+		100MG/ML	N21171 004			May	CAHN

MEPERIDINE HCL PRESERVATIVE FREE

AP	+	HOSPIRA	10MG/ML	N88432 001	Aug 16, 1984		May	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CARBOCAINE

AP	+	HOSPIRA	1%	N12250 001			May	CAHN
AP	+		1.5%	N12250 005			May	CAHN
AP	+		2%	N12250 002			May	CAHN

MERCAPTOPURINE

TABLET; ORAL
MERCAPTOPURINE

AB		PROMETHEUS LABS	50MG	N40461 001	Feb 11, 2004		Feb	NEWA
AB		ROXANE	50MG	N40528 001	Feb 13, 2004		Feb	NEWA

PURINETHOL

AB	+	TEVA	50MG	N09053 002			Feb	CFTG

MESNA

INJECTABLE; INTRAVENOUS
MESNA

AP		BEDFORD	100MG/ML	N75739 001	Jan 09, 2004		Jan	NEWA

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP		HOSPIRA	500MG/ML	N75151	001	Apr 25, 2000	May	CAHN

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	HOSPIRA	1GM/100ML	N20488	001	Jul 11, 1995	May	CAHN
	+		2GM/100ML	N20488	002	Jul 11, 1995	May	CAHN

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	+	HOSPIRA	80MG/ML	N20309	002	Jun 24, 1994	May	CAHN
	+		4GM/100ML	N20309	001	Jun 24, 1994	May	CAHN

MALATHION

LOTION; TOPICAL

OVIDE

>D>	+	MEDICIS	0.5%	N18613	001	Aug 02, 1982	Jun	CAHN
>A>	+	TARO PHARMS NORTH	0.5%	N18613	001	Aug 02, 1982	Jun	CAHN

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

		HOSPIRA	EQ 0.1MG MANGANESE/ML	N18962	001	Jun 26, 1986	May	CAHN

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

		@ HOSPIRA	10GM/100ML	N16269	002		May	CAHN

MANNITOL 10% IN PLASTIC CONTAINER

AP		HOSPIRA	10GM/100ML	N19603	002	Jan 08, 1987	May	CAHN

MANNITOL 15%

		@ HOSPIRA	15GM/100ML	N16269	003		May	CAHN

MANNITOL 15% IN PLASTIC CONTAINER

AP		HOSPIRA	15GM/100ML	N19603	003	Jan 08, 1990	May	CAHN

MANNITOL 20%

		@ HOSPIRA	20GM/100ML	N16269	004		May	CAHN

MANNITOL 20% IN PLASTIC CONTAINER

AP		HOSPIRA	20GM/100ML	N19603	004	Jan 08, 1990	May	CAHN

MANNITOL 25%

		@ HOSPIRA	12.5GM/50ML	N16269	005		May	CAHN
AP			12.5GM/50ML	N16269	006	Aug 25, 1994	May	CAHN

MANNITOL 5%

		@ HOSPIRA	5GM/100ML	N16269	001		May	CAHN

MANNITOL 5% IN PLASTIC CONTAINER

AP		HOSPIRA	5GM/100ML	N19603	001	Jan 08, 1987	May	CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

		@ HOSPIRA	540MG/100ML;2.7GM/100ML	N80224	001		May	CAHN

SORBITOL-MANNITOL IN PLASTIC CONTAINER

AT		HOSPIRA	540MG/100ML;2.7GM/100ML	N17636	001		May	CAHN
AT			540MG/100ML;2.7GM/100ML	N18316	001		May	CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

>D>	AB	NOVARTIS	25MG	N17543	001		Jun	DISC

			TABLET; ORAL						
			LUDIOMIL						
>A>			@ NOVARTIS	25MG	N17543	001		Jun	DISC
>D>	AB	+		50MG	N17543	002		Jun	DISC
>A>			@	50MG	N17543	002		Jun	DISC
>D>	AB			75MG	N17543	003	Sep 30, 1982	Jun	DISC
>A>			@	75MG	N17543	003	Sep 30, 1982	Jun	DISC
			MAPROTILINE HCL						
>D>	AB		MYLAN	50MG	N72285	001	Oct 03, 1988	Jun	CRLD
>A>	AB	+		50MG	N72285	001	Oct 03, 1988	Jun	CRLD
			MELOXICAM						
>A>			SUSPENSION; ORAL						
>A>			MOBIC						
>A>		+	BOEHRINGER INGELHEIM	7.5MG/5ML	N21530	001	Jun 01, 2004	Jun	NEWA
			MENOTROPINS (FSH;LH)						
			INJECTABLE; INJECTION						
			PERGONAL						
			@ SERONO	75 IU/AMP;75 IU/AMP	N17646	001		May	DISC
			REPRONEX						
		+	FERRING	75 IU/VIAL;75 IU/VIAL	N21047	001	Aug 27, 1999	May	CTEC
			MEPERIDINE HYDROCHLORIDE						
			INJECTABLE; INJECTION						
			DEMEROL						
	AP	+	HOSPIRA	25MG/ML	N21171	001		May	CAHN
	AP	+		50MG/ML	N21171	002		May	CAHN
	AP	+		75MG/ML	N21171	003		May	CAHN
	AP	+		100MG/ML	N21171	004		May	CAHN
			MEPERIDINE HCL PRESERVATIVE FREE						
	AP	+	HOSPIRA	10MG/ML	N88432	001	Aug 16, 1984	May	CAHN
			MEPIVACAINE HYDROCHLORIDE						
			INJECTABLE; INJECTION						
			CARBOCAINE						
	AP	+	HOSPIRA	1%	N12250	001		May	CAHN
	AP	+		1.5%	N12250	005		May	CAHN
	AP	+		2%	N12250	002		May	CAHN
			MERCAPTOPURINE						
			TABLET; ORAL						
			MERCAPTOPURINE						
	AB		PROMETHEUS LABS	50MG	N40461	001	Feb 11, 2004	Feb	NEWA
	AB		ROXANE	50MG	N40528	001	Feb 13, 2004	Feb	NEWA
			PURINETHOL						
	AB	+	TEVA	50MG	N09053	002		Feb	CFTG
			MESNA						
			INJECTABLE; INTRAVENOUS						
			MESNA						
	AP		BEDFORD	100MG/ML	N75739	001	Jan 09, 2004	Jan	NEWA

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

		SERENTIL					
		@ NOVARTIS	EQ 25MG BASE/ML	N16997	001		May DISC

TABLET; ORAL

		SERENTIL					
		@ NOVARTIS	EQ 25MG BASE	N16774	002		May DISC
		@	EQ 100MG BASE	N16774	004		May DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		FORTAMET					
	BX	ANDRX	500MG	N21574	001	Apr 27, 2004 Apr	NEWA
	+		1GM	N21574	002	Apr 27, 2004 Apr	NEWA
		GLUCOPHAGE XR					
	AB	BRISTOL MYERS SQUIBB	500MG	N21202	001	Oct 13, 2000 Jan	CFTG
		METFORMIN HCL					
>A>	AB	ANDRX PHARMS	500MG	N76172	001	Jun 16, 2004 Jun	NEWA
	AB	IVAX PHARMS	500MG	N76545	001	Dec 01, 2003 Jan	NEWA
>A>	AB	RANBAXY	500MG	N76413	001	Jun 18, 2004 Jun	NEWA
>A>	AB	TEVA	500MG	N76269	001	Jun 18, 2004 Jun	NEWA

METHADONE HYDROCHLORIDE

TABLET; ORAL

		METHADONE HCL					
	AA	MALLINCKRODT	5MG	N40517	001	Apr 27, 2004 Apr	NEWA
	AA		10MG	N40517	002	Apr 27, 2004 Apr	NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

		DESOXYN					
	AB +	OVATION PHARMS	5MG	N05378	002		Feb CFTG
		METHAMPHETAMINE HCL					
	AB	ABLE	5MG	N40529	001	Feb 25, 2004 Feb	NEWA

METHIMAZOLE

TABLET; ORAL

		TAPAZOLE					
	AB	KING PHARMS	5MG	N07517	002		Mar CAHN
	AB		10MG	N07517	004		Mar CAHN

METHYLDOPA

TABLET; ORAL

		METHYLDOPA					
>A>		@ ACCORD HEALTH	125MG	N70070	003	Oct 15, 1985 Jun	CAHN
>A>	AB		250MG	N70084	001	Oct 15, 1985 Jun	CAHN
>A>	AB		500MG	N70085	001	Oct 15, 1985 Jun	CAHN
>D>		@ CLONMEL HLTHCARE	125MG	N70070	003	Oct 15, 1985 Jun	CAHN
>D>	AB		250MG	N70084	001	Oct 15, 1985 Jun	CAHN
>D>	AB		500MG	N70085	001	Oct 15, 1985 Jun	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

		METHYLDOPATE HCL					
	AP	HOSPIRA	50MG/ML	N70698	001	Jun 15, 1987 May	CAHN

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	HOSPIRA	50MG/ML	N70699	001	Jun 15, 1987	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

BX	CELLTECH PHARMS	10MG	N21259	003	May 27, 2003	May	CTEC

RITALIN LA

	NOVARTIS	10MG	N21284	004	Apr 10, 2004	Apr	NEWA
BX		10MG	N21284	004	Apr 10, 2004	May	CTEC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853	001		May	CAHN
AP		EQ 125MG BASE/VIAL	N85855	001		May	CAHN
AP		EQ 500MG BASE/VIAL	N85854	001		May	CAHN
AP		EQ 500MG BASE/VIAL	N89173	001	Aug 18, 1987	May	CAHN
AP		EQ 1GM BASE/VIAL	N85852	001		May	CAHN
AP		EQ 1GM BASE/VIAL	N89174	001	Aug 18, 1987	May	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	HOSPIRA	EQ 5MG BASE/ML	N70505	001	Jun 23, 1989	May	CAHN
	@	EQ 5MG BASE/ML	N70506	001	Jun 22, 1989	May	CAHN
AP		EQ 5MG BASE/ML	N73117	001	Jan 17, 1991	May	CAHN
AP		EQ 5MG BASE/ML	N73118	001	Jan 17, 1991	May	CAHN
AP		EQ 5MG BASE/ML	N74147	001	Aug 02, 1996	May	CAHN

METOLAZONE

TABLET; ORAL
METOLAZONE

AB	ROXANE	10MG	N76482	002	Apr 29, 2004	Apr	NEWA
AB	TEVA	2.5MG	N76600	001	Jan 06, 2004	Jan	NEWA
AB		5MG	N76833	001	Mar 01, 2004	Mar	NEWA

MYKROX

	@ CELLTECH PHARMS	0.5MG	N19532	001	Oct 30, 1987	Jan	DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP	HOSPIRA	1MG/ML	N74133	001	Dec 21, 1993	May	CAHN
AP		1MG/ML	N75160	001	Jul 06, 1998	May	CAHN

TABLET; ORAL
LOPRESSOR

AB	NOVARTIS	100MG	N17963	002		Mar	CRLD

METOPROLOL TARTRATE

AB	CARACO	25MG	N76670	001	Jan 15, 2004	Mar	CTEC
		25MG	N76670	001	Jan 15, 2004	Jan	NEWA
	+ MYLAN	25MG	N76704	001	Jan 16, 2004	Jan	NEWA
AB		25MG	N76704	001	Jan 16, 2004	Mar	CTEC
AB		50MG	N76704	002	Jan 16, 2004	Jan	NEWA
AB	+	100MG	N76704	003	Jan 16, 2004	Mar	CRLD
AB		100MG	N76704	003	Jan 16, 2004	Jan	NEWA

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

AB		KALI LABS	375MG	N76522	001	Jan 29, 2004	Jan NEWA

CREAM; TOPICAL

METROCREAM

AB	+	GALDERMA LABS LP	0.75%	N20531	001	Sep 20, 1995	May CFTG

METRONIDAZOLE

AB		ALTANA	0.75%	N76408	001	May 28, 2004	May NEWA

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	+	HOSPIRA	500MG/100ML	N18890	002	Nov 18, 1983	May CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

	@	HOSPIRA	EQ 1MG BASE/ML	N75293	001	Jun 20, 2000	May DISC
AP			EQ 1MG BASE/ML	N75409	002	Jun 20, 2000	May CAHN
AP			EQ 1MG BASE/ML	N75856	001	Jun 13, 2002	May CAHN
AP	+		EQ 1MG BASE/ML	N75857	001	Jul 22, 2002	May CAHN
	@		EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	May DISC
AP			EQ 5MG BASE/ML	N75409	001	Jun 20, 2000	May CAHN
AP			EQ 5MG BASE/ML	N75856	002	Jun 13, 2002	May CAHN
AP	+		EQ 5MG BASE/ML	N75857	002	Jul 22, 2002	May CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HCL

AB		IMPAX PHARMS	2.5MG	N76449	001	May 27, 2004	May NEWA
AB			5MG	N76449	002	May 27, 2004	May NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP		HOSPIRA	EQ 1MG BASE/ML	N75884	001	May 28, 2002	May CAHN

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		HOSPIRA	EQ 20MG BASE/100ML	N75885	001	May 28, 2002	May CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HCL

AB		MEDICIS	EQ 50MG BASE	N65131	001	Apr 16, 2003	Jan CFTG
AB			EQ 75MG BASE	N65131	002	Apr 16, 2003	Jan CFTG
AB	+		EQ 100MG BASE	N65131	003	Apr 16, 2003	Jan CFTG
AB		RANBAXY	EQ 50MG BASE	N65156	001	Jan 06, 2004	Jan NEWA
AB			EQ 75MG BASE	N65156	002	Jan 06, 2004	Jan NEWA
AB			EQ 100MG BASE	N65156	003	Jan 06, 2004	Jan NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

		CARACO	7.5MG	N76541	004	Apr 22, 2004	Apr NEWA
AB			15MG	N76541	001	Apr 22, 2004	Apr NEWA
AB			30MG	N76541	002	Apr 22, 2004	Apr NEWA
AB			45MG	N76541	003	Apr 22, 2004	Apr NEWA

MOLINDONE HYDROCHLORIDE

CONCENTRATE; ORAL

		MOBAN						
		@ ENDO PHARMS	20MG/ML	N17938	001		May	DISC

TABLET; ORAL

		MOBAN						
		@ ENDO PHARMS	100MG	N17111	008		May	DISC

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

		DEPODUR						
		SKYEPHARMA	10MG/ML	N21671	001	May 18, 2004	May	NEWA
			15MG/1.5ML(10MG/ML)	N21671	002	May 18, 2004	May	NEWA
	+		20MG/2ML(10MG/ML)	N21671	003	May 18, 2004	May	NEWA

INJECTABLE; INJECTION

		MORPHINE SULFATE						
AP	+	HOSPIRA	0.5MG/ML	N19917	001	Oct 30, 1992	May	CAHN
AP			0.5MG/ML	N71849	001	May 11, 1988	May	CAHN
AP			0.5MG/ML	N73509	001	Sep 30, 1992	May	CAHN
AP	+		1MG/ML	N19916	001	Oct 30, 1992	May	CAHN
AP			1MG/ML	N71850	001	May 11, 1988	May	CAHN
AP			1MG/ML	N73510	001	Sep 30, 1992	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

		MORPHINE SULFATE						
AB		KV PHARM	15MG	N76733	001	May 19, 2004	May	NEWA
AB			60MG	N76720	001	May 19, 2004	May	NEWA
		ORAMORPH SR						
BC	+	AAIPHARMA	60MG	N19977	002	Aug 15, 1991	Mar	CRLD

MYCOPHENOLIC ACID

TABLET, EXTENDED RELEASE; ORAL

		MYFORTIC						
		NOVARTIS	180MG	N50791	001	Feb 27, 2004	Feb	NEWA
	+		360MG	N50791	002	Feb 27, 2004	Feb	NEWA

NABILONE

CAPSULE; ORAL

		CESAMET						
		@ VALEANT	1MG	N18677	001	Dec 26, 1985	Jan	CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

		NAFCILLIN SODIUM						
>D>	+	APOTHECON	EQ 500MG BASE/VIAL	N62527	001	Aug 02, 1984	Jun	CAHN
>D>	AP		EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Jun	CAHN
>D>	AP		EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Jun	CAHN
>D>	AP		EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Jun	CAHN
>A>	+	SANDOZ	EQ 500MG BASE/VIAL	N62527	001	Aug 02, 1984	Jun	CAHN
>A>	AP		EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Jun	CAHN
>A>	AP		EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Jun	CAHN
>A>	AP		EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Jun	CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

AP		HOSPIRA	10MG/ML	N70914	001	Feb 03, 1989	May	CAHN
AP			10MG/ML	N70915	001	Feb 03, 1989	May	CAHN
AP			20MG/ML	N70916	001	Feb 03, 1989	May	CAHN
AP			20MG/ML	N70918	001	Feb 03, 1989	May	CAHN
		@ KING PHARMS	10MG/ML	N74471	001	Mar 19, 1998	Mar	DISC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

AP		HOSPIRA	0.02MG/ML	N70171	001	Sep 24, 1986	May	CAHN
AP			0.02MG/ML	N70252	001	Jan 16, 1987	May	CAHN
AP			0.02MG/ML	N70253	001	Jan 16, 1987	May	CAHN
		@	0.4MG/ML	N70172	001	Sep 24, 1986	May	CAHN
AP			0.4MG/ML	N70254	001	Jan 07, 1987	May	CAHN
AP			0.4MG/ML	N70255	001	Jan 07, 1987	May	CAHN
AP			0.4MG/ML	N70256	001	Jan 07, 1987	May	CAHN
AP			0.4MG/ML	N70257	001	Jan 07, 1987	May	CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB		WESTWARD	250MG	N76494	001	Jan 14, 2004	Jan	NEWA
AB			375MG	N76494	002	Jan 14, 2004	Jan	NEWA
AB			500MG	N76494	003	Jan 14, 2004	Jan	NEWA

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

>D>	AB	+	ELAN PHARMA	EQ 375MG BASE	N20353	001	Jan 05, 1996	Jun	CAHN
>D>	AB	+		EQ 500MG BASE	N20353	002	Jan 05, 1996	Jun	CAHN
>D>			@	EQ 750MG BASE	N20353	003	Jan 05, 1996	Jun	CAHN
>A>	AB	+	STAT TRADE	EQ 375MG BASE	N20353	001	Jan 05, 1996	Jun	CAHN
>A>	AB	+		EQ 500MG BASE	N20353	002	Jan 05, 1996	Jun	CAHN
>A>			@	EQ 750MG BASE	N20353	003	Jan 05, 1996	Jun	CAHN

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

	+	KING PHARMS	1.75MG/INH	N19660	001	Dec 30, 1992	Jan	CAHN

NIACIN

TABLET; ORAL

NIACIN

		@ MK LABS	500MG	N83525	001		Feb	DISC
		@ TABLICAPS	500MG	N84237	001		Feb	DISC

NIACOR

AA	+	UPSHER SMITH	500MG	N40378	001	May 03, 2000	Feb	CRLD

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2		MARTEC	90MG	N75414	003	Mar 23, 2004	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL
PROCARDIA XL

AB2	+	PFIZER	90MG	N19684	003	Sep 06, 1989	Mar	CFTG

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACROBID

AB	+	PROCTER AND GAMBLE	75MG;25MG	N20064	001	Dec 24, 1991	Mar	CFTG

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		MYLAN	EQ 75MG BASE;25MG	N76648	001	Mar 22, 2004	Mar	NEWA
AB			75MG;25MG	N76648	001	Mar 22, 2004	Apr	CPOT

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

AP	+	HOSPIRA	5MG/ML	N18531	001		May	CAHN

NITROGLYCERIN IN DEXTROSE 5%

AP		HOSPIRA	0.1MG/ML	N74083	001	Oct 26, 1994	May	CAHN
AP			10MG/100ML	N71846	001	Aug 31, 1990	May	CAHN
AP			20MG/100ML	N71847	001	Aug 31, 1990	May	CAHN
AP			40MG/100ML	N71848	001	Aug 31, 1990	May	CAHN

NIZATIDINE

SOLUTION; ORAL
AXID

	+	RELIANT PHARMS	15MG/ML	N21494	001	May 25, 2004	May	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED

AP	+	HOSPIRA	EQ 1MG BASE/ML	N07513	001		May	CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

>D>		AVENTYL HCL						
>D>	BD	LILLY	EQ 10MG BASE	N14684	001		Jun	DISC
>A>		@	EQ 10MG BASE	N14684	001		Jun	DISC
>D>	BD		EQ 25MG BASE	N14684	002		Jun	DISC
>A>		@	EQ 25MG BASE	N14684	002		Jun	DISC

NYSTATIN

PASTILLE; ORAL

>D>		MYCOSTATIN						
>D>	+	BRISTOL MYERS SQUIBB	200,000 UNITS	N50619	001	Apr 09, 1987	Jun	DISC
>A>		@	200,000 UNITS	N50619	001	Apr 09, 1987	Jun	DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OCUFLOX

AT	+	ALLERGAN	0.3%	N19921	001	Jul 30, 1993	May	CFTG

OFLOXACIN

AT		ALCON	0.3%	N76231	001	May 14, 2004	May	NEWA
AT		BAUSCH AND LOMB	0.3%	N76622	001	May 14, 2004	May	NEWA
AT		HI TECH PHARMA	0.3%	N76615	001	May 14, 2004	May	NEWA
AT		NOVEX	0.3%	N76513	001	May 14, 2004	May	NEWA

SOLUTION/DROPS; OTIC

FLOXIN

>D> + DAIICHI 0.3% N20799 001 Dec 16, 1997 Jun CTNA

FLOXIN OTIC

>A> + DAIICHI 0.3% N20799 001 Dec 16, 1997 Jun CTNA

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA

+ LILLY 10MG/VIAL N21253 001 Mar 29, 2004 Mar NEWA

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

>A> + CELLTECH PHARMS 250MG N19715 001 Jul 31, 1990 Jun CAHN

>D> + PHARMACIA AND UPJOHN 250MG N19715 001 Jul 31, 1990 Jun CAHN

OMEPRAZOLE

>A> FOR SUSPENSION; ORAL

>A> ZEGERID

>A> + SANTARUS 20MG/PACKET N21636 001 Jun 15, 2004 Jun NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

>D> AP + APOTHECON EQ 250MG BASE/VIAL N61490 001 Jun CAHN

AP + EQ 250MG BASE/VIAL N61490 001 Mar CRLD

>D> AP + EQ 500MG BASE/VIAL N61490 002 Jun CAHN

>D> AP + EQ 1GM BASE/VIAL N61490 003 Jun CAHN

>D> AP + EQ 2GM BASE/VIAL N61490 004 Jun CAHN

AP + EQ 2GM BASE/VIAL N61490 004 Mar NEWA

AP EQ 2GM BASE/VIAL N62737 002 Dec 23, 1986 Mar CRLD

>D> AP + EQ 10GM BASE/VIAL N61490 006 May 09, 1991 Jun CAHN

>A> AP + SANDOZ EQ 250MG BASE/VIAL N61490 001 Jun CAHN

>A> AP + EQ 500MG BASE/VIAL N61490 002 Jun CAHN

>A> AP + EQ 1GM BASE/VIAL N61490 003 Jun CAHN

>A> AP + EQ 2GM BASE/VIAL N61490 004 Jun CAHN

>A> AP + EQ 10GM BASE/VIAL N61490 006 May 09, 1991 Jun CAHN

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

@ PFIZER 250MG N18069 001 Mar DISC

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HCL

AB ENDO PHARMS 10MG N75923 001 Mar 23, 2004 Mar NEWA

AB 20MG N75923 002 Mar 23, 2004 Mar NEWA

AB 40MG N75923 003 Mar 23, 2004 Mar NEWA

AB TEVA 80MG N76168 001 Mar 23, 2004 Mar NEWA

OXYCONTIN

AB PURDUE PHARMA LP 10MG N20553 001 Dec 12, 1995 Mar CFTG

AB 20MG N20553 002 Dec 12, 1995 Mar CFTG

AB + 40MG N20553 003 Dec 12, 1995 Mar CFTG

>D> AB + 80MG N20553 004 Jan 06, 1997 Jun CRLD

		TABLET, EXTENDED RELEASE; ORAL						
		OXYCONTIN						
>A>	AB	PURDUE PHARMA LP	80MG	N20553	004	Jan 06, 1997	Jun	CRLD
	AB	+	80MG	N20553	004	Jan 06, 1997	Mar	CFTG
		TABLET; ORAL						
		OXYCODONE HCL						
	AB	AMIDE PHARM	15MG	N76636	001	Feb 06, 2004	Feb	NEWA
	AB		30MG	N76636	002	Feb 06, 2004	Feb	NEWA
>A>	AB	MALLINCKRODT	15MG	N76758	001	Jun 30, 2004	Jun	NEWA
>A>	AB		30MG	N76758	002	Jun 30, 2004	Jun	NEWA
		ROXICODONE						
	AB	+ AAIPHARMA	15MG	N21011	001	Aug 31, 2000	Feb	CFTG
	AB		30MG	N21011	002	Aug 31, 2000	Feb	CFTG
		PANCURONIUM BROMIDE						
		INJECTABLE; INJECTION						
		PANCURONIUM BROMIDE						
	AP	HOSPIRA	1MG/ML	N72320	001	Jan 19, 1989	May	CAHN
	AP		2MG/ML	N72321	001	Jan 19, 1989	May	CAHN
		PARICALCITOL						
		INJECTABLE; INJECTION						
		ZEMPLAR						
		ABBOTT	0.002MG/ML	N20819	002	Feb 01, 2000	Mar	NEWA
		PAROXETINE HYDROCHLORIDE						
		TABLET; ORAL						
		PAROXETINE HCL						
	AB	ALPHAPHARM	EQ 10MG BASE	N75716	001	Mar 08, 2004	Mar	NEWA
	AB		EQ 20MG BASE	N75716	002	Mar 08, 2004	Mar	NEWA
	AB		EQ 30MG BASE	N75716	003	Mar 08, 2004	Mar	NEWA
	AB		EQ 40MG BASE	N75716	004	Mar 08, 2004	Mar	NEWA
	AB	SANDOZ	EQ 10MG BASE	N75566	001	Mar 08, 2004	Mar	NEWA
	AB		EQ 20MG BASE	N75566	002	Mar 08, 2004	Mar	NEWA
	AB		EQ 30MG BASE	N75566	003	Mar 08, 2004	Mar	NEWA
	AB		EQ 40MG BASE	N75566	004	Mar 08, 2004	Mar	NEWA
		PEMETREXED DISODIUM						
		INJECTABLE; IV (INFUSION)						
		ALIMTA						
		+ LILLY	EQ 500MG BASE/VIAL	N21462	001	Feb 04, 2004	Feb	NEWA
		PENTAMIDINE ISETHIONATE						
		INJECTABLE; INJECTION						
		PENTAMIDINE ISETHIONATE						
	AP	HOSPIRA	300MG/VIAL	N73479	001	Jun 30, 1992	May	CAHN
		PENTAZOCINE LACTATE						
		INJECTABLE; INJECTION						
		TALWIN						
		+ HOSPIRA	EQ 30MG BASE/ML	N16194	001		May	CAHN
		PENTOBARBITAL SODIUM						
		CAPSULE; ORAL						
		NEMBUTAL SODIUM						
		@ OVATION PHARMS	30MG	N84095	001		May	DISC

CAPSULE; ORAL
NEMBUTAL SODIUM

	@ OVATION PHARMS	100MG	N83245	001		May	DISC

SODIUM PENTOBARBITAL

+	VALEANT PHARM INTL	100MG	N83264	001		May	CRLD

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON

>D>	+ JOHNSON AND JOHNSON	100MG	N20193	001	Sep 26, 1996	Jun	CAHN
>A>	+ ORTHO MCNEIL PHARM	100MG	N20193	001	Sep 26, 1996	Jun	CAHN

PHENYTOIN

SUSPENSION; ORAL
PHENYTOIN

AB	TARO	125MG/5ML	N40521	001	Mar 08, 2004	Mar	NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

	@ HOSPIRA	50MG/ML	N89521	001	Mar 17, 1987	May	CAHN
	@	50MG/ML	N89744	001	Dec 18, 1987	May	CAHN

PHYTONADIONE

INJECTABLE; INJECTION
VITAMIN K1

BP	HOSPIRA	1MG/0.5ML	N87954	001	Jul 25, 1983	May	CAHN
BP		10MG/ML	N87955	001	Jul 25, 1983	May	CAHN
	@	10MG/ML	N87956	001	Jul 25, 1983	May	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
NULYTELY

AA	+ BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797	001	Apr 22, 1991	Feb	CFTG

NULYTELY-FLAVORED

AA	+ BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797	002	Nov 18, 1994	Feb	CFTG

TRILYTE

AA	SCHWARZ PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N76491	001	Feb 05, 2004	Feb	NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL
OCL

+	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284	001	Apr 30, 1986	May	CAHN

POTASSIUM ACETATE

INJECTABLE; INJECTION
POTASSIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N18896	001	Jul 20, 1984	May	CAHN

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

	@ HOSPIRA	1MEQ/ML	N80205	003		May	CAHN
	@	1MEQ/ML	N83345	003		May	CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	+	HOSPIRA	1.5MEQ/ML	N83345	001		May	CAHN
AP	+		2MEQ/ML	N80205	001		May	CAHN
AP			2MEQ/ML	N83345	002		May	CAHN
	@		2.4MEQ/ML	N80205	004		May	CAHN
	@		3.2MEQ/ML	N80205	005		May	CAHN

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

	@	HOSPIRA	14.9MG/ML	N20161	005	Nov 30, 1992	May	CAHN
	@		745MG/100ML	N20161	001	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	29.8MG/ML	N20161	006	Aug 11, 1998	May	CAHN
	@		1.49GM/100ML	N20161	002	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.24GM/100ML	N20161	003	Aug 11, 1998	May	CAHN

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.98GM/100ML	N20161	004	Aug 11, 1998	May	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	149MG/100ML;900MG/100ML	N19686	001	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	298MG/100ML;900MG/100ML	N19686	002	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

	@	HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025	001		May	CAHN

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

	@	EVERYLIFE	2.5MG	N84439	002		May	DISC
	@		5MG	N84439	003		May	DISC
	@	SPERTI	1MG	N80358	001		May	DISC
	@		2.5MG	N80358	002		May	DISC
	@		5MG	N80358	003		May	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA		PADDOCK	EQ 5MG BASE/5ML	N75988	001	May 25, 2004	May	NEWA

PREDNISONE

TABLET; ORAL

PREDNISONE

AB		WEST WARD	2.5MG	N40538	001	Jan 08, 2004	Jan	NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

AP		HOSPIRA	100MG/ML	N89069	001	Feb 12, 1986	May	CAHN
AP			500MG/ML	N89070	001	Feb 12, 1986	May	CAHN
AP			500MG/ML	N89537	001	Aug 25, 1987	May	CAHN

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

AP	+	HOSPIRA	1%	N85362	003		May	CAHN
AP	+		2%	N85362	004		May	CAHN
	+		10%	N86797	001		May	CAHN

PROCAINE HCL

AP		HOSPIRA	1%	N80416	001		May	CAHN
AP			2%	N80416	002		May	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP		BEDFORD	EQ 5MG BASE/ML	N40540	001	May 28, 2004	May	NEWA
AP		HOSPIRA	EQ 5MG BASE/ML	N89703	001	Apr 07, 1988	May	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

AP		BEDFORD LABS	25MG/ML	N40524	001	Mar 17, 2004	Mar	NEWA
AP			50MG/ML	N40524	002	Mar 17, 2004	Mar	NEWA
AP		HOSPIRA	25MG/ML	N40372	001	Jun 08, 2000	May	CAHN
AP			50MG/ML	N40372	002	Jun 08, 2000	May	CAHN
AP			50MG/ML	N83838	002		May	CAHN

SYRUP; ORAL

PROMETH PLAIN

		@ ALPHARMA	6.25MG/5ML	N85953	001		Feb	DISC

PROMETHAZINE HCL

AA		HI TECH PHARMA	6.25MG/5ML	N40026	001	Sep 25, 1998	May	CRLD
AA	+		6.25MG/5ML	N40026	001	Sep 25, 1998	Feb	CRLD

PROMETHAZINE PLAIN

AA	+	MORTON GROVE	6.25MG/5ML	N87953	001	Nov 15, 1982	May	CRLD

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HCL

AB		PLIVA	150MG	N76550	001	Apr 23, 2004	Apr	NEWA
AB			225MG	N76550	002	Apr 23, 2004	Apr	NEWA
AB			300MG	N76550	003	Apr 23, 2004	Apr	NEWA

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL

AP		AM PHARM PARTNERS	1MG/ML	N75826	001	Aug 31, 2001	Jan	NEWA

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

	+	AM PHARM PARTNERS	10MG/ML	N89454	001	Apr 07, 1987	Mar	CRLD
		@ LILLY	10MG/ML	N06460	002		Mar	DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

>A>		@ ODYSSEY PHARMS	5MG	N16012	001		Jun	CAHN

TABLET; ORAL
VIVACTIL

>A>	@ ODYSSEY PHARMS	10MG	N16012	002		Jun	CAHN
>D>	@ PLIVA	5MG	N16012	001		Jun	CAHN
>D>	@	10MG	N16012	002		Jun	CAHN

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 25

	GLAXOSMITHKLINE	EQ 25MG BASE	N20251	003	Apr 01, 2004	Apr	NEWA

RIBAVIRIN

CAPSULE; ORAL
REBETOL

AB	+ SCHERING PLOUGH RES	200MG	N20903	002	Jul 25, 2001	Apr	CFTG

RIBASPHERE

AB	THREE RIVERS PHARMS	200MG	N76203	001	Apr 06, 2004	Apr	NEWA

RIBAVIRIN

AB	SANDOZ	200MG	N76192	001	Apr 06, 2004	Apr	NEWA

RIFAXIMIN

TABLET; ORAL
XIFAXAN

+	SALIX PHARMS	200MG	N21361	001	May 25, 2004	May	NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

>A>	JANSSEN PHARMA	0.5MG	N21444	001	Apr 02, 2003	Jun	CAHN
>A>	+	1MG	N21444	002	Apr 02, 2003	Jun	CAHN
>A>		2MG	N21444	003	Apr 02, 2003	Jun	CAHN
>D>	JOHNSON AND JOHNSON	0.5MG	N21444	001	Apr 02, 2003	Jun	CAHN
>D>	+	1MG	N21444	002	Apr 02, 2003	Jun	CAHN
>D>		2MG	N21444	003	Apr 02, 2003	Jun	CAHN

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL

+	HOSPIRA	10MG/ML	N71618	001	Feb 28, 1991	May	CAHN
+		15MG/ML	N71619	001	Feb 28, 1991	May	CAHN

RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA	30MG/100ML	N71438	001	Jan 22, 1991	May	CAHN

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON

>D>	@ ORGANON USA INC	10MG/ML	N20214	002	Mar 17, 1994	Jun	CMFD
>A>		10MG/ML	N20214	002	Mar 17, 1994	Jun	CMFD

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP

	GLAXOSMITHKLINE	EQ 5MG BASE	N20658	005	Sep 19, 1997	May	CRLD

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

+	HOSPIRA	5%;5% (5GM/100ML)	N18997	001	Aug 27, 1984	May	CAHN

LIPOSYN II 20%

+	HOSPIRA	10%;10% (10GM/100ML)	N18991	001	Aug 27, 1984	May	CAHN

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

HUMAN SECRETIN

+	CHIRHOCLIN	16UGM/VIAL	N21256	001	Apr 09, 2004	Apr	NEWA

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

>D>	+ GENZYME	403MG	N20926	001	Oct 30, 1998	Jun	DISC
>A>	@	403MG	N20926	001	Oct 30, 1998	Jun	DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

	WYETH PHARMS INC	2MG	N21110	002	Aug 22, 2002	Feb	CRLD
+		5MG	N21110	003	Feb 23, 2004	Feb	NEWA

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N18893	001	May 04, 1983	May	CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP +	HOSPIRA	9MG/ML	N18800	001	Oct 29, 1982	May	CAHN

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	450MG/100ML	N18090	001		May	CAHN
AP		450MG/100ML	N19759	001	Jun 08, 1988	May	CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	9MG/ML	N18803	001	Oct 29, 1982	May	CAHN
AP		9MG/ML	N19217	001	Jul 13, 1984	May	CAHN
AP		9MG/ML	N19465	002	Jul 15, 1985	May	CAHN
AP		900MG/100ML	N16366	001		May	CAHN
AP		900MG/100ML	N19465	001	Jul 15, 1985	May	CAHN
AP		900MG/100ML	N19480	001	Sep 17, 1985	May	CAHN

SODIUM CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	2.5MEQ/ML	N18897	001	Jul 20, 1984	May	CAHN

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT	HOSPIRA	450MG/100ML	N17670	001		May	CAHN
	@	450MG/100ML	N18380	001		May	CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	HOSPIRA	900MG/100ML	N17514	001		May	CAHN
AT		900MG/100ML	N18314	001		May	CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

+	WATSON PHARMS	62.5MG/5ML	N20955	001	Feb 18, 1999	Feb	CAHN

SODIUM IODIDE, I-131

SOLUTION; ORAL

SODIUM IODIDE I 131

@	CIS	50mCi/ML	N17315	001		Apr	DISC

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP		HOSPIRA	1.87GM/100ML	N18249	001		May	CAHN

SODIUM LACTATE IN PLASTIC CONTAINER

		HOSPIRA	5MEQ/ML	N18947	001	Sep 05, 1984	May	CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

AP	+	HOSPIRA	25MG/ML	N71961	001	Aug 01, 1988	May	CAHN
	+		50MG/VIAL	N70566	001	Jun 09, 1986	May	CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

		HOSPIRA	142MG/ML;276MG/ML	N18892	001	May 10, 1983	May	CAHN

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

SAIZEN

@	SERONO	6MG/VIAL	N19764	001	Oct 08, 1996	May	DISC

SEROSTIM

BX		SERONO	4MG/VIAL	N20604	003	Jul 25, 1997	Jan	CTEC
	@		8.8MG/VIAL	N20604	004	Sep 06, 2001	Jan	DISC

ZORBTIVE

	@	SERONO INC	4MG/VIAL	N21597	001	Dec 01, 2003	May	DISC
	@		5MG/VIAL	N21597	002	Dec 01, 2003	May	DISC
	@		6MG/VIAL	N21597	003	Dec 01, 2003	May	DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HCL

AB2		MUTUAL PHARM	80MG	N76576	001	Apr 08, 2004	Apr	NEWA
AB2			120MG	N76576	002	Apr 08, 2004	Apr	NEWA
AB2			160MG	N76576	003	Apr 08, 2004	Apr	NEWA

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%

AP	+	HOSPIRA	10%	N18969	001	Sep 24, 1984	May	CAHN

LIPOSYN III 20%

AP	+	HOSPIRA	20%	N18970	001	Sep 25, 1984	May	CAHN

LIPOSYN III 30%

AP	+	HOSPIRA	30%	N20181	001	Jan 13, 1998	May	CAHN

SPARFLOXACIN

TABLET; ORAL
ZAGAM
@ MYLAN 200MG N20677 001 Dec 19, 1996 Mar DISC

STAVUDINE

>D> CAPSULE, EXTENDED RELEASE; ORAL
>D> ZERIT XR
>D> BRISTOL MYERS SQUIBB 37.5MG N21453 001 Dec 31, 2002 Jun DISC
>A> @ 37.5MG N21453 001 Dec 31, 2002 Jun DISC
>D> 50MG N21453 002 Dec 31, 2002 Jun DISC
>A> @ 50MG N21453 002 Dec 31, 2002 Jun DISC
>D> 75MG N21453 003 Dec 31, 2002 Jun DISC
>A> @ 75MG N21453 003 Dec 31, 2002 Jun DISC
>D> + 100MG N21453 004 Dec 31, 2002 Jun DISC
>A> @ 100MG N21453 004 Dec 31, 2002 Jun DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
QUELICIN
AP + HOSPIRA 20MG/ML N08845 006 May CAHN
QUELICIN PRESERVATIVE FREE
AP + HOSPIRA 20MG/ML N08845 001 May CAHN
@ 50MG/ML N08845 002 May CAHN
+ 100MG/ML N08845 004 May CAHN

SUCRALFATE

TABLET; ORAL
CARAFATE
AB + AXCAN SCANDIPHARM 1GM N18333 001 Feb CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SULFENTANIL CITRATE
AP HOSPIRA EQ 0.05MG BASE/ML N74534 001 Dec 11, 1996 May CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULF-10
AT NOVARTIS 10% N80025 001 Mar CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM
AP HOSPIRA 80MG/ML;16MG/ML N73199 001 Sep 11, 1992 May CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
ACUTECT
>A> BERLEX LABS N/A N20887 001 Sep 14, 1998 Jun CAHN
>D> DIATIDE RES LABS N/A N20887 001 Sep 14, 1998 Jun CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT

>A>	+	BERLEX LABS	N/A	N21012	001	Aug 03, 1999	Jun	CAHN
>D>	+	DIATIDE RES LABS	N/A	N21012	001	Aug 03, 1999	Jun	CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
DRAXIMAGE MDP

AP	+	DRAXIMAGE	N/A	N18035	001		May	CTNA

TELITHROMYCIN

TABLET; ORAL
KETEK

	+	AVENTIS PHARMS	400MG	N21144	001	Apr 01, 2004	Apr	NEWA

TERBINAFINE

GEL; TOPICAL
LAMISIL

		NOVARTIS	1%	N20846	001	Apr 29, 1998	Jan	CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

AP	+	AAIPHARMA LLC	1MG/ML	N18571	001		Apr	CFTG

TERBUTALINE SULFATE

AP		AM PHARM	1MG/ML	N76887	001	May 26, 2004	May	NEWA
AP		BEDFORD	1MG/ML	N76770	001	Apr 23, 2004	Apr	NEWA

TERCONAZOLE

CREAM; VAGINAL
TERAZOL 3

AB	+	ORTHO MCNEIL PHARM	0.8%	N19964	001	Feb 21, 1991	Apr	CFTG

TERCONAZOLE

AB		TARO	0.8%	N75953	001	Apr 06, 2004	Apr	NEWA

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

>D>	+	FLEMING PHARMS	65MG	N85075	003	Nov 24, 1986	Jun	DISC
>A>		@	65MG	N85075	003	Nov 24, 1986	Jun	DISC

AEROLATE JR

>D>	BC	FLEMING PHARMS	130MG	N85075	002	Nov 24, 1986	Jun	DISC
>A>		@	130MG	N85075	002	Nov 24, 1986	Jun	DISC

AEROLATE SR

>D>	BC	FLEMING PHARMS	260MG	N85075	001	Nov 24, 1986	Jun	DISC
>A>		@	260MG	N85075	001	Nov 24, 1986	Jun	DISC

INJECTABLE; INJECTION
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	4MG/ML	N19211	007	Dec 14, 1984	May	CAHN
AP	+		40MG/100ML	N19211	001	Dec 14, 1984	May	CAHN
AP	+		80MG/100ML	N19211	002	Dec 14, 1984	May	CAHN
AP	+		160MG/100ML	N19211	003	Dec 14, 1984	May	CAHN
AP	+		200MG/100ML	N19211	004	Dec 14, 1984	May	CAHN
AP	+		320MG/100ML	N19211	006	Jan 20, 1988	May	CAHN

		INJECTABLE; INJECTION						
		THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	AP	+ HOSPIRA	400MG/100ML	N19211	005	Dec 14, 1984	May	CAHN
		SOLUTION; ORAL						
>D>		AEROLATE						
>D>		+ FLEMING PHARMS	150MG/15ML	N89141	001	Dec 03, 1986	Jun	DISC
>A>		@	150MG/15ML	N89141	001	Dec 03, 1986	Jun	DISC
		TABLET, EXTENDED RELEASE; ORAL						
>D>		THEOLAIR-SR						
>D>	BC	3M	200MG	N88369	001	Jul 16, 1987	Jun	DISC
>A>		@	200MG	N88369	001	Jul 16, 1987	Jun	DISC
>D>			250MG	N86363	002	Jul 16, 1987	Jun	DISC
>A>		@	250MG	N86363	002	Jul 16, 1987	Jun	DISC
>D>	BC		300MG	N88364	001	Jul 16, 1987	Jun	DISC
>A>		@	300MG	N88364	001	Jul 16, 1987	Jun	DISC
>D>		+	500MG	N89132	001	Jul 16, 1987	Jun	DISC
>A>		@	500MG	N89132	001	Jul 16, 1987	Jun	DISC
		THEOPHYLLINE						
	AB	ABLE	300MG	N40548	001	Apr 30, 2004	Apr	NEWA
	AB		400MG	N40543	001	Apr 27, 2004	Apr	NEWA
	AB		450MG	N40546	001	Apr 30, 2004	Apr	NEWA
	AB		600MG	N40539	001	Apr 27, 2004	Apr	NEWA
		UNIPHYL						
	AB	+ PURDUE FREDERICK	400MG	N87571	001	Sep 01, 1982	Apr	CFTG
	AB	+	600MG	N40086	001	Apr 15, 1996	Apr	CFTG
		THIAMINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		THIAMINE HCL						
	AP	HOSPIRA	100MG/ML	N40079	001	May 03, 1996	May	CAHN
		TIMOLOL MALEATE						
		SOLUTION/DROPS; OPHTHALMIC						
>A>		ISTALOL						
>A>		+ SENJU	EQ 0.5% BASE	N21516	001	Jun 04, 2004	Jun	NEWA
>A>		TIMOLOL MALEATE						
>A>	AT	HI TECH PHARMA	EQ 0.5% BASE	N75163	001	Sep 10, 2002	Jun	CDFR
>D>		SOLUTION; OPHTHALMIC						
>D>		TIMOLOL MALEATE						
>D>	AT	HI TECH PHARMA	EQ 0.5% BASE	N75163	001	Sep 10, 2002	Jun	CDFR
		TINIDAZOLE						
		TABLET; ORAL						
		TINDAMAX						
		PRESUTTI LABS	250MG	N21618	001	May 17, 2004	May	NEWA
		+	500MG	N21618	002	May 17, 2004	May	NEWA
		TIOTROPIUM BROMIDE MONOHYDRATE						
		CAPSULE; INHALATION						
		SPIRIVA						
		+ BOEHRINGER INGELHEIM	EQ 0.018MG BASE	N21395	001	Jan 30, 2004	Jan	NEWA
		TIZANIDINE HYDROCHLORIDE						
		TABLET; ORAL						
		TIZANIDINE HCL						
	AB	TORPHARM	EQ 2MG BASE	N76533	001	Jan 16, 2004	Jan	NEWA

TABLET; ORAL
TIZANIDINE HCL

AB	TORPHARM	EQ 4MG BASE	N76533	002	Jan 16, 2004	Jan	NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
NEBCIN

>D>		LILLY	EQ 10MG BASE/ML	N50477	005		Jun	DISC
>D>	AP +		EQ 10MG BASE/ML	N50477	005		Jun	DISC
>A>	@		EQ 10MG BASE/ML	N50477	005		Jun	DISC
>D>	AP		EQ 10MG BASE/ML	N62008	004		Jun	DISC
>A>	@		EQ 10MG BASE/ML	N62008	004		Jun	DISC
>D>	AP		EQ 10MG BASE/ML	N62707	001	Apr 29, 1987	Jun	DISC
>A>	@		EQ 10MG BASE/ML	N62707	001	Apr 29, 1987	Jun	DISC
>D>	AP +		EQ 40MG BASE/ML	N62008	001		Jun	DISC
>A>	@		EQ 40MG BASE/ML	N62008	001		Jun	DISC
>D>	AP +		EQ 1.2GM BASE/VIAL	N50519	001		Jun	DISC
>A>	@		EQ 1.2GM BASE/VIAL	N50519	001		Jun	DISC
	TOBRAMYCIN							
>D>	AP	PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013	001	Aug 17, 2001	Jun	CRLD
>A>	AP +		EQ 1.2GM BASE/VIAL	N65013	001	Aug 17, 2001	Jun	CRLD
	TOBRAMYCIN SULFATE							
>D>	AP	HOSPIRA	EQ 10MG BASE/ML	N63080	001	Apr 30, 1991	Jun	CRLD
>A>	AP +		EQ 10MG BASE/ML	N63080	001	Apr 30, 1991	Jun	CRLD
	AP		EQ 10MG BASE/ML	N63080	001	Apr 30, 1991	May	CAHN
	AP		EQ 10MG BASE/ML	N63112	001	Apr 30, 1991	May	CAHN
	AP		EQ 40MG BASE/ML	N63111	001	Apr 30, 1991	May	CAHN
	AP +		EQ 40MG BASE/ML	N63116	001	May 18, 1992	May	CAHN
	AP		EQ 40MG BASE/ML	N63161	001	May 29, 1991	May	CAHN
	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	+	HOSPIRA	EQ 1.2MG BASE/ML	N63081	003	Jul 31, 1990	May	CAHN
	+		EQ 1.6MG BASE/ML	N63081	006	Jun 02, 1993	May	CAHN
	+		EQ 80MG BASE/100ML	N63081	001	Jul 31, 1990	May	CAHN

TOPIRAMATE

TABLET; ORAL
TOPAMAX

>D>	@ ORTHO MCNEIL PHARM	50MG	N20505	005	Dec 24, 1996	Jun	CMFD
>A>		50MG	N20505	005	Dec 24, 1996	Jun	CMFD

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVATAN

	+	ALCON	0.004%	N21257	001	Mar 16, 2001	May	CAHN

TRIAMCINOLONE

TABLET; ORAL
ARISTOCORT

>D>	BP	FUJISAWA HLTHCARE	4MG	N11161	007		Jun	CRLD
>A>	BP +		4MG	N11161	007		Jun	CRLD
>D>		KENACORT						
>D>	+	BRISTOL MYERS SQUIBB	8MG	N11283	010		Jun	DISC
>A>	@		8MG	N11283	010		Jun	DISC
>D>		TRIAMCINOLONE						
>D>	BP	WATSON LABS	4MG	N84270	001		Jun	DISC
>A>	@		4MG	N84270	001		Jun	DISC

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

+	KOS	0.1MG/INH	N18117	001	Apr 23, 1982	Apr	CAHN

SPRAY, METERED; NASAL

NASACORT HFA

+	AVENTIS PHARMS	0.055MG/SPRAY	N20784	001	Apr 07, 2004	Apr	NEWA

>D> TRIAMCINOLONE DIACETATE

>D> INJECTABLE; INJECTION

>D> ARISTOCORT

>D>	+ SABEX 2002	25MG/ML	N11685	003		Jun	DISC
>A>	@	25MG/ML	N11685	003		Jun	DISC
>D>	+	40MG/ML	N12802	001		Jun	DISC
>A>	@	40MG/ML	N12802	001		Jun	DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

AP	HOSPIRA	100MG/ML	N88804	001	Apr 03, 1987	May	CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

>A>	ODYSSEY PHARMS	EQ 25MG BASE	N16792	001		Jun	CAHN
>A>		EQ 50MG BASE	N16792	002		Jun	CAHN
>A>	+	EQ 100MG BASE	N16792	003	Sep 15, 1982	Jun	CAHN
>D>	PLIVA	EQ 25MG BASE	N16792	001		Jun	CAHN
>D>		EQ 50MG BASE	N16792	002		Jun	CAHN
>D>	+	EQ 100MG BASE	N16792	003	Sep 15, 1982	Jun	CAHN

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

	@ PURDUE FREDERICK	10%	N11340	002		May	DISC

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+	HOSPIRA	3.6GM/100ML	N13025	002		May	CAHN

TROSPIUM CHLORIDE

TABLET; ORAL

SANCTURA

+	INDEVUS	20MG	N21595	001	May 28, 2004	May	NEWA

>D> TROVAFLOXACIN MESYLATE

>D> TABLET; ORAL

>D> TROVAN

>D>	PFIZER	EQ 100MG BASE	N20759	001	Dec 18, 1997	Jun	DISC
>A>	@	EQ 100MG BASE	N20759	001	Dec 18, 1997	Jun	DISC
>D>	+	EQ 200MG BASE	N20759	002	Dec 18, 1997	Jun	DISC
>A>	@	EQ 200MG BASE	N20759	002	Dec 18, 1997	Jun	DISC

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

>D>	AP	+	BRISTOL MYERS SQUIBB	3MG/ML	N05657	001		Jun	CTEC
>A>		+		3MG/ML	N05657	001		Jun	CTEC
>D>	AP	+	HOSPIRA	3MG/ML	N06095	001		Jun	DISC
>A>		@		3MG/ML	N06095	001		Jun	DISC
	AP	+		3MG/ML	N06095	001		May	CAHN

UREA

INJECTABLE; INJECTION

STERILE UREA

		@	HOSPIRA	40GM/VIAL	N17698	001		May	CAHN

UREAPHIL

		+	HOSPIRA	40GM/VIAL	N12154	001		May	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

		+	GLAXOSMITHKLINE	EQ 1GM BASE	N20487	002	Jun 23, 1995	Feb	CRLD

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

>D>		+	LILLY	EQ 250MG BASE/5ML	N61667	002	Jul 13, 1983	Jun	DISC
>A>		@		EQ 250MG BASE/5ML	N61667	002	Jul 13, 1983	Jun	DISC
>D>		+		EQ 500MG BASE/6ML	N61667	001		Jun	DISC
>A>		@		EQ 500MG BASE/6ML	N61667	001		Jun	DISC

INJECTABLE; INJECTION

VANCOCIN HCL

>D>	AP	+	LILLY	EQ 500MG BASE/VIAL	N60180	001		Jun	DISC
>A>		@		EQ 500MG BASE/VIAL	N60180	001		Jun	DISC
>D>	AP			EQ 500MG BASE/VIAL	N62476	001	Mar 15, 1984	Jun	DISC
>A>		@		EQ 500MG BASE/VIAL	N62476	001	Mar 15, 1984	Jun	DISC
>D>	AP			EQ 500MG BASE/VIAL	N62716	001	Mar 13, 1987	Jun	DISC
>A>		@		EQ 500MG BASE/VIAL	N62716	001	Mar 13, 1987	Jun	DISC
>D>	AP			EQ 500MG BASE/VIAL	N62812	001	Nov 17, 1987	Jun	DISC
>A>		@		EQ 500MG BASE/VIAL	N62812	001	Nov 17, 1987	Jun	DISC
>D>	AP	+		EQ 1GM BASE/VIAL	N60180	002	Mar 21, 1986	Jun	DISC
>A>		@		EQ 1GM BASE/VIAL	N60180	002	Mar 21, 1986	Jun	DISC
>D>	AP			EQ 1GM BASE/VIAL	N62476	002	Mar 21, 1986	Jun	DISC
>A>		@		EQ 1GM BASE/VIAL	N62476	002	Mar 21, 1986	Jun	DISC
>D>	AP			EQ 1GM BASE/VIAL	N62716	002	Mar 13, 1987	Jun	DISC
>A>		@		EQ 1GM BASE/VIAL	N62716	002	Mar 13, 1987	Jun	DISC
>D>	AP			EQ 1GM BASE/VIAL	N62812	002	Nov 17, 1987	Jun	DISC
>A>		@		EQ 1GM BASE/VIAL	N62812	002	Nov 17, 1987	Jun	DISC
>D>	AP	+		EQ 10GM BASE/VIAL	N62812	003	Nov 17, 1987	Jun	DISC
>A>		@		EQ 10GM BASE/VIAL	N62812	003	Nov 17, 1987	Jun	DISC

VANCOMYCIN HCL

	AP		HOSPIRA	EQ 500MG BASE/VIAL	N62911	001	Aug 04, 1988	May	CAHN
	AP			EQ 500MG BASE/VIAL	N62931	001	Oct 29, 1992	May	CAHN
	AP			EQ 1GM BASE/VIAL	N62912	001	Aug 04, 1988	May	CAHN
	AP			EQ 1GM BASE/VIAL	N62933	001	Oct 29, 1992	May	CAHN
	AP			EQ 5GM BASE/VIAL	N63076	001	Dec 21, 1990	May	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

+	ABBOTT	4MG/VIAL	N75558	001	Sep 11, 2001	Apr	CAHN
+	HOSPIRA	4MG/VIAL	N75558	001	Sep 11, 2001	May	CAHN
AP		10MG/VIAL	N75164	001	Oct 21, 1999	May	CAHN
AP		20MG/VIAL	N75164	002	Oct 21, 1999	May	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

	WYETH PHARMS INC	EQ 50MG BASE	N20151	003	Dec 28, 1993	May	CRLD
+		EQ 100MG BASE	N20151	005	Dec 28, 1993	May	CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP	HOSPIRA	2.5MG/ML	N70577	001	Feb 02, 1987	May	CAHN
AP		2.5MG/ML	N70737	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70738	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70739	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70740	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N75136	001	Oct 20, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HCL

AB	BARR	120MG	N75072	001	May 25, 1999	May	CMFD
AB		240MG	N75072	003	May 25, 1999	May	CMFD

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

	@ LILLY	1MG/ML	N14103	003	Mar 07, 1984	Mar	DISC

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+	MAYNE PHARMA USA	EQ 50,000 UNITS BASE/ML	N06823	001		Apr	CAHN

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	HOSPIRA	100%	N18802	001	Oct 27, 1982	May	CAHN

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

	@ B BRAUN	100%	N19077	001	Mar 02, 1984	May	DISC
AP	HOSPIRA	100%	N18233	001		May	CAHN
AP		100%	N18801	001	Oct 27, 1982	May	CAHN
AP		100%	N19869	001	Dec 26, 1989	May	CAHN

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	HOSPIRA	100%	N17513	001		May	CAHN
AT		100%	N18313	001		May	CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 1MG ZINC/ML	N18959	001	Jun 26, 1986	May	CAHN

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

	SANOFI SYNTHELABO	5MG	N19908	001	Dec 16, 1992	Apr	CAHN
+		10MG	N19908	002	Dec 16, 1992	Apr	CAHN

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+	NOVARTIS	0.5%;0.05%	N18746	002	Jul 11, 1994	Feb	CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

>A>	+	BAYER	2%	N20421	001	Dec 21, 1995	Jun	CAHN
>D>	+	ROCHE PALO	2%	N20421	001	Dec 21, 1995	Jun	CAHN

>D> CHLORHEXIDINE GLUCONATE

>D> SOLUTION; TOPICAL

>D> CHLORAPREP ONE-STEP

>D>	+	BECKLOFF	2%	N21555	001	Oct 07, 2002	Jun	CAIN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

>D> CHLORAPREP

>D>	+	MEDI FLEX HOSP	2%;70%	N20832	001	Jul 14, 2000	Jun	CTNA

>A> CHLORAPREP ONE-STEP FREPP

>A>	+	MEDI FLEX HOSP	2%;70%	N20832	001	Jul 14, 2000	Jun	CTNA

>A> SWAB; TOPICAL

>A> CHLORAPREP ONE-STEP SEPP

>A>	+	MEDI FLEX HOSP	2%;70%	N21555	001	Oct 07, 2002	Jun	CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

	@	SANDOZ	12MG	N70797	001	Aug 12, 1988	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 CHLORPHENIRAMINE MALEATE

+		ALZA	16MG	N19746	002	Nov 18, 1994	Mar	CRLD

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+		WYETH CONS	1MG/5ML;100MG/5ML;15MG/5ML	N21587	001	Feb 24, 2004	Feb	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

		ADAMS LABS	30MG;600MG	N21620	002	Apr 29, 2004	Apr	NEWA
+			60MG;1.2GM	N21620	001	Apr 29, 2004	Apr	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

>A> TABLET, EXTENDED RELEASE; ORAL

>A> MUCINEX D

>A>		ADAMS	600MG;60MG	N21585	001	Jun 22, 2004	Jun	NEWA
>A>	+		1.2GM;120MG	N21585	002	Jun 22, 2004	Jun	NEWA

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

	TARO	100MG/5ML	N21604	001	Jan 07, 2004	Jan	NEWA

TABLET, CHEWABLE; ORAL

IBUPROFEN

	PERRIGO	50MG	N76359	001	Jan 16, 2004	Jan	NEWA
		100MG	N76359	002	Jan 16, 2004	Jan	NEWA

TABLET; ORAL

IBUPROFEN

>A>	LNK	100MG	N76741	001	Jun 17, 2004	Jun	NEWA

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+	WYETH CONS	200MG;30MG	N21374	001	May 30, 2002	Mar	CAIN

LORATADINE

TABLET; ORAL

LORATADINE

>A>	PERRIGO	10MG	N21512	001	Jun 24, 2004	Jun	NEWA
>A>		10MG	N76301	001	Jun 25, 2004	Jun	NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

	ANDRX PHARMS	5MG;120MG	N76208	001	Jan 28, 2004	Jan	NEWA
	IMPAX LABS	10MG;240MG	N75989	001	Mar 04, 2004	Mar	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

	G AND W LABS	2%,100MG	N76585	001	Mar 26, 2004	Mar	NEWA

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

	PERRIGO	2%,4%	N76357	001	Mar 30, 2004	Mar	NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL

	PERRIGO	EQ 200MG BASE;120MG	N76518	001	Mar 17, 2004	Mar	NEWA

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL

LAMISIL AT

+	NOVARTIS	1%	N21124	002	Mar 17, 2000	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2004

NO JUNE 2004 APPROVALS

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List

June 2004

Generic Name:
sodium thiosulfate

Trade Name (if present):

Date Designated 3/17/2004
Date Approved

Designated Indication:
Prevention of platinum-induced ototoxicity in pediatric patients

Sponsor Contact Information
Adherex Technologies, Inc.
600 Peter Morand Crescent
Ottawa, Ontario

CANADA

****

Generic Name:
1-Deoxygalactonojirimycin

Trade Name (if present):

Date Designated 2/25/2004
Date Approved

Designated Indication:
Treatment of Fabry Disease

Sponsor Contact Information
Amicus Therapeutics, Inc.
675 US Route 1
North Brunswick NJ 08902

****

Generic Name:
Suberoylanilide Hydroxamic Acid (SAHA)

Trade Name (if present):

Date Designated 3/16/2004
Date Approved

Designated Indication:
Treatment of T-cell non-Hodgkin's lymphoma

Sponsor Contact Information
Aton Pharma, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591-6717

****

Generic Name:
Suberoylanilide Hydroxamic Acid

Trade Name (if present):

Date Designated 3/17/2004
Date Approved

Designated Indication:
Treatment of mesothelioma

Sponsor Contact Information
Aton Pharma, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591-6717

****

Generic Name:
Liarozole

Trade Name (if present):

Date Designated 6/18/2004

Designated Indication:
The treatment of congenital ichthyosis

Sponsor Contact Information
Barrier Therapeutics, Inc
600 College Road East

Orphan Products Designations and Approvals List
June 2004

Date Approved

Princeton NJ 08540

****

Generic Name:
Designated Indication:
temocillin sodium
caused by

Treatment of cystic fibrosis patients with pulmonary infection

Burkholderia cepacia

Trade Name (if present):
Negaban

Sponsor Contact Information
Belpharma N.V.
67 Winston Churchill Avenue
Brussels

Date Designated 4/21/2004
Date Approved

BELGIUM

****

Generic Name:
Alpha-1-acid glycoprotein

Designated Indication:
Treatment of tricyclic antidepressant poisoning

Trade Name (if present):

Sponsor Contact Information
Bio Products Laboratory
Dagger Lane
Elstree, Hertfordshire

Date Designated 3/17/2004
Date Approved

UNITED KINGDOM

****

Generic Name:
alpha-1-acid glycoprotein

Designated Indication:
Treatment of cocaine overdose

Trade Name (if present):

Sponsor Contact Information
Bio Products Laboratory
Dagger Lane, Elstree
Hertfordshire

Date Designated 3/5/2004
Date Approved

UNITED KINGDOM

****

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-
1,4-imino-D-ribitol-hydrochloride

Designated Indication:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Sponsor Contact Information
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated 1/29/2004
Date Approved

Orphan Products Designations and Approvals List
June 2004

****

Generic Name:
Rituximab

Designated Indication:
Treatment of chronic lymphocytic leukemia

Trade Name (if present):
Rituxan

Date Designated 1/29/2004
Date Approved

Sponsor Contact Information
Biogen IDEC, Inc.
3030 Callan Road
San Diego CA 92121

****

Generic Name:
tetrahydrobiopterin

Designated Indication:
For treatment of hyperphenylalaninemia

Trade Name (if present):

Date Designated 1/29/2004
Date Approved

Sponsor Contact Information
Biomarin Pharmaceutical Inc.
371 Bel Marin Blvd.
Novato CA 94949

****

Generic Name:
Vaccinia Immune Globulin (Human) Intravenous

Designated Indication:
Treatment of complications of vaccinia vaccination

Trade Name (if present):
CNJ-016

Date Designated 6/18/2004
Date Approved

Sponsor Contact Information
Cangene Corporation
104 Chancellor Matheson Road
Winnipeg, ManitobaR3T 5Y3

CANADA

****

Generic Name:
3-4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione (CC-5013)

Designated Indication:
Treatment of myelodysplastic syndromes

Trade Name (if present):
REVIMID

Date Designated 1/29/2004
Date Approved

Sponsor Contact Information
Celgene Corporation
7 Powder Horn Drive
Warren NJ 07059

****

Generic Name:
diethylenetriaminepentaacetate (DPTA) contamination with

elimination.

Designated Indication:
For treatment of patients with known or suspected internal

plutonium, americium or curium to increase the rates of

Trade Name (if present):

Date Designated 4/14/2004
Date Approved

Sponsor Contact Information
CIS-US
10 DeAngelo Drive
Bedford MA 01730

Orphan Products Designations and Approvals List
June 2004

****

Generic Name:
recombinant human fibroblast growth factor-20

Trade Name (if present):

Date Designated 1/29/2004
Date Approved

Designated Indication:
Treatment of radiation induced oral mucositis

Sponsor Contact Information
CuraGen Corporation
322 East Main Street
Branford CT 06405

****

Generic Name: Designated Indication:
Trisodium zinc Diethylenetriaminepentaacetate
contamination with

Trade Name (if present):

Date Designated 2/27/2004
Date Approved

Treatment of patients with known or suspected internal

plutonium, americium, or curium to increase the rate of elimination.

Sponsor Contact Information
CustomCare Pharmacy
5710 Hoover Blvd
Tampa FL 33634

****

Generic Name:
chenodeoxycholic acid

Trade Name (if present):
Chenofalk

Date Designated 1/29/2004
Date Approved

Designated Indication:
Treatment of cerebrotendinous xanthomatosis

Sponsor Contact Information
Dr. Falk Pharma GmbH
Leinenweberstrasse 5
Postfach 6529

GERMANY

****

Generic Name:
Vaccinia Immune Globulin (Human) Intravenous

Trade Name (if present):

Date Designated 6/18/2004
Date Approved

Designated Indication:
Treatment of severe complications from the smallpox vaccine

Sponsor Contact Information
DynPort Vaccine Company LLC
64 Thomas Johnson Drive
Frederick MD 21702

****

Generic Name:
hydralazine
pressure greater

160)

Trade Name (if present):

Designated Indication:
Treatment of severe intrapartum hypertension (diastolic blood

than or equal to 110 or systolic blood pressure less than or equal to

associated with severe preeclampsia/eclampsia of pregnancy

Orphan Products Designations and Approvals List
June 2004

Date Designated 4/9/2004
Date Approved

Sponsor Contact Information
Esp Pharma, Inc.
2035 Lincoln Hwy.
Suite 2150
Edison NJ 08817

****

Generic Name:
DEAE-rebeccamycin

Designated Indication:
Treatment of bile duct tumors

Trade Name (if present):

Date Designated 3/1/2004
Date Approved

Sponsor Contact Information
Exelixis, Inc.
170 Harbor Way
South San Francisco CA 94083-0511

****

Generic Name:
Ubiquinol

Designated Indication:
Treatment of Huntington's Disease

Trade Name (if present):
Ubi-Q-Nol, Li-Q-Nol

Date Designated 4/12/2004
Date Approved

Sponsor Contact Information
Gel-Tec
Division of Tishcon Corp
P. O. Box 331
Westbury NY 11590

****

Generic Name:
ubiquinol, coenzyme Q10, ubiquinone

Designated Indication:
Treatment of pediatric concgestive heart failure

Trade Name (if present):
UBI-Q-NOL

Date Designated 4/12/2004
Date Approved

Sponsor Contact Information
Gel-Tec, Division of TISHCON Corporation
30 New York Avenue
P.O. Box 331
Westbury NY 11590

****

Generic Name:
Deferitrin

Designated Indication:
For the treatment of iron overload

Trade Name (if present):

Date Designated 4/14/2004
Date Approved

Sponsor Contact Information
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

****

Generic Name:
Diethylnorspermine (DENSPM)

Designated Indication:
Treatment for hepatocellular carcinoma

Trade Name (if present):

Sponsor Contact Information

Orphan Products Designations and Approvals List
June 2004

Date Designated 5/25/2004
Date Approved

Genzyme Corporation
153 Second Avenue
Waltham MA 02451

****

Generic Name:
mepolizumab

Designated Indication:
For first-line treatment in patients with hypereosinophilic syndrome

Trade Name (if present):

Sponsor Contact Information
GlaxoSmithKline Pharmaceuticals
P.O. Box 7929
Philadelphia PA 19101

Date Designated 5/28/2004
Date Approved

****

Generic Name:
vapreotide

Designated Indication:
Treatment of symptomatic carcinoid tumors

Trade Name (if present):
Sanvar

Sponsor Contact Information
H3 Pharma, Inc.
666 Sherbrooke Street West Suite 1400
Montreal, Quebec,

CANADA

Date Designated 4/6/2004
Date Approved

****

Generic Name:
Diethylenetriaminepentaacetic acid (DTPA)

Designated Indication:
Treatment of patients with known or suspected internal contamination with plutonium, americum, or curium to increase the rates of elimination.

Trade Name (if present):

Sponsor Contact Information
Hameln Pharmaceuticals gmbh
Langes Feld 13
Hameln

GERMANY

Date Designated 4/28/2004
Date Approved

****

Generic Name:
pentetate trisodium

Designated Indication:
Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.

Trade Name (if present):
diethylenetriaminepentaacetate

Sponsor Contact Information
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
Goerzallee 253
Fedderal of Republic of Germany

GERMANY

Date Designated 4/12/2004
Date Approved

Orphan Products Designations and Approvals List

June 2004

****

Generic Name:
90Y-hPAMA4

Designated Indication:
Treatment of pancreatic cancer

Trade Name (if present):
PAN-Cide

Date Designated 1/29/2004
Date Approved

Sponsor Contact Information
Immunomedics, Inc.
300 American Road
Morris Plains NJ 07950

****

Generic Name:
5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)

Designated Indication:
Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):
Pirfenidone

Date Designated 3/5/2004
Date Approved

Sponsor Contact Information
InterMune, Inc.
3280 Bayshore Blvd
Brisbane CA 94005

****

Generic Name:
Recombinant Porcine Factor VIII, B-domain inhibitor
Deleted

Designated Indication:
Treatment and prevention of episodic bleeding in patients with antibodies to human coagulation factor VIII

Trade Name (if present):

Date Designated 3/16/2004
Date Approved

Sponsor Contact Information
Ipsen Limited
190 Bath Road
Berkshire S11 3XE

UNITED KINGDOM

****

Generic Name:
Icatibant acetate

Designated Indication:
Treatment of burn patients hospitalized with burn-induced edema

Trade Name (if present):

Date Designated 5/5/2004
Date Approved

Sponsor Contact Information
Jerini AG
Invalidenstr, 130
10115 Berlin

GERMANY

****

Generic Name:
multi-vitiam infusion without vitamin K anticoagulant

Designated Indication:
Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type therapy

Trade Name (if present):

Orphan Products Designations and Approvals List
June 2004

M.V.I.-12

Date Designated 3/8/2004
Date Approved

Sponsor Contact Information
Mayne Pharma (USA) Inc.
Mack-Cali Centre II
Second Floor
Paramus NJ 07652

****

Generic Name:
human immunoglobulin (IgG1k)antiCTLA-4 monoclonal antibody

Designated Indication:
Treatment of high risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Date Designated 6/3/2004
Date Approved

Sponsor Contact Information
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

****

Generic Name:
rofecoxib

Designated Indication:
Treatment of juvenile rheumatoid arthritis

Trade Name (if present):
VIOXX

Date Designated 3/16/2004
Date Approved

Sponsor Contact Information
MERCK & Co., Inc.
126 East Lincoln Ave.
Rahway NJ 07065

****

Generic Name:
Quinine Sulfate

Designated Indication:
Treatment of malaria

Trade Name (if present)

Date Designated 6/3/2004
Date Approved

Sponsor Contact Information
Mutual Pharmaceutical Company, Inc.
1100 Orthodox Street
Philadelphia PA 19124

****

Generic Name:
Idebenone (INN)

Designated Indication:
Treatment of cardiomyopathy associated with Friedreich's ataxia

Trade Name (if present):

Date Designated 3/25/2004
Date Approved

Sponsor Contact Information
MyoContract Ltd.
Hammerstrasse 25
CH-4410 Liestal

SWITZERLAND

****

Generic Name:
Staphylococcus aureus Immune Globulin weight neonates
(Human)

Designated Indication:
Prophylaxis against Staphylococcus aureus infections in low birth

Orphan Products Designations and Approvals List
June 2004

Trade Name (if present):
Altastaph

Date Designated 1/29/2004
Date Approved

Sponsor Contact Information
Nabi Biopharmaceuticals
12276 Wilkins Avenue
Rockville MD 20852

****

Generic Name:
Coagulation factor VIIa (Recombinant)

Designated Indication:
Treatment of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Date Designated 6/18/2004
Date Approved

Sponsor Contact Information
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

****

Generic Name:
Coagulation factor VIIa (recombinant)
with or

Designated Indication:
Prevention of bleeding episodes in patients with hemophilia A or B,

without inhibitors

Trade Name (if present):
NovoSeven

Date Designated 6/18/2004
Date Approved

Sponsor Contact Information
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

****

Generic Name:
Coagulation factor VIIa (recombinant)

Designated Indication:
Prevention of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Date Designated 6/18/2004
Date Approved

Sponsor Contact Information
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

****

Generic Name:
Immune Globulin (Human) containing high
titers of West Nile virus antibodies

Designated Indication:
Treatment of the West Nile virus infection

Trade Name (if present):
Omr-IgG-am (tm) 5% (WNV)

Date Designated 3/17/2004
Date Approved

Sponsor Contact Information
OMRIX Biopharmaceuticals, Ltd.
Plasma Fractionation Institute
Ramat Gan 52621

ISRAEL

****

Generic Name:
Aplidin

Designated Indication:
Treatment of Acute Lymphoblastic Leukemia

Orphan Products Designations and Approvals List
June 2004

Trade Name (if present):

Date Designated 6/18/2004
Date Approved

Sponsor Contact Information
PharmaMar USA, Inc
320 Putnam Avenue
Cambridge MA 02139

****

Generic Name:
sarsasapogenin

Designated Indication:
Treatment of amyotrophic lateral sclerosis (ALS)

Trade Name (if present):

Date Designated 6/18/2004
Date Approved

Sponsor Contact Information
Phytopharm plc
Corpus Christi House
Godmanchester, Cambridgeshire PE29 2HY

UNITED KINGDOM

****

Generic Name:
mannopentaose phosphate sulfate

Designated Indication:
Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Date Designated 4/27/2004
Date Approved

Sponsor Contact Information
Progen Industries Limited
P. O. Box 28
Richlands 4077

AUSTRALIA

****

Generic Name:
antivenin crotaline (pit-viper) equine immune F(ab)2)

Designated Indication:
Treatment of envenomation by Crotaline snakes

Trade Name (if present):
Antivipmyn

Date Designated 1/29/2004
Date Approved

Sponsor Contact Information
Rare Disease Therapeutics, Inc.
1101 Kermit Drive,
Suite 608
Nashville TN 37217

****

Generic Name:
Thymosin Beta 4

Designated Indication:
Treatment of Epidermolysis Bullosa

Trade Name (if present):

Date Designated 5/28/2004
Date Approved

Sponsor Contact Information
RegeneRx Biopharmaceuticals, Inc.
3 Bethesda Metro Center
Suite 700
Bethesda MD 20814

Orphan Products Designations and Approvals List
June 2004

****

Generic Name:
SGN-30 (anti-CD30 antibody)

Trade Name (if present):

Date Designated 2/18/2004
Date Approved

Designated Indication:
For the treatment of CD30 positive T-cell lymphomas

Sponsor Contact Information
Seattle Genetics, Inc.
21823 30th Drive Southeast
Bothell WA 98021

****

Generic Name:
somatropin
syndrome

Trade Name (if present):
Serostim

Date Designated 3/16/2004
Date Approved

Designated Indication:
Treatment of patients with HIV-associated adipose redistribution

Sponsor Contact Information
Serono, Inc.
One Technology Place
Rockland MA 02370

****

Generic Name:
rh-microplasmin

Trade Name (if present):

Date Designated 3/16/2004
Date Approved

Designated Indication:
Adjunct to surgery in cases of pediatric vitrectomy

Sponsor Contact Information
ThromboGenics Ltd
Unit 14
Bridgecourt Office Park
Dublin 12
IRELAND

****

Generic Name:
Dexrazoxane

Trade Name (if present):

Date Designated 3/25/2004
Date Approved

Designated Indication:
Treatment of anthracycline extravasation during chemotherapy

Sponsor Contact Information
Topo Target A/S
Fruebjergvej 3, 2100
Copenhagen

DENMARK

****

Generic Name:
oral unfractionated heparin

Trade Name (if present):

Date Designated 1/29/2004
Date Approved

Designated Indication:
Treatment of sickle cell disease

Sponsor Contact Information
TRF Technologies, Inc.
108 Eagle Trace Drive
Half Moon Bay CA 94019

Orphan Products Designations and Approvals List
June 2004

****

Generic Name:
Immune Globulin Intravenous (human)

Designated Indication:
Treatment for Guillain Barre Syndrome

Trade Name (if present):
Carimune NF

Date Designated 5/4/2004
Date Approved

Sponsor Contact Information
ZLB Bioplasma AG
Wankdorfstrasse 10
CH-3000 Bern 22

SWITZERLAND

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 2004 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021320 001	ABARELIX;PLENAXIS	5968895	DEC 11, 2016	DP		
		6180608	DEC 11, 2016	DP U549		
		6423686	JUN 07, 2015	DS		
		6455499	JUN 07, 2015	U549		
		5843901	DEC 01, 2015	DS DP		
		6699833	DEC 11, 2016	DP		
021539 001	ACETYLCYSTEINE;ACETADOTE				ODE	JAN 23, 2011
020899 001	ALBUMIN HUMAN;OPTISON	6273303	APR 20, 2021	DP		
020949 001	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
020949 002	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
020560 005	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
021575 001	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
020886 001	ALITRETINOIN;PANRETIN	5932622	AUG 03, 2016	U562		
021540 001	AMLODIPINE BESYLATE;CADUET	5273995	DEC 28, 2010	DS DP U162	NC	JAN 30, 2007
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161		
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
021540 002	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 003	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021540 004	AMLODIPINE BESYLATE;CADUET	6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
021540 005	AMLODIPINE BESYLATE;CADUET	6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
021540 006	AMLODIPINE BESYLATE;CADUET	6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
021540 007	AMLODIPINE BESYLATE;CADUET	6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
			5969156	JUL 08, 2016	DS		
			5969156*PED	JAN 08, 2017			
			5686104	NOV 11, 2014	DP U213		
			5686104*PED	MAY 11, 2015			
			6126971	JAN 19, 2013	DP		
			6126971*PED	JUL 19, 2013			
	021540 008	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
			4681893*PED	MAR 24, 2010			
			4879303	MAR 25, 2007	DS DP		
			4879303*PED	SEP 25, 2007			
			4572909	JUL 31, 2006	DS DP U3		
			4572909*PED	JAN 31, 2007			
			5273995	DEC 28, 2010	DS DP U162		
			5273995*PED	JUN 28, 2011			
			6455574	AUG 11, 2018	U552		
			5969156	JUL 08, 2016	DS		
			5969156*PED	JAN 08, 2017			
			5686104	NOV 11, 2014	DP U213		
			5686104*PED	MAY 11, 2015			
			6126971	JAN 19, 2013	DP		
			6126971*PED	JUL 19, 2013			
	021007 001	AMPRENAVIR;AGENERASE	6730679	NOV 11, 2017	DP		
	021007 002	AMPRENAVIR;AGENERASE	6730679	NOV 11, 2017	DP		
	020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						PED	SEP 14, 2004
	020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						PED	SEP 14, 2004
	021264 001	APOMORPHINE HYDROCHLORIDE;APOKYN				NCE	APR 20, 2009
	021264 002	APOMORPHINE HYDROCHLORIDE;APOKYN				NCE	APR 20, 2009
	021248 001	ARSENIC TRIOXIDE;TRISENOX	6723351	NOV 10, 2018	U573		
>ADD>	021567 001	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
>ADD>	021567 002	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
>ADD>	021567 003	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
	020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	U207		
			5164194*PED	MAY 01, 2011			
	019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	021551 001	BISACODYL;HALFLYTELY				NP	MAY 10, 2007
>ADD>	021602 001	BORTEZOMIB;VELCADE	6747150	OCT 28, 2014	DP		
			6713446	JAN 25, 2022	DP		
	020746 001	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
	020746 002	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
	019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	020452 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 004	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	021621 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565		
			4525358*PED	DEC 25, 2007			
	021621 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	6455533	JUL 02, 2018	DP		
			4525358	JUN 25, 2007	DS DP U565		
			4525358*PED	DEC 25, 2007			
	020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	6455533	JUL 02, 2018	DP		
	021587 001	CHLORPHENIRAMINE MALEATE;CHILDREN'S ADVIL ALL	5340821	JUL 07, 2013	U309		
	021149 002	CHORIOGONADOTROPIN ALFA;OVIDREL				NP	FEB 24, 2007
	021688 001	CINACALCET HYDROCHLORIDE;SENSIPAR	6706681	MAR 16, 2021	DP		
			6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	021688 002	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016		ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	021688 003	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
>ADD>	020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	5965549	JUN 06, 2015	DP		
	019847 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	020780 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	020780 002	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLO	4670444	DEC 09, 2003			
			4705789	NOV 10, 2004			
			4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4670444*PED	JUN 09, 2004			
			4705789*PED	MAY 10, 2005			
			4808583*PED	AUG 28, 2006			
			4957922*PED	MAR 18, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021473 002	CIPROFLOXACIN;CIPRO XR	4670444	DEC 09, 2003	DS DP U555		
			4670444*PED	JUN 09, 2004			
	021644 001	CLOBETASOL PROPIONATE;CLOBEX				NDF	FEB 05, 2007
	021038 001	DEXMEDETOMIDINE;PRECEDEX	6716867	MAR 31, 2019	U572		
	021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6528090	DEC 18, 2018	DP		
			6713086	DEC 18, 2018	DP U579		
			5212326	JAN 29, 2008	DS DP		
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6528090	DEC 18, 2018	DP		
			6528091	DEC 18, 2018			
			6713086	DEC 18, 2018	DP U579		
			5212326	JAN 29, 2008	DS DP		
	020449 001	DOCETAXEL;TAXOTERE				I-429	MAY 19, 2007
	020931 001	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020931 002	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020931 003	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6316443	APR 17, 2011	DP U561		
	020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	DS DP U103		
			4619939	OCT 28, 2003	DP U104		
	020862 001	DOXERCALCIFEROL;HECTOROL				I-424	APR 23, 2007
	020862 002	DOXERCALCIFEROL;HECTOROL				I-424	APR 23, 2007
	018651 001	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	018651 002	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	018651 003	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	021500 001	EMTRICITABINE;EMTRIVA	6703396	MAR 09, 2021	DS DP		
	021504 001	EPINEPHRINE;LIDOSITE TOPICAL SYS				NP	MAY 04, 2007
>ADD>	021437 001	EPLERENONE;INSPRA	6747020	NOV 05, 2019	U587		
>ADD>	021437 002	EPLERENONE;INSPRA	6747020	NOV 05, 2019	U587		
>ADD>	021437 003	EPLERENONE;INSPRA	6747020	NOV 05, 2019	U587		
>ADD>	021371 001	ESTRADIOL HEMIHYDRATE;ESTRASORB	5629021	JAN 31, 2015	DP	NDF	OCT 09, 2006
	021166 001	ESTRADIOL;ESTROGEL				NDF	FEB 09, 2007
>ADD>	021674 001	ESTRADIOL;MENOSTAR				NP	JUN 08, 2007
	021040 001	ESTRADIOL;PREFEST	6747019	MAR 20, 2020	U311		
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 006	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NS	FEB 05, 2007
						D-85	FEB 05, 2007
>ADD>	021443 003	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	MAY 10, 2007
>ADD>	021443 004	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	MAY 10, 2007
	021490 001	ETHINYL ESTRADIOL;OVCON-35	6667050	JUN 12, 2021	DP U1		
>ADD>	020363 001	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
>ADD>			5866581	OCT 04, 2014	U96		
>ADD>			5916893	SEP 01, 2015	U96		
>ADD>			6124304	OCT 04, 2014	U96		
>ADD>	020363 002	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
>ADD>			5866581	OCT 04, 2014	U96		
>ADD>			5916893	SEP 01, 2015	U96		
>ADD>			6124304	OCT 04, 2014	U96		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020363 003	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
>ADD>			5866581	OCT 04, 2014	U96		
			5916893	SEP 01, 2015	U96		
>ADD>			6124304	OCT 04, 2014	U96		
	019922 001	FENOLDOPAM MESYLATE;CORLOPAM				I-422	APR 01, 2007
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	DS DP U262		
			5886184	NOV 19, 2012	DS		
			6046183	MAR 20, 2011	DP U577		
	019949 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019949 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019949 003	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019949 004	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	020090 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	020985 001	FLUOROURACIL;CARAC	6670335	JUN 02, 2021	DP U68		
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U396		
			5985322	MAY 29, 2017	U397		
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50				M-33	APR 21, 2007
>ADD>	021433 001	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
>ADD>			6315173	DEC 23, 2017	DP		
>ADD>			6510969	DEC 23, 2017	DP		
>ADD>			6743413	JUN 01, 2021	DP U581		
>ADD>			6253762	APR 14, 2015	DP U582		
>ADD>			6546928	APR 14, 2015	DP U583		
>ADD>	021433 002	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
>ADD>			6315173	DEC 23, 2017	DP		
>ADD>			6510969	DEC 23, 2017	DP		
>ADD>			6743413	JUN 01, 2021	DP U581		
>ADD>			6253762	APR 14, 2015	DP U582		
>ADD>			6546928	APR 14, 2015	DP U583		
>ADD>	021433 003	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
>ADD>			6315173	DEC 23, 2017	DP		
>ADD>			6510969	DEC 23, 2017	DP		
>ADD>			6743413	JUN 01, 2021	DP U581		
>ADD>			6253762	APR 14, 2015	DP U582		
>ADD>			6546928	APR 14, 2015	DP U583		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021211 001	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
			5767251	JUN 16, 2015	DS		
			4589402	JUL 26, 2004	U568		
			4589402	JUL 26, 2004	U569		
			4589402	JUL 26, 2004	U570		
	021211 002	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
			4589402	JUL 26, 2004	U568		
			5767251	JUN 16, 2015	DS		
			4589402	JUL 26, 2004	U569		
			4589402	JUL 26, 2004	U570		
	021765 001	FOLLITROPIN ALFA/BETA;GONAL-F				NP	MAR 25, 2007
	021765 002	FOLLITROPIN ALFA/BETA;GONAL-F				NP	MAR 25, 2007
	021765 003	FOLLITROPIN ALFA/BETA;GONAL-F				NP	MAR 25, 2007
>ADD>	021061 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
>ADD>	021061 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
>ADD>	021062 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
>ADD>	021062 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
>ADD>	021062 003	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
>ADD>	021062 004	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
>ADD>	021493 001	GATIFLOXACIN;ZYMAR	4980470	DEC 25, 2007			
			6333045	AUG 20, 2019	DP		
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2004
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
	021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6723734	MAR 20, 2018	DS DP		
>ADD>	021667 001	GLUTAMINE;GLUTAMINE				NCE	JUN 10, 2009
	076345 001	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 002	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 003	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076604 001	HYDROCODONE BITARTRATE;HYDROCODONE BITARTRA				PC	OCT 11, 2004
	021604 001	IBUPROFEN;CHILDREN'S ELIXSURE				NP	JAN 07, 2007
	076478 001	IBUPROFEN;IBUPROFEN AND PSEUDO				PC	JUL 29, 2004
	020723 001	IMIQUIMOD;ALDARA				I-420	MAR 02, 2007
>ADD>						I-433	JUL 14, 2007
	020685 001	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 003	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 005	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 006	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	021629 001	INSULIN GLULISINE RECOMBINANT;APIDRA	6221633	JUN 18, 2018	DS DP U471	NCE	APR 16, 2009
	020563 001	INSULIN LISPRO RECOMBINANT;HUMALOG				D-86	JUN 02, 2007
	020563 002	INSULIN LISPRO RECOMBINANT;HUMALOG PEN				D-86	JUN 02, 2007
	021425 003	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	DS DP U113		
>ADD>	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007		M-34	JUN 24, 2007
>ADD>			6403569	APR 28, 2020	U449	PED	DEC 24, 2007
			4604463*PED	FEB 20, 2008			
			6403569*PED	OCT 28, 2020			
	021281 001	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021281 002	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021428 001	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021428 002	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
	021566 001	LANSOPRAZOLE;PREVACID IV				NDF	MAY 27, 2007
	020905 001	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020905 002	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
	020905 003	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
	020182 001	LEVOCARNITINE;CARNITOR	6696493	JAN 18, 2021	U433		
	021571 001	LEVOFLOXACIN;IQUIX				NP	MAR 01, 2007
	021451 001	LIDOCAINE;ORAQIX	6031007	APR 01, 2017	DP U553		
>ADD>	021130 001	LINEZOLID;ZYVOX				I-431	JUN 23, 2007
>ADD>	021130 002	LINEZOLID;ZYVOX				I-431	JUN 23, 2007
>ADD>	021131 001	LINEZOLID;ZYVOX				I-431	JUN 23, 2007
>ADD>	021132 001	LINEZOLID;ZYVOX				I-431	JUN 23, 2007
	021226 001	LOPINAVIR;KALETRA	6703403	JUN 26, 2016	U257		
	021251 001	LOPINAVIR;KALETRA	6703403	JUN 26, 2016	U257		
	075505 001	LORATADINE;LORATADINE				PC	AUG 20, 2004
	020386 001	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020386 002	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020386 003	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020803 001	LOTEPREDNOL ETABONATE;ALREX	5747061	OCT 25, 2013	DP U576		
	020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	5747061	OCT 25, 2013	DP U575		
>ADD>	021249 001	LOVASTATIN;ADVICOR	6746691	SEP 20, 2013	U586		
			6676967	SEP 20, 2013	U548		
>ADD>	021249 002	LOVASTATIN;ADVICOR	6746691	SEP 20, 2013	U586		
			6676967	SEP 20, 2013	U548		
>ADD>	021249 003	LOVASTATIN;ADVICOR	6746691	SEP 20, 2013	U586		
			6676967	SEP 20, 2013	U548		
>ADD>	020938 001	MELOXICAM;MOBIC				I-430	JUL 16, 2007
>ADD>	020938 002	MELOXICAM;MOBIC				I-430	JUL 16, 2007
>ADD>	021530 001	MELOXICAM;MOBIC				I-430	JUL 16, 2007
>ADD>						NCE	APR 13, 2005
	013217 001	METAXALONE;SKELAXIN	6683102	DEC 03, 2021	U189		
	013217 002	METAXALONE;SKELAXIN	6683102	DEC 03, 2021	U189		
	021574 001	METFORMIN HYDROCHLORIDE;FORTAMET				NP	APR 27, 2007
	021574 002	METFORMIN HYDROCHLORIDE;FORTAMET				NP	APR 27, 2007
>ADD>	076172 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	DEC 14, 2004
	076545 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	MAY 29, 2004
	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI				RTO	JUN 29, 2004
	076307 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
	076307 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	6723713	JAN 27, 2014	U574		
			6723713*PED	JUL 27, 2014			
>ADD>	021671 001	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
>ADD>			5807572	SEP 15, 2015	DP		
>ADD>			5891467	JAN 31, 2017	DP		
>ADD>			5931089	JUL 14, 2015	U584		
>ADD>			5997899	SEP 01, 2016	DP		
>ADD>			5962016	JAN 31, 2017	DP U584		
>ADD>			6071534	FEB 18, 2008			
>ADD>			6171613	OCT 01, 2016	DP		
>ADD>			6193998	SEP 01, 2016	DP		
>ADD>			6241999	SEP 01, 2016	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021671 002	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
>ADD>			5807572	SEP 15, 2015	DP		
>ADD>			5891467	JAN 31, 2017	DP		
>ADD>			5931089	JUL 14, 2015	U584		
>ADD>			5997899	SEP 01, 2016	DP		
>ADD>			5962016	JAN 31, 2017	DP U584		
>ADD>			6071534	FEB 18, 2008			
>ADD>			6171613	OCT 01, 2016	DP		
>ADD>			6193998	SEP 01, 2016	DP		
>ADD>			6241999	SEP 01, 2016	DP		
>ADD>	021671 003	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
>ADD>			5807572	SEP 15, 2015	DP		
>ADD>			5891467	JAN 31, 2017	DP		
>ADD>			5931089	JUL 14, 2015	U584		
>ADD>			5997899	SEP 01, 2016	DP		
>ADD>			5962016	JAN 31, 2017	DP U584		
>ADD>			6071534	FEB 18, 2008			
>ADD>			6171613	OCT 01, 2016	DP		
>ADD>			6193998	SEP 01, 2016	DP		
>ADD>			6241999	SEP 01, 2016	DP		
	021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	6716830	SEP 20, 2019	DP	NCE	DEC 10, 2004
			6716830*PED	MAR 29, 2020		PED	JUN 10, 2005
>ADD>	020381 001	NIACIN;NIASPAN	6746691	SEP 20, 2013	U586		
>ADD>	020381 002	NIACIN;NIASPAN	6746691	SEP 20, 2013	U586		
			6676967	SEP 20, 2013	U548		
>ADD>	020381 003	NIACIN;NIASPAN	6746691	SEP 20, 2013	U586		
			6676967	SEP 20, 2013	U548		
>ADD>	020381 004	NIACIN;NIASPAN	6746691	SEP 20, 2013	U586		
			6676967	SEP 20, 2013	U548		
>ADD>	020381 005	NIACIN;NIASPAN TITRATION ST	6746691	SEP 20, 2013	U586		
	076648 001	NITROFURANTOIN;NITROFURANTOIN (MONO				PC	SEP 19, 2004
	021494 001	NIZATIDINE;AXID				NDF	MAY 25, 2007
	020592 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2001	U547		
	020592 002	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 003	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 004	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 006	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	DS DP U547		
	021253 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U571	NDF	MAR 29, 2007
						NP	MAR 29, 2007
	021086 001	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006
	021086 002	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006
	021086 003	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021086 004	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006
	021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
			5866601	FEB 02, 2016		PED	APR 27, 2005
			5952375	FEB 02, 2016			
			5763483*PED	JUN 27, 2017			
			5866601*PED	AUG 02, 2016			
			5952375*PED	AUG 02, 2016			
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5866601	FEB 02, 2016		NCE	OCT 27, 2004
			5952375	FEB 02, 2016		PED	APR 27, 2005
			5763483	DEC 27, 2016	U376		
			5763483*PED	JUN 27, 2017			
			5866601*PED	AUG 02, 2016			
			5952375*PED	AUG 02, 2016			
	021492 001	OXALIPLATIN;ELOXATIN				I-425	JAN 09, 2007
	021492 002	OXALIPLATIN;ELOXATIN				I-425	JAN 09, 2007
>ADD>	013718 001	OXANDROLONE;OXANDRIN	5872147	DEC 05, 2017	U585		
>ADD>			6670351	OCT 20, 2012	U585		
>ADD>			6576659	DEC 05, 2017	U585		
>ADD>			6090799	JUL 18, 2017	U585		
>ADD>	013718 002	OXANDROLONE;OXANDRIN	5872147	DEC 05, 2017	U585		
>ADD>			6670351	OCT 20, 2012	U585		
>ADD>			6576659	DEC 05, 2017	U585		
>ADD>			6090799	JUL 18, 2017	U585		
	021351 002	OXYBUTYNIN;OXYTROL	6743441	APR 26, 2020	DP U318		
	076168 001	OXYCODONE HYDROCHLORIDE;OXYCODONE HCL				PC	SEP 26, 2004
	020819 001	PARICALCITOL;ZEMPLAR				M-31	MAR 31, 2007
						PED	OCT 01, 2007
	020819 002	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U314	M-31	MAR 31, 2007
			5246925*PED	OCT 17, 2012		PED	OCT 01, 2007
			5587497	DEC 24, 2013			
			5587497*PED	JUN 24, 2014			
			6136799	APR 08, 2018			
			6136799*PED	OCT 08, 2019			
			6361758	APR 08, 2018	DP		
			6361758*PED	OCT 08, 2018			
	021462 001	PEMETREXED DISODIUM;ALIMTA	5217974	MAR 29, 2011	U551	NCE	FEB 04, 2009
			5344932	SEP 06, 2011	DS DP	ODE	FEB 04, 2011
>ADD>	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
>ADD>	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
>ADD>	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020741 001	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020741 002	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 003	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020903 002	RIBAVIRIN;REBETOL	6177074	NOV 01, 2016	U454		
		6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
		6472373	SEP 21, 2017	U479		
		6472373*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
		6524570*PED	MAY 01, 2017	U499		
076203 001	RIBAVIRIN;RIBASPHERE				PC	OCT 03, 2004
076192 001	RIBAVIRIN;RIBAVIRIN				PC	OCT 03, 2004
021361 001	RIFAXIMIN;XIFAXAN				NCE	MAY 25, 2009
020659 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		
020945 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		
021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U266	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
		6239173*PED	DEC 24, 2013			
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U266	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
		6239173*PED	DEC 24, 2013			
021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013	DS DP U266	NCE	MAY 20, 2004
		5474995	JUN 24, 2013	DS DP U266	I-353	APR 11, 2005
		5691374	MAY 18, 2015		M-27	AUG 06, 2006
		6063811	MAY 06, 2017		PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
		6239173*PED	DEC 24, 2013			
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013		PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	FEB 06, 2007
		5691374*PED	NOV 18, 2015		PED	OCT 11, 2005
		6063811*PED	NOV 06, 2017			
		6239173*PED	DEC 24, 2013			
021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013		PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	FEB 06, 2007
		5691374*PED	NOV 18, 2015		PED	OCT 11, 2005
		6063811*PED	NOV 06, 2017			
		6239173*PED	DEC 24, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021256 001	SECRETIN SYNTHETIC HUMAN;HUMAN SECRETIN				ODE	APR 04, 2009
					NCE	APR 09, 2009
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	6727283	OCT 11, 2019	DP U580		
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013			
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013			
021110 003	SIROLIMUS;RAPAMUNE				NCE	SEP 15, 2004
					I-386	APR 11, 2006
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	4968299	JUN 28, 2008	DP		
020168 001	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
020168 002	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ	5763394	JUN 09, 2015	DP		
020522 002	SOMATROPIN RECOMBINANT;NUTROPIN AQ PEN	5763394	JUN 09, 2015	DP		
020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
021368 001	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
021368 002	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
021368 003	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
021388 001	TALC;TALC				ODE	DEC 24, 2004
021144 001	TELITHROMYCIN;KETEK	D459798	SEP 24, 2015	DP	NCE	APR 01, 2009
		5635485	APR 21, 2015	DS DP U578		
021124 002	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	5681849	OCT 28, 2014			
		4755534	DEC 30, 2006	U73		
		4680291	JUL 14, 2004	U73		
		6121314	MAY 18, 2012	U504		
020846 001	TERBINAFINE;LAMISIL	5681849	OCT 28, 2014	DP		
		6121314	MAY 18, 2012	DP U504		
		6121314	MAY 18, 2012	DP U540		
		6121314	MAY 18, 2012	DP U502		
		6005001	MAY 18, 2012	DP U540		
		6005001	MAY 18, 2012	U502		
		6005001	MAY 18, 2012	U504		
		5856355	MAY 18, 2012	DP U502		
		5856355	MAY 18, 2012	U504		
		5856355	MAY 18, 2012	U540		
020898 001	THYROTROPIN ALFA;THYROGEN	6365127	NOV 24, 2015	DS DP U556		
021618 001	TINIDAZOLE;TINDAMAX				NCE	MAY 17, 2009
021618 002	TINIDAZOLE;TINDAMAX				NCE	MAY 17, 2009
021395 001	TIOTROPIUM BROMIDE MONOHYDRATE;SPIRIVA	5610163	MAR 11, 2014	DS DP U566	NCE	JAN 30, 2009
020771 002	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U318		
		5559269*PED	MAY 05, 2014			
020505 001	TOPIRAMATE;TOPAMAX				D-88	DEC 16, 2006
020505 002	TOPIRAMATE;TOPAMAX				D-88	DEC 16, 2006
020505 003	TOPIRAMATE;TOPAMAX				D-88	DEC 16, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020505 004	TOPIRAMATE;TOPAMAX				D-88	DEC 16, 2006
	020505 005	TOPIRAMATE;TOPAMAX				D-88	DEC 16, 2006
	020505 006	TOPIRAMATE;TOPAMAX				D-88	DEC 16, 2006
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				D-88	DEC 16, 2006
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				D-88	DEC 16, 2006
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				D-88	DEC 16, 2006
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	DP		
			5849792	DEC 22, 2014	DP U383		
			5889052	DEC 02, 2014	DP U383		
			5510383	AUG 03, 2013	DP U383		
	021595 001	TROSPIUM CHLORIDE;SANCTURA				NCE	MAY 28, 2009
>ADD>	020675 001	URSODIOL;URSO	4859660	NOV 19, 2007			
	021630 001	VORICONAZOLE;VFEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
			5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
			5567817	OCT 22, 2013	DS DP U540		
			5773443	JAN 25, 2011	DS DP U540		
>ADD>	021450 004	ZOLMITRIPTAN;ZOMIG	6750237	NOV 28, 2020	DP		
>ADD>			6750237*PED	MAY 28, 2021			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(c)(3)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM.

PATENT & EXCLUSIVITY ABBREVIATIONS

W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS

EXCLUSIVITY INDICATION

I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS

I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE

I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)

EXCLUSIVITY MISCELLANEOUS

M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION

M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)

M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES

M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA

M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST

M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY

PATENT USE

U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE

U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER

U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER

U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER

U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA

U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID

U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION

U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS

U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS

U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING

U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)

U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL

U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM

U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS

U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY

U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA

U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-567 METHOD OF TREATING INFERTILITY

U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION

U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED

U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG

U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

U-572 INTENSIVE CARE UNIT SEDATION

U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
U-576	ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION

Approved Drug Products, ADP
SUBSCRIPTION ORDER FORM

Order Processing Code:
8414

Easy Secure Internet:
bookstore.gpo.gov

Toll Free: (866) 512-1800
Phone: (202) 512-1800
Fax: (202) 512-2250

Mail: Superintendent of Documents
P.O. Box 371954
Pittsburgh, PA 15250-7954

❒ **YES,** enter my subscription(s) as follows:

_____ subscription(s) of **Approved Drug Products with Therapeutic Equivalence Evaluations, ADP,** and the monthly Cumulative Supplements, for $110.00 per year. The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

Personal name (Please type or print)

Company name

Street address City, State, Zip code

Daytime phone including area code

Purchase order number (optional)

VISA MasterCard DISCOVER

Check method of payment:

❒ Check payable to Superintendent of Documents

❒ SOD Deposit Account ☐☐☐☐☐☐☐ — ☐

❒ VISA ❒ MasterCard ❒ Discover/NOVUS ❒ American Express

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

☐☐☐☐ (expiration date)

Thank you for your order!

Authorizing signature 02/04